THE UNITED REPUBLIC OF TANZANIA
MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERLY AND CHILDREN.

ISO 9001:2015 Certified

MEDICAL STORES DEPARTMENT

TENDER NUMBER: IE-009/2018/2019/HQ/G/101
FOR SUPPLY OF PHARMACEUTICALS AND MEDICAL SUPPLIES FROM MANUFACTURERS TO SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC) MEMBER STATES UNDER FRAMEWORK AGREEMENT

Director General
Medical Stores Department
Off Nyerere road, Keko Mwanga
P.O.Box 9081
Dar es Salaam, Tanzania
Tel: 255 22 2860890/7
Fax: 255 22 2865814/9

April 2019

SECTION I: INVITATION FOR TENDERS

THE UNITED REPUBLIC OF TANZANIA
MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER, ELDERLY AND CHILDREN

ISO 9001:2015 Certified

MEDICAL STORES DEPARTMENT

TENDER NUMBER: IE-009/2018/2019/HQ/G/101
FOR SUPPLY OF PHARMACEUTICALS AND MEDICAL SUPPLIES FROM MANUFACTURERS TO SOUTHERN AFRICAN DEVELOPMENT COMMUNITY (SADC) MEMBER STATES UNDER FRAMEWORK AGREEMENT

INVITATION FOR TENDER

Tuesday 23rd April 2019

1. This Invitation for Tenders follows the General Procurement Notice for this project which appeared in the Procurement Journal dated 24th July 2018, MSD website (www.msd.go.tz) and PPRA Website (www.ppra.go.tz)

2. The Government of the United Republic of Tanzania through its Medical Stores Department, in collaboration with SADC Secretariat will mobilize funds for sustainable Pooled Procurement Services of essential Medicines and Health Commodities in the SADC Region. It is intended that part of the proceeds of the fund will be used to cover eligible payment under the contract for the Supply of Pharmaceuticals and Medical supplies from Manufacturers Using Framework Agreement;

3. The Medical Stores Department Tender board on behalf of the Government of Tanzania now invites sealed tenders from eligible Pharmaceutical and Medical supplies Manufacturers for carrying out the Supply of Pharmaceuticals and Medical supplies to SADC Member states under Framework Agreement;

4. Tendering will be conducted through the International competitive tendering procedures specified in the Procurement Regulations, 2013 – Government Notice No. 446 and is open to all Tenderers as defined in the Regulations;

5. Interested eligible Tenderers may obtain further information from and inspect the Tendering Documents at the office of the Secretary, Medical Stores Department Tender Board, Off Nyerere Road, Keko Mwanga, P.O. Box 9081 Dar es Salaam, Tanzania from Tuesday 23rd April 2019 at **8.00 a.m to 3.30 p.m** on Mondays to Fridays respectively, except on public holidays. Alternatively the interested Tenderers may view the tender document on the Medical Stores Department **website *(www.msd.go.tz),*** PPRA **website (www.ppra.go.tz),** Member state **websites** and SADC **website;**

6. A complete set of the Tendering Document(s) in English and additional sets may be purchased by the interested Tenderers on submission of a written application letter to the address given in paragraph 5 and upon payment of a non-refundable fee of US Dollar 100 equivalent to TZS 240,000. Payment should either be by Banker's Draft, Banker's Cheque, or through bank transfer (Extra charges of US Dollar 25 as a bank transfer charges should be added in the fee) payable to **Director General Medical Stores Department, Off Nyerere road, Keko Mwanga, P.O. Box 9081, Dar es Salaam, Tanzania;**

   The following bank details should be used.

   BANK: TIB CORPORATE BANK – 7TH FLOOR, SAMORA TOWER, CORNER OF SAMORA AVENUE/BRIGE STREET, DAR ES SALAAM, TANZANIA
   ACCOUNT No. TZS: 004600000793401
   USD: 004600000793402
   SWIFT CODE: TAINTZTZ

7. All tenders must be accompanied with a Tender securing declaration in the format provided in the Tender document;

8. All tenders in one original plus "ONE COPY", and a soft copy (compulsory) of the price schedule properly filled in the format provided, and enclosed in plain envelopes must be delivered to the address below at or **before 10.00 Tuesday 21st May 2019.** Envelopes shall bear the words: **''IFT NO IE-009/2018/2019/HQ/G/101: DO NOT OPEN BEFORE TUESDAY 21ST MAY 2019 AT 10.00 HOURS LOCAL TANZANIA TIME".** Tenders will be opened promptly in public and in the presence of Tenderers' representatives who choose to attend in the opening at the Medical Stores Department Board Room, Off Nyerere Road, Keko Mwanga, P.O. Box 9081 Dar es Salaam, Tanzania*;*

9. Late Tenders, portion of Tenders, Electronic Tenders, Tenders not received, Tender not Opened in and not readout in public at the Tender open ceremony shall not be accepted for evaluation irrespective of the circumstances.

Director General
Medical Stores Department
Off Nyerere road, Keko Mwanga
P.O. Box 9081
Dar es Salaam, Tanzania

Tel: 255 22 2860890/7
Fax: 255 22 2865814/9

SECTION II: INSTRUCTION TO TENDERERS

Table of Clauses

G. Review of Procurement Decisions

A. Introduction

1. Scope of Tender

1.1 The Procuring Entity, as specified in the **Tender Data Sheet** and in the Special Conditions of Contract (SCC), invites Tenders for supply of Goods (pharmaceuticals, Medical supplies vaccines, contraceptives, or nutritional supplements as specified in the **Tender Data Sheet)** described in the Schedule of Requirements.

1.2 The successful Tenderer will be expected to supply the goods within the period stated in the **Tender Data Sheet** from the start date and completion date specified in the **Tender Data Sheet.**

2. Source of Funds

2.1 The Government of the United Republic of Tanzania through Medical stores Department in collaboration with SADC secretariat will mobilize sufficient funds for the operations of the Procuring Entity named in the **Tender Data Sheet** during the Financial Year indicated in the **Tender Data Sheet.** It is intended that part of the proceeds of the funds will be applied to cover eligible payments under the contract for the supply of goods as described in the **Tender Data Sheet.**

2.2 Payments will be made directly by the Procuring Entity (or by financing institution specified in the **Tender Data Sheet** upon request of the Procuring Entity to so pay) and will be subject in all respects to the terms and conditions of the resulting contract placed by the Procuring Entity.

3. Eligible Tenderers

3.1 A Tenderer may be natural persons, companies or firms or public or semi-public agencies of Tanzania and foreign countries, subject to ITT sub-Clause 3.4 or any combination of them with a formal intent or letter of intent to enter into an agreement or under an existing agreement in the form of a joint venture, consortium, or association. In the case of a joint venture, consortium, or association, all members shall be jointly and severally liable for the execution of the Contract in accordance with the Contract terms. The joint venture, consortium, or association shall nominate a Lead Member who shall have the authority to conduct all business for and on behalf of any and all the members of the joint venture, consortium, or association during the tendering process and, in the event the joint venture, consortium, or association is awarded the Contract, during contract execution. Unless specified in the **Tender Data Sheet**, there is no limit on the number of members in a joint venture, consortium, or association.

3.2 The Lead Member shall at the time of contract award confirm the appointment by submission of a Power of Attorney to the Procuring Entity.

3.3 Any Tender from a joint venture, consortium or association

shall indicate the part of proposed contract to be performed by each party and each party shall be evaluated or post qualified with respect to its contribution only and the responsibilities of each party and shall not be substantially altered without prior written approval of the Procuring Entity.

3.4 The invitation for Tenders is open to all service providers as defined in the Public Procurement Regulations, 2013 – Government Notice No. 446, except as provided hereinafter.

3.5 National Tenderers shall satisfy all relevant licensing and/or registration requirements with the appropriate statutory bodies in Tanzania. Foreign Tenderers are exempted from this requirement but where selected as having submitted the lowest evaluated Tender the successful Tenderer shall register with the appropriate statutory body and shall be required to submit evidence of registration as an approved Manufacturer in Tanzania before signing the contract.

3.6 A Tender shall not have a conflict of interest. All Tenderers found to be in conflict of interest shall be disqualified. A Tenderer may be considered to have a conflict of interest with one or more parties in this Tendering process, if they:

a) Are associated or have been associated in the past, directly or indirectly with a firm or any of it's affiliates which have been engaged by the Procuring Entity to provide consulting services for the preparation of the specifications and other documents to be used for the procurement of the goods to be procured under this Invitation for Tenders.

b) have controlling shareholders in common; or

c) receive or have received any direct or indirect subsidy from any of them; or

d) have the same legal representative for purposes of this Tender; or

e) have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Tender of another Tenderer, or influence the decisions of the Procuring Entity regarding this Tendering process; or

f) submit more than one Tender in this Tendering process. However, this does not limit the participation of subcontractors in more than one Tender, or as Tenderers and subcontractors simultaneously; or

g) participated as a consultant in the preparation of the design or technical specifications of the services that are the subject of the Tender.

3.7 A Tenderer may be ineligible if –

(a) the Tenderer is declared bankrupt or, in the case of company or firm, insolvent;

(b) payments in favour of the Tenderer is suspended in accordance with the judgment of a court of law other than a judgment declaring bankruptcy and resulting, in accordance with the national laws, in the total or partial loss of the right to administer and dispose of its property;

(c) legal proceedings are instituted against such Tenderer involving an order suspending payments and which may result, in accordance with the national laws, in a declaration of bankruptcy or in any other situation entailing the total or partial loss of the right to administer and dispose of the property;

(d) the Tenderer is convicted, by a final judgment, of any offence involving professional conduct;

(e) the Tenderer is debarred and blacklisted in accordance with Section 62 of the Act or ineligible in accordance with section 84(7) of the Act, from participating in public procurement for corrupt, coercive, collusive, fraudulent or obstructive practices, failure to abide with a Tender Securing Declaration, breach of a procurement contract, making false representation about his qualifications during tender proceeding or other grounds as may be deemed necessary by the Authority company or firm is found guilty of serious misrepresentation with regard to information required for participation in an invitation to tender or to submit proposals.

3.8 Public or semi-public owned enterprises in the United Republic of Tanzania may participate only if they are legally and financially autonomous, if they operate under commercial law, and if they are not a dependent agency of the Government. And are registered by relevant registration board

3.9 Tenderers shall provide to the Procuring Entity evidence of their eligibility, proof of compliance with the necessary legal, technical and financial requirements and their capability and, adequacy of resources to carry out the contract effectively.

3.10 Tenderers shall provide such evidence of their continued eligibility satisfactory to the Procuring Entity, as the Procuring Entity shall reasonably request.

3.11 Tenderers shall submit proposals relating to the nature, conditions and modalities of sub-contracting wherever the sub-contracting of any elements of the contract amounting to the more than ten percent of the tender price is envisaged.

4. Eligible Goods and Related Services

4.1 All goods and related services to be supplied under the contract shall have their origin in eligible source countries, and all expenditures made under the contract will be limited to such goods and services. For the purpose of this Tender ineligible countries are stated in the **Tender Data Sheet.**

4.2 For the purposes of this Clause, the term "goods" includes commodities, raw materials, machinery, equipment and industrial plants, and "related services" includes services such as insurance, installation, training and initial maintenance.

4.3 For purposes of this Clause, "origin" means the place where the goods are mined, grown, cultivated, produced, manufactured, or processed, or through manufacture, procession, or assembly, another commercially recognized article results that differs substantially in its basic characteristics from its imported components or the place from which the related services are supplied.

4.4 The nationality of the firm that produces, assembles, distributes, or sells the goods and services shall not determine their origin.

4.5 To establish the eligibility of the supplies and the related services, Tenderers shall fill the country of origin declarations included in the form of Tender.

4.6 To establish the eligibility good and eligibility services the country of origin of declaration of the price schedule included in the forms of Tender.

5. One Tender per Tenderer

5.1 A firm shall submit only one Tender, in the same Tendering process, either individually as a Tenderer or as a partner in a joint venture.

5.2 No firm can be a subcontractor while submitting a Tender individually or as a partner of a joint venture in the same Tendering process.

5.3 A firm, if acting in the capacity of subcontractor in any Tender, may participate in more than one Tender but only in that capacity.

5.4 A Tenderer who submits or participates in more than one Tender (other than as a subcontractor or in cases of alternatives that have been permitted or requested) will cause all the proposals in which the Tenderer has participated to be disqualified.

6. Cost of Tendering

6.1 The Tenderer shall bear all costs associated with the preparation and submission of its Tender, and the Procuring Entity will in no case be responsible or liable for those costs, regardless of the conduct or outcome of the tendering process except as provided for under Section 97(5) (f) of the Public Procurement Act No. 7 of 2011.

B. Tendering Documents

7. Content of Tendering Documents

7.1 The goods required, Tendering procedures, and contract terms are prescribed in the Tendering Documents. In addition to the

Invitation for Tenders, the Tendering documents which should be read in conjunction with any addenda issued in accordance with ITT clause 9.2 include:

Section II. Instructions to Tenderers (ITT)
Section III. Tender Data Sheet (TDS)
Section IV. General Conditions of Contract (GCC)
Section V. Special Conditions of Contract (SCC)
Section VI. Schedule of Requirements
Section VII. Technical Specifications
Section VIII. Forms - Tender
- a) Form of Tender
- b) Letter of acceptance
- c) Form of Contract
- d) Price Schedules
- e) Form of qualification information

Section IX: Forms of Security
- f) Tender Security Form or Tender Securing Declaration
- g) Performance Security Form
- h) Bank Guarantee for Advance Payment Form

Section X : Integrity Undertaking by Tenderer on anti-bribery Policy

7.2 The number of copies to be completed and returned with the Tender is specified in the **Tender Data Sheet**

7.3 The Invitation for Tenders (Section I) issued by the Procuring Entity is not part of the Tendering Documents. In case of discrepancies between the Invitation for Tender and the Tendering Documents listed in sub-Clause 7.1 above, said Tendering Documents will take precedence.

7.4 The Procuring Entity is not responsible for the completeness of the Tendering Documents and their addenda, if they were not obtained directly from the Procuring Entity.

7.5 The Tenderer is expected to examine all instructions, forms, terms and specifications in the Tendering documents. Failure to furnish all information required by the Tendering Documents or to submit a Tender substantially responsive to the Tendering documents in every respect will be at the Tenderer's risk and may result in the rejection of its Tender.

8. Clarification of Tendering Documents

8.1 A prospective Tenderer requiring any clarification of the Tendering Documents shall contact the writing or in electronic forms that provide record of the content of communication at the Procuring Entity's address indicated in the **Tender Data Sheet.**

8.2 The Procuring Entity will within three (3) working days after receiving the request for clarification respond in writing or in electronic forms that provide record of the content of communication to any request for clarification provided that such request is received no later than fourteen (14) days prior to

the deadline for the submission of Tenders prescribed in sub-Clause 22.1 and in case of non competitive methods, three (3) days prior to the deadline for submission of Tenders.

8.3 Copies of the Procuring Entity's response shall be sent to all prospective Tenderers who have purchased the Tendering Documents, including a description of the inquiry but without identifying its source.

8.4 Should the Procuring Entity deem it necessary to amend the Tendering documents as a result of a clarification, it shall do so following the procedure under ITT Clause 9.

9. Amendment of Tendering Documents

9.1 Before the deadline for submission of Tenders, the Procuring Entity, for any reason, whether at its own initiative or in the response to clarification requested by a prospective Tenderer, may modify the Tendering Documents by issuing Addenda.

9.2 Any addendum issued including the notice of any extension of the deadline shall be part of the Tender documents pursuant to sub-Clause 7.1 and shall be communicated in writing or in electronic forms that provide record of the content of communication to tenderers to which the Procuring Entity provided the Tendering Documents.

9.3 In order to allow prospective Tenderers reasonable time in which to take an addendum into account in preparing their Tenders, the Procuring Entity shall extend, at its discretion, the deadline for submission of Tenders, pursuant to ITT sub-Clause 22.2.

C. Preparation of Tenders

10. Language of Tender

10.1 The Tender prepared by Tenderer, as well as all correspondence and documents relating to the Tender exchanged by the Tenderer and the Procuring Entity, shall be written in the language specified in the **Tender Data Sheet.** Supporting documents and printed literature furnished by the Tenderer may be in another language provided they are accompanied by an accurate translation of the relevant passages in the language specified in the Tender Data Sheet, in which case, for purposes of interpretation of the Tender, the translation shall govern.

11. Documents Constituting the Tender

11.1 The Tender prepared by the Tenderer shall constitute the following components:

a) Form of Tender and a Price Schedule completed in accordance with **ITT Clauses 14, 15, and 16**;

b) Form of Sample(s) as requested in the **Tender Data Sheet.**

c) Documentary evidence established in accordance with **ITT Clause 13** that the Tenderer is eligible to Tender and is qualified to perform the contract if its Tender is accepted;

d) Documentary evidence established in accordance with

sub-Clause 13.3(a) that the Tender has been authorized by the manufacturer to supply the goods into the SADC region, where required and where the Manufacturers is not the manufacturer of those goods;

e) Documentary evidence established in accordance with **ITT Clause 12** that the goods and ancillary services to be supplied by the Tenderer are eligible goods and services and conform to the Tendering Documents;

f) Tender security or Tender securing declaration furnished in accordance with **ITT Clause 18**;

g) Written Power of Attorney (in the format provided in Section VIII – Forms of Tender) authorizing the signatory of the Tender to commit the Tenderer, in accordance with ITT Clause 20.2;

h) Documentary evidence in accordance with ITT Clause 12 that the goods and related services conform to the Tendering Documents; and

i) Any other document required in the **Tender Data Sheet**.

11.2 Where a sample(s) is required by a procuring entity, the sample shall be:

(a) submitted as part of the tender, in the quantities, sizes and other details requested in the invitation to tender;

(b) carriage paid;

(c) received on, or before, the closing time and date for the submission of tenders; and

(d) evaluated to determine compliance with all characteristics listed in the **Tender Data Sheet**..

11.3 The Procuring Entity shall retain the sample of the successful tenderer. A Procuring Entity shall reject the tender if the sample-

(a) does not conform to all characteristics prescribed in the solicitation documents and

(b) are not submitted within the specified time.

11.4 Where it is not possible to avoid using a propriety article as a sample, a tenderer shall make it clear that the propriety article is displayed only as an example of the type or quality of the goods being tendered for and that competition shall not thereby be limited to that article only.

11.5 Samples made up from materials supplied by a procuring entity shall not be returned to a tenderer nor shall a Procuring Entity be liable for the cost of making them.

11.6 All samples produced from materials belonging to an unsuccessful tenderer which are not claimed by the tenderer

within a period of thirty (30) days from the date of award of contract shall be the property of the procuring entity and shall dispose them in such a manner as may be directed by the Accounting Officer.

12. Documents Establishing Eligibility of Goods and Related Services and Conformity to Tendering Documents

12.1 Pursuant to ITT Clause 11, the Tenderer shall furnish, as part of its Tender, documents establishing the eligibility of the Health Sector Goods and Related Services to be supplied under the Contract.

12.2 The documentary evidence of the eligibility of the goods and related services shall consist of a statement in the Price Schedule of the country of origin of the goods and services offered which shall be confirmed by a certificate of origin issued at the time of shipment.

12.3 The documentary evidence of conformity of the Goods and Related Services to the Tendering Documents may be in the form of literature, drawings, and data and shall consist of:

(a) a detailed description of the essential technical and performance characteristics of the Goods;

(b) an item-by-item commentary on the Procuring Entity's Technical Specifications demonstrating substantial responsiveness of the Goods and Related Services to those specifications, or a statement of deviations and exceptions to the provisions of the Technical Specifications;

(c) any other procurement specific documentation requirement as stated in the **Tender Data Sheet**.

12.4 Unless the **Tender Data Sheet** stipulates otherwise, the Goods to be supplied under the contract shall be registered with the relevant authority in the SADC Member states. A Tenderer who has already registered its Goods by the time of Tendering should submit a copy of the Registration Certificates, with its Tender. Otherwise, the successful Tenderer, by the time of contract signing, shall submit to the Procuring Entity either;

(a) A copy of the Registration Certificate of the Goods for use in the SADC region, OR if such Registration Certificate has not yet been obtained;

(b) Evidence establishing to the Procuring Entity's satisfactions that the Tenderer has complied with all the documentary requirements for registration as specified in the **Tender Data Sheet.**

12.4.1 The Procuring Entity shall at all times cooperate with the successful Tenderer to facilitate the registration process within the SADC Member states. The agency and contact person able to provide additional information about registration are identified in the **Tender Data Sheet.**

12.4.2 If the Goods of the successful Tender have not been registered in the SADC Member states at the time of contract signing, then the contract shall become effective upon such date as the certificate of Registration is obtained.

12.5 For purposes of the commentary to be furnished pursuant to ITT Clause 12.3 (b) above, the Tenderer shall note that standards as well as references to brand names designated by the Procuring Entity in its Technical Specifications are intended to be descriptive only and not restrictive. The Tenderer may substitute alternative standards, brand names, and/or catalogue numbers in its Tender, provided that it demonstrates to the Procuring Entity's satisfaction that the substitutions ensure substantial equivalence to those designated in the Technical Specifications.

12.6 The required documents and other accompanying documents must be typewritten in English. In case any other language than English is used the pertinent translation into English shall be attached to the original version to all manufacturers except those mentioned above.

13. Documents Establishing Eligibility and Qualifications of the Tenderer

13.1 Pursuant to ITT Clause 11, the Tenderer shall furnish, as part of its Tender, documents establishing the Tenderer's eligibility to Tender and its qualifications to perform the contract if its Tender is accepted

13.2 The documentary evidence of the Tenderer's eligibility to Tender shall establish to the Procuring Entity's satisfaction that the Tenderer, at the time of submission of its Tender, is from an eligible country as defined under **ITT Clause** 4.

13.3 The documentary evidence of the Tenderer's qualifications to perform the contract if its Tender is accepted shall establish to the Procuring Entity's satisfaction:

a) that, in the case of a Tenderer offering to supply goods under the contract which the Tenderer did not manufacture or otherwise produce, the Tenderer has been duly authorized by the goods' Manufacturer or producer to supply the goods in the SADC region;

b) the Tenderer has the financial, technical, and production capability necessary to perform the Contract, meets the qualification criteria specified in **Tender Data Sheet**;

c) that, in the case of a Tenderer not doing business within the SADC region, the Tenderer is or will be (if awarded the contract) represented by an Agent equipped, and able to carry out the Manufacturers's maintenance, repair, and spare parts-stocking obligations prescribed in the General Conditions of Contract and/or Technical Specifications; and

d) That the Tenderer meets the qualification criteria listed in

the **Tender Data Sheet.**

13.4 When Tendering for more than one Contract under the slice and package arrangements, the Tenderer must provide evidence that it meets or exceeds the sum of all the individual requirements for the slices or lots being applied for in regard to:-

a) average annual turnover;

b) particular experience including key production rates;

c) financial means, etc;

d) personnel capabilities; and

e) equipment capabilities.

In case the Tenderer fails to fully meet any of these criteria, it may be qualified only for those slices for which the Tenderer meets the above requirement.

14. Form of Tender

14.1 The Tenderer shall fill the Form of Tender furnished in the Tendering Documents. The Tender Form must be completed without any alterations to its format and no substitute shall be accepted.

15. Tender Prices

15.1 The Tender prices and discounts quoted by the Tenderer in the Tender Form and in the Price Schedules shall conform to the requirements specified below.

15.2 All items in the Schedule of Requirements must be listed and priced separately in the Price Schedules. If a Price Schedule shows items listed but not priced, the Tender will be rejected as being substantially non-responsive. Items not listed in the Price Schedule shall be assumed to be not included in the Tender and the Tender will be rejected as being substantially non-responsive.

15.3 The Tender price to be quoted in the Form of Tender in accordance with sub-Clause 15.1 shall be the total price of the Tender, excluding any discounts offered.

15.4 The Tenderer shall quote any unconditional discounts and the methodology for their application in the Tender Form in accordance with sub-Clause 15.9.

15.5 The Tenderer shall indicate on the appropriate Price Schedule the unit prices (where applicable) and total Tender price of the goods it proposes to supply under the contract

15.6 Prices indicated on the Price Schedule shall be entered separately in the following manner:

a) For goods manufactured from within the SADC Member states:

i) the price of the goods quoted EXW (ex works, ex factory, ex warehouse, ex showroom, or off-the-shelf, as applicable), including all customs duties and sales and other taxes already paid or payable:

A. on the components and raw material used in the manufacture or assembly of goods quoted ex works or ex factory;
or
B. on the previously imported goods of foreign origin quoted ex warehouse, ex showroom, or off-the-shelf.

ii) sales and other taxes which will be payable on the goods if the contract is awarded.

iii) the price for inland transportation, insurance, and other local costs incidental to delivery of the goods to their final destination, if specified in the **Tender Data Sheet.**

iv) the price of other (incidental) services, if any, listed in the Tender **Data Sheet**.

b) For goods offered from abroad, to be imported:

i) the price of the goods shall be quoted CIF named port of destination, or CIP border point, or CIP named place of destination, in the Procuring Entity's country, as specified in the **Tender Data Sheet**. In quoting the price, the Tenderer shall be free to use transportation through carriers registered in any eligible countries. Similarly, the Tenderer may obtain insurance services from any eligible source country.

ii) the price of the goods quoted FOB port of shipment (or FCA, as the case may be), if specified in the **Tender Data Sheet**.

iii) the price of goods quoted CIF and DDP port of destination (or CPT as the case may be), if specified in the **Tender Data Sheet.**

iv) the price for inland transportation, insurance, and other local costs incidental to delivery of the goods from the port of entry to their final destination, if specified in the **Tender Data Sheet**.

v) the price of (incidental) services, if any, listed in the **Tender Data Sheet**.

c) For Goods manufactured outside the SADC region, already imported:

(i) the price of the Goods, including the original import value of the Goods; plus any mark-up (or rebate); plus any other related local cost, and custom duties and other import taxes already paid or to be paid on the Goods already imported.

(ii) the custom duties and other import taxes already paid (need to be supported with documentary evidence) or to be paid on the Goods already imported;

(iii) the price of the Goods, obtained as the difference between (i) and (ii) above;

(iv) any Procuring Entity's Country sales and other taxes which will be payable on the Goods if the contract is awarded to the Bidder; and

(v) the price for inland transportation, insurance, and other local services required to convey the Goods from the named place of destination to their final

d) for Related Services, other than inland transportation and other services required to convey the Goods to their final destination, whenever such Related Services are specified in the Schedule of Requirements:

(i) the price of each item comprising the Related Services (inclusive of any applicable taxes).

15.7 Prices proposed on the Price Schedule for goods and related services shall be disaggregated, where appropriate as indicated in this sub-Clause. This desegregation shall be solely for the purpose of facilitation the comparison of Tenders by the Procuring Entity. This, shall not in any way limit the Procuring Entity's right to contract on any of the terms offered:-

a) **For Goods:-**

i) the price of the Goods, quoted DDP or other INCOTERMS as specified in the **Tender Data Sheet**

ii) ll customs duties, sales tax, value added tax, and other taxes applicable in the United goods or on the components and raw materials used in their manufacture or assembly, if the contract is awarded to the Tenderer, and

b) **For Related Services**

i) The price of the related services,

ii) All customs duties, sales tax value added tax, and

other taxes applicable in the SADC Member states, paid or payable, on the related services, if the contract is awarded to the Tenderer; and

iii) The total price for the item

15.8 Prices quoted by the Tenderer shall be fixed during the Tenderer's performance of the contract and not subject to variation on any account, unless otherwise specified in the **Tender Data Sheet**. A Tender submitted with an adjustable price quotation will be treated as non-responsive and shall be rejected, pursuant to ITT Clause 28. If, however, in accordance with the **Tender Data Sheet**, prices quoted by the Tenderer shall be subject to adjustment during the performance of the contract, a Tender submitted with a fixed price quotation will not be rejected, but the price adjustment would be treated as zero.

15.9 If so indicated in the **Tender Data Sheet** and Instructions to Tenderers, that Tenders are being invited for individual contracts (Lots) or for any combination of contracts (packages), Tenderers wishing to offer any price reduction for the award of more than one contract shall specify in their Tender the price reductions applicable to each package, or alternatively, to individual contracts within a package.

16. Tender Currencies

16.1 Prices shall be quoted in the following currencies:

a) For goods and services that the Tenderer will supply from within the SADC Member states, the prices shall be quoted in USD, unless otherwise specified in the **Tender Data Sheet.**

b) For goods and related services that the Tender will supply from outside the SADC region, or for imported parts or components of goods and related services originating outside the SADC region, the Tender prices shall be quoted in USD or EURO. If the Tenderer wishes to be paid in a combination of amounts in different currencies, it may quote its price accordingly but use no more than three foreign currencies

16.2 The rates of exchange to be used by the Tenderer in arriving at the local currency equivalent and the proportions mentioned in sub-Clause.16.1 above shall be the selling rates for similar transactions established by the authority specified in the **Tender Data Sheet** prevailing on the date 28 days prior to the latest deadline for submission of Tenders. These exchange rates shall apply for all payments so that no exchange risk will be borne by the Tenderer. If the Tenderer uses other rates of exchange, the provisions of sub-Clause 30.1 shall apply. In any case, payments will be computed

using the rates quoted in the Tender.

16.3 Tenderers shall indicate details of their expected foreign currency requirements in the Tender.

16.4 Tenderers may be required by the Procuring Entity to clarify their foreign currency requirements and to substantiate that the amounts included in Lump Sum and in the Special Conditions of Contract are reasonable and responsive to sub-Clause 16.1.

17. Tender Validity Period

17.1 Tenders shall remain valid for the period stipulated in the **Tender Data Sheet** after the date of Tender submission specified in ITT Clause 22. A Tender valid for a shorter period shall be rejected by the Procuring Entity as non-responsive.

17.2 In exceptional circumstances, prior to the expiration of the Tender validity period, the Procuring Entity may request that the Tenderer's consent to an extension of the period of validity of their Tenders. The request and the Tenderers responses shall be made in writing or in electronic forms that provide record of the content of communication. The Tender Security provided under ITT Clause 18 shall also be suitably extended. A Tenderer may refuse the request without forfeiting its Tender security or causing to be executed its Tender securing declaration. A Tenderer agreeing to the request will not be required nor permitted to modify its Tender, but will be required to extend the validity of its Tender security or Tender Securing declaration for the period of the extension, and in compliance with ITT Clause 18 in all respects.

17.3 In the case of fixed price contracts, if the award is delayed by a period exceeding sixty (60) days beyond the expiry of the initial Tender validity period, the contract price will be increased by a factor specified in the request for extension. The Tender evaluation shall be based on the Tender price without taking into consideration on the above correction.

18. Tender Security or Tender Securing Declaration

18.1 Pursuant to ITT Clause 11, unless otherwise specified in the **Tender Data Sheet**, the Tenderer shall furnish as part of its Tender, a Tender Security in original form and in the amount and currency specified in the **Tender Data Sheet** or Tender Securing Declaration as specified in the **Tender Data Sheet** in the format provided in Section IX.

18.2 The Tender security or Tender securing declaration is required to protect the Procuring Entity against the risk of Tenderer's conduct which would warrant the security's forfeiture, pursuant to sub-Clause 18.9.

18.3 The Tender Security shall be denominated in local currency or in a freely convertible currency, and shall be, at the Tenderer's option, in one of the following forms:

a) a bank guarantee, an irrevocable letter of credit issued by a reputable bank, or an insurance bond issued by a reputable insurance firm located in the SADC Member states or abroad, in the form provided in the Tendering Documents or another form acceptable to the Procuring Entity and valid for twenty eight (28) days beyond the end of the validity of the Tender. This shall also apply if the period for Tender validity is extended. In either case, the form must include the complete name of the Tenderer; or,

b) a cashier's or certified check; or

c) another security indicated in the **Tender Data Sheet**, from a reputable source from an eligible country.

18.4 The Tender security shall be in accordance with the Form of the Tender Security or Tender Security Declaration included in Section IX or another form approved by the Procuring Entity prior to the Tender submission

18.5 The Tender security shall be payable promptly upon written demand by the Procuring Entity in case any of the conditions listed in sub-Clause 18.9 are invoked.

18.6 Any Tender not accompanied by a Tender security or Declaration in accordance with sub-Clauses 18.1 and 18.3 shall be rejected by the Procuring Entity as non-responsive, pursuant to ITT Clause 28.

18.7 Unsuccessful Tenderers' Tender security will be discharged or returned as promptly as possible but not later than thirty (30) days after the expiration of the period of Tender validity prescribed by the Procuring Entity pursuant to ITT Clause 17.

18.8 The successful Tenderer's Tender security will be discharged upon the Tenderer signing the contract or pursuant to ITT Clause 41, and furnishing the performance security, pursuant to ITT Clause 42.

18.9 The Tender security may be forfeited or the Tender securing declaration executed:

a) if a Tenderer

i) withdraws its Tender during the period of Tender validity specified by the Tenderer on the Tender Form except as provided for in sub-Clause 17.2; or

ii) does not accept the correction of errors pursuant to sub-Clause 30.3; or

b) in the case of a successful Tenderer, if the Tenderer fails:

i) to sign the contract in accordance with ITT Clause 41; **or**

ii) to furnish performance security in accordance with ITT Clause 42.

18.10 The Tender security or the Tender Securing Declaration of a joint venture must be in the name of the joint venture submitting the Tender.

18.11 A Tenderer shall be suspended from being eligible for Tendering in any contract with the Procuring Entity for the period of time indicated in the Tender Securing Declaration:

(a) if the Tenderer withdraws its Tender, except as provided in sub-Clauses 17.2 and 30.2; or

(b) in the case of a successful Tenderer, if the Tenderer fails within the specified time limit to:

(i) sign the contract, or

(ii) furnish the required performance security

19. Alternative Tenders by Tenderers

19.1 Tenderers shall submit offers that comply with the requirements of the Tendering Documents, including the basic Tenderer's specification as indicated in the specifications and Schedule of Requirements. Alternatives will not be considered, unless specifically allowed for in the **Tender Data Sheet**. If so allowed, sub-Clause 19.2 shall prevail.

19.2 When alternative schedule for delivery of goods is explicitly invited, a statement of that effect will be included in the Tender Data Sheet as will the method for evaluating different schedule for delivery of goods.

19.3 If so allowed in the **Tender Data Sheet**, Tenderers wishing to offer technical alternatives to the requirements of the Tendering documents must also submit a Tender that complies with the requirements of the Tendering documents, including the basic technical design as indicated in the specifications. In addition to submitting the basic Tender, the Tenderer shall provide all information necessary for a complete evaluation of the alternative by the Procuring Entity, including technical specifications, breakdown of prices, and other relevant details. Only the technical alternatives, if any, of the lowest evaluated Tenderer conforming to the basic technical requirements shall be considered by the Procuring Entity.

20. Format and Signing of Tender

20.1 The Tenderer shall prepare an original and the number of copies/sets of the Tender indicated in the **Tender Data Sheet,** clearly marking each one as "ORIGINAL TENDER" and "COPY OF TENDER," as appropriate. In the event of any discrepancy between them, the original shall prevail.

20.2 The original and the copy or copies of the Tender shall be typed or written in indelible ink and shall be signed by the Tenderer or a person or persons duly authorized to sign on behalf of the Tenderer. This authorization shall consist of a written confirmation as specified in the **Tender Data Sheet** and shall be attached to the Tender. The name and position held by each person signing the authorization must be typed or printed below the signature. All pages of the Tender, except for un-amended printed literature, shall be initialed by the person or persons signing the Tender.

20.3 Any interlineations, erasures, or overwriting to correct errors made by the Tenderer should be initialed by the person or persons signing the Tender.

20.4 The Tenderer shall furnish information as described in the Form of Tender on commissions or gratuities, if any, paid or to be paid to agents relating to this Tender and to contract execution if the Tenderer is awarded the contract.

D. Submission of Tenders

21. Sealing and Marking of Tenders

21.1 The Tenderer shall seal the original and each copy of the Tender in separate envelopes, duly marking the envelopes as "ORIGINAL" and "COPY." The envelopes shall then be sealed in an outer envelope securely sealed in such a manner that opening and resealing cannot be achieved undetected.

21.2 The inner and outer envelopes shall:

a) be addressed to the Procuring Entity at the address given in the **Tender Data Sheet**; and

b) bear the Project name indicated in the **Tender Data Sheet**, the Invitation for Tenders (IFT) title and number indicated in the **Tender Data Sheet**, and a statement: "DO NOT OPEN BEFORE," to be completed with the time and the date specified in the **Tender Data Sheet**, pursuant to sub-Clause 22.1.

21.3 In addition to the identification required in sub-Clause 21.2, the inner envelopes shall also indicate the name and address of the Tenderer to enable the Tender to be returned unopened in case it is declared "late" pursuant to ITT Clause 22 and for matching purpose under ITT Clause 21.

21.4 If all envelopes are not sealed and marked as required by sub-Clause 21.2, the Procuring Entity will assume no responsibility for the misplacement or premature opening of Tender.

21.5 If the outer envelope discloses the Tenderer's identity, the Procuring Entity will not guarantee the anonymity of the Tender submission, but this shall not constitute grounds for rejection of the Tender.

22. Deadline for Submission of Tenders

22.1 Tenders shall be received by the Procuring Entity at the address specified under sub-Clause 21.2 no later than the date and time specified in the **Tender Data Sheet.**

22.2 The Procuring Entity may, in exceptional circumstances and at its discretion, extend the deadline for the submission of Tenders by amending the Tendering documents in accordance with ITT Clause 9, in which case all rights and obligations of the Procuring Entity and Tenderers previously subject to the deadline will thereafter be subject to the new deadline.

22.3 The extension of the deadline for submission of Tenders shall not be made later than the period specified in the **Tender Data Sheet** before the expiry of the original deadline.

23. Late Tenders

23.1 The Procuring Entity shall not consider for evaluation any Tender that arrives after the deadline for submission of Tenders, in accordance with ITT Clause 22.

23.2 Any Tender received by the Procuring Entity after the deadline for submission of Tenders shall be declared late, rejected and returned unopened to the Tenderer.

24. Modification, Substitution and Withdrawal of Tenders

24.1 A Tenderer may modify or substitute or withdraw its Tender after it has been submitted, provided that written notice of the modification, including modification, substitution or withdrawal of the Tender, is received by the Procuring Entity prior to the deadline for submission of Tenders.

24.2 The Tenderer's modification, substitution or withdrawal notice shall be prepared, sealed, marked, and dispatched in accordance with the provisions of ITT Clauses 20 and 21 with the outer and inner envelopes additionally marked "**MODIFICATION**" "**SUBSTITUTION**" or "**WITHDRAWAL"** as appropriate. The notice may also be sent by electronic mail, telex and facsimile but followed by a signed confirmation copy, postmarked not later than the deadline for submission of Tenders.

24.3 Tenders may only be modified by withdrawal of the original Tender and submission of a replacement Tender in accordance with sub-Clause 24.1. Modifications submitted in any other way shall not be taken into account in the evaluation of Tenders.

24.4 Tenderers may only offer discounts to or otherwise modify the prices of their Tenders by substituting Tender modifications in accordance with this Clause or included in the original Tender submission.

24.5 No Tender may be withdrawn, replaced or modified in the interval between the deadline for submission of Tenders and the expiration of the period of Tender validity specified by the Tenderer on the Form of Tender. Withdrawal of a Tender during this interval shall result in the Tenderer's forfeiture of its Tender security or execution of the Tender Securing Declaration,

pursuant to the sub-Clause 18.9.

E. Opening and Evaluation of Tenders

25. Opening of Tenders

25.1 The Procuring Entity will open all Tenders including modifications, substitutions or withdrawal notices made pursuant to ITT Clause 24, in public, in the presence of Tenderers' or their representatives who choose to attend, and other parties with a legitimate interest in the Tender proceedings at the place, on the date and at the time, specified in the **Tender Data Sheet**. The Tenderers' representatives present shall sign a register as proof of their attendance.

25.2 Envelopes marked "WITHDRAWAL" shall be opened and read out first. Tenders for which an acceptable notice of withdrawal has been submitted pursuant to ITT Clause 24 shall not be opened but returned to the Tenderer. If the withdrawal envelope does not contain a copy of the "Power of Attorney" confirming the signature as a person duly authorized to sign on behalf of the Tenderer, the corresponding Tender will be opened. Subsequently, all envelopes marked "MODIFICATION" shall be opened and the submissions therein read out in appropriate detail. Thereafter all envelopes marked "SUBSTITUTION" shall be opened and the submissions therein read out in appropriate detail.

25.3 All other envelopes shall be opened one at a time. The Tenderers' names, the Tender prices, the total amount of each Tender and of any alternative Tender (if alternatives have been requested or permitted), any discounts, the presence or absence of Tender security, Tender Securing Declaration and such other details as the appropriate Tender board may consider appropriate, will be announced by the secretary of the Tender Board or his delegate at the opening.

25.4 Tenders or modifications that are not opened and not read out at the Tender opening shall not be considered further for evaluation, irrespective of the circumstances. In particular, any discount offered by a Tenderer which is not read out at Tender opening shall not be considered further.

25.5 Tenderers are advised to send in a representative with the knowledge of the content of the Tender who shall verify the information read out from the submitted documents. Failure to send a representative or to point out any un-read information by the sent Tenderer's representative shall indemnify the Procuring Entity against any claim or failure to read out the correct information contained in the Tenderers Tender.

25.6 No Tender will be rejected at Tender opening except for late Tenders which will be returned unopened to the Tenderer, pursuant to ITT Clause 23.

25.7 The Procuring Entity shall prepare minutes of the Tender

opening. The record of the Tender opening shall include, as a minimum: the name of the Tenderer and whether or not there is a withdrawal, substitution or modification, the Tender price per Lot if applicable, including any discounts and alternative offers and the presence or absence of a Tender Security or Tender Securing Declaration.

25.8 The Tenderers' representatives who are present shall be requested to sign the record. The omission of a Tenderer's signature on the record shall not invalidate the contents and affect the record. A copy of the record shall be distributed to all the Tenderers.

25.9 A copy of the minutes of the Tender opening shall be furnished to individual Tenderers upon request.

26. Confidentiality

26.1 Information relating to the examination, clarification, evaluation and comparison of Tenders and recommendation of contract award shall not be disclosed to Tenderers or any other persons not officially concerned with such process until the award to the successful Tenderer has been announced.

26.2 Any effort by a Tenderer to influence the Procuring Entity processing of Tenders or award decisions may result in the rejection of its Tender.

26.3 Notwithstanding sub-Clause 26.2 from the time of Tender opening to the time of contract award, if any Tenderer wishes to contact the Procuring Entity on any matter related to the Tendering process, it should do so in writing or in electronic forms that provide record of the content of communication.

27. Clarification of Tenders

27.1 To assist in the examination, evaluation and comparison of Tenders and post-qualification of the Tenderers, the Procuring Entity may, at its discretion, ask any Tenderer for a clarification of its Tender including breakdown of prices. Any clarification submitted by a Tenderer that is not in response to a request by the Procuring Entity shall not be considered.

27.2 The request for clarification and the response shall be in writing or in electronic forms that provide record of the content of communication. No change in the prices or substance of the Tender shall be sought, offered, or permitted except to confirm the correction of arithmetic errors discovered by the Procuring Entity in the evaluation of Tenders in accordance with ITT Clause 30.

27.2 From the time of Tender opening to the time of Contract award if any Tenderer wishes to contact the Procuring Entity on any matter related to the Tender it should do so in writing or in electronic forms that provide record of the content of communication.

28. Preliminary Examination of Tenders

28.1 Prior to the detailed evaluation of Tenders, the Procuring Entity will determine whether each Tender:

a) meets the eligibility criteria defined in ITT Clause 3 and Clause 4;

b) has been properly signed;

c) is accompanied by the required securities; and

d) is substantially responsive to the requirements of the Tendering Documents.

The Procuring Entity's determination of a Tender's responsiveness will be based on the contents of the Tender itself.

28.2 A substantially responsive Tender is one which conforms to all the terms, conditions, and specifications of the Tendering Documents, without material deviation or reservation. A material deviation or reservation is one that:-

a) affects in any substantial way the scope, quality, or performance of the Services;

b) limits in any substantial way, inconsistent with the Tendering documents, the Procuring Entity's rights or the Tenderer's obligations under the Contract; or

c) if rectified, would affect unfairly the competitive position of other Tenderers presenting substantially responsive Tenders.

28.3 The Procuring Entity will confirm that the documents and information specified under ITT Clause 11, ITT Clause 12 and ITT Clause 13 have been provided in the Tender. If any of these documents or information is missing, or is not provided in accordance with the Instructions to Tenderers, the Tender shall be rejected.

28.4 The Procuring Entity may waive any minor informality, nonconformity, or irregularity in a Tender which does not constitute a material deviation, provided such waiver does not prejudice or affect the relative ranking of any Tenderer.

28.5 If a Tender is not substantially responsive, it will be rejected by the Procuring Entity and may not subsequently be made responsive by the Tenderer by correction of the nonconformity.

29. Examination of Terms and Condition; Technical Evaluation

29.1 The Procuring Entity shall examine the Tender to confirm that all terms and conditions specified in the General Conditions of Contract and the Special Conditions of Contract have been accepted by the Tenderer without any material deviation or reservation.

29.2 The Procuring Entity shall evaluate the technical aspects of the Tender submitted in accordance with ITT Clause 12, to confirm that all requirements specified in Section VI – Schedule of Requirements of the Tendering Documents and Section VII – Technical Specifications have been met without material deviation or reservation.

29.3 If after the examination of the terms and conditions and the technical evaluation, the Procuring Entity determines that the

Tender is not substantially responsive in accordance with ITT Clause 28, it shall reject the Tender.

30. Correction of Errors

30.1 Tenders determined to be substantially responsive will be checked for any arithmetic errors. Errors will be corrected as follows:-

a) if there is a discrepancy between unit prices and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail, and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which the total price as quoted shall govern and the unit price shall be corrected;

b) if there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and

c) where there is a discrepancy between the amounts in figures and in words, the amount in words will govern.

30.2 The amount stated in the Tender will, be adjusted by the Procuring Entity in accordance with the above procedure for the correction of errors and, with, the concurrence of the Tenderer, shall be considered as binding upon the Tenderer. If the Tenderer does not accept the corrected amount, its Tender will then be rejected, and the Tender security may be forfeited or the Tender securing declaration may be executed in accordance with sub-Clause 18.9.

31. Conversion to Single Currency

31.1 To facilitate evaluation and comparison, the Procuring Entity will convert all Tender prices expressed in the amounts in various currencies in which the Tender prices are payable to either:

a) in Tanzania Shillings at the selling exchange rate established for similar transactions by the Bank of Tanzania or a commercial bank in the United Republic of Tanzania;

OR

b) a currency widely used in international trade, such as U.S. Dollars, at the selling rate of exchange published in the international press for the amount payable in foreign currency; and at the selling exchange rate established for similar transactions by the Bank of Tanzania in the United Republic of Tanzania for the amount payable in Tanzania Shillings.

31.2 The currency selected for converting Tender prices to a common base for the purpose of evaluation, along with the source and date of the exchange rate, are specified in the **Tender Data Sheet**.

32. Commercial Evaluation of Tenders

32.1 The Procuring Entity shall evaluate and compare only the Tenders determined to be substantially responsive, pursuant to ITT Clause 28.

32.2 The Procuring Entity's evaluation of a Tender will exclude and not take into account:

(a) in the case of Goods manufactured in the SADC Member states or Goods of foreign origin already located in the SADC Member states, sales and other similar taxes, that will be payable on the Goods if a contract is awarded to the Tenderer;

(b) in the case of Goods of foreign origin offered from if abroad, customs duties and other similar import taxes that will be payable on the Goods if the contract is awarded to the Tenderer; and

(c) any allowance for price adjustment during the period of execution of the Contract, if provided in the Tender.

32.3 The comparison shall be between the EXW price of the goods offered from within the region, such price to include all costs, as well as duties and taxes paid or payable on components and raw material incorporated or to be incorporated in the goods, and the CIF named port of destination (or CIP border point, or CIP named place of destination) price of the goods offered from outside the region.

32.4 The Procuring Entity's evaluation of a Tender will take into account, in addition to the Tender price quoted in accordance with ITT sub-Clause 15.2, one or more of the following factors as specified in the **TDS**, and quantified in ITT sub-Clause 31.5:

(a) subject to ITT sub-Clause 15.2 (a) (iii) or 16.2 (b) (iv) the cost of inland transportation, insurance, and other costs within the SADC region incidental to delivery of the Goods to their final destination;

(b) delivery schedule offered in the Tender; (c) deviations in payment schedule from that specified in the Special Conditions of Contract;

(c) other specific criteria indicated in the **Tender Data Sheet** and/or in the Technical Specifications.

32.5 For factors retained in the **Tender Data Sheet** pursuant to ITT sub-Clause 31.4, one or more of the following quantification methods will be applied, as detailed in the **Tender Data Sheet:**

(a) *Inland transportation from EXW/port of entry/border point, insurance, and incidentals*.

Inland transportation, insurance, and other incidental costs for delivery of the Health Sector Goods from EXW/port of

entry/border point to the site named in the **Tender Data Sheet** will be computed for each Tender by the Procuring Entity on the basis of published tariffs by the rail or road transport agencies, insurance companies, and/or other appropriate sources. To facilitate such computation, Tenderer shall furnish in its Tender the estimated dimensions and shipping weight and the approximate EXW/CIF (or CIP border point) value of each package. The above cost will be added by the Procuring Entity to EXW/CIF/CIP border point price.

(b) Delivery schedule.

i) The Procuring Entity requires that the Health Sector Goods under these Tendering Documents shall be delivered (shipped) at the time specified in the Schedule of Requirements. The estimated time of arrival of the Health Sector Goods at the site will be calculated for each Tender after allowing for reasonable international and inland transportation time. A delivery "adjustment" will be calculated for and added to each Tender by applying a percentage, specified in the **Tender Data Sheet,** of the EXW/CIF/CIP price for each week of delay beyond the expected time of arrival specified in the Tendering Documents for evaluation purposes. No credit shall be given to early delivery.

Or

ii) The Health Sector Goods covered under these Tendering Documents are required to be delivered (shipped) within an acceptable range of weeks specified in the Schedule of Requirements. No credit will be given to earlier deliveries, and Tenders offering delivery beyond this range will be treated as non-responsive. Within this acceptable range, an adjustment per week, as specified in the **Tender Data Sheet,** will be added for evaluation to the Tender price of Tenders offering deliveries later than the earliest delivery period specified in the Schedule of Requirements.

Or

iii) The Health Sector Goods covered under this invitation are required to be delivered (shipped) in partial shipments, as specified in the Schedule of Requirements. Tenders offering deliveries earlier or later than the specified deliveries will be adjusted in the evaluation by adding to the Tender price a factor equal to a percentage, specified in the **Tender Data Sheet,** of EXW/CIF/CIP price per week of variation from the specified delivery schedule.

(c) Deviation in payment schedule.

i) Tenderers shall state their Tender price for the payment schedule outlined in the SCC. -Tenders will be evaluated on the basis of this base price. Tenderers are, however, permitted to state an alternative payment schedule and indicate the reduction in Tender price they wish to offer for such alternative payment schedule. The Procuring Entity may consider the alternative payment schedule offered by the selected Tenderer.

or

ii) The SCC stipulates the payment schedule offered by the Procuring Entity. If a Tender deviates from the schedule and if such deviation is permitted in the **Tender Data Sheet**, the Tender will be evaluated by calculating interest earned for any earlier payments involved in the terms outlined in the Tender as compared with those stipulated in this invitation, at the rate per annum specified in the **Tender Data Sheet**.

(d) Other specific additional criteria to be considered in the evaluation and the evaluation method shall be detailed in the **Tender Data Sheet** and/or in the Technical Specifications.

32.6 If these Tendering documents allow Tenderers to quote separate prices for different Lots, and the award to a single Tenderer of multiple Lots, the methodology of evaluation to determine the lowest evaluated Lot combinations, including any discounts offered in the Tender Form, is specified in the **Tender Data Sheet.**

33. National Preference

33.1 If the **Tender Data Sheet** so specifies, the Procuring Entity will grant a margin of preference to goods manufactured in the SADC Member states for the purpose of Tender comparison, in accordance with the procedures outlined in subsequent paragraphs, provided the Tenderer shall have established to the satisfaction of the Procuring Entity that its Tender complies with the criteria specified in sub-Clause 14.2.

33.2 The Procuring Entity will first review the Tenders to confirm the appropriateness of, and to modify as necessary, the Tender group classification to which Tenderers assigned their Tenders in preparing their Tender Forms and Price Schedules, pursuant to ITT Clauses 14 and 15.

33.3 For the purpose of granting a margin of domestic preference, Tenders will be classified in one of three groups, as follows:

a) Group A: Tenders offering goods manufactured, grown, mined or extracted within the Member states, for which:

(i) labour, raw materials, and components from the Member

states' account for more than thirty (30) percent of the EXW price of the goods offered; and

(ii) the production facility in which they will be manufactured, assembled or processed has been engaged in manufacturing, assembling or processing such goods at least since the time of Tender submission.

b) **Group B:** All other Tenders offering goods from within the region.

c) **Group C:** Tenders offering goods from overseas which are to be directly imported.

33.4 All evaluated Tenders in each group will then be compared among themselves to determine the lowest evaluated Tender of each group. The lowest evaluated Tender of each group will next be compared with the lowest evaluated Tenders of the other groups. If this comparison results in a Tender from Group A or Group B being the lowest, it will be selected for contract award.

33.5 If, as a result of the preceding comparison, the lowest evaluated Tender is from Group C, all Group C Tenders will then be further compared with the lowest evaluated Tender from Group A, after adding to the evaluated Tender price of the imported goods offered in each Group C Tender, for the purpose of this further comparison only:

a) the amount of customs duties and other import taxes that a non-exempt importer would have to pay for the importation of goods offered in each Group C Tender;

or

b) fifteen (15) percent of the CIF (or CIP border point or CIP named place of destination, as the case may be) Tender price of such goods, if the customs duties and taxes exceed fifteen (15) percent of the CIF (or CIP border point or CIP place of destination) price of such goods.

33.6 If the Group A Tender in the further comparison is the lowest, it will be selected for award. If not, the lowest evaluated Tender from Group C, as determined from the comparison under sub-Clause 32.3 above, will be selected for award.

34. Determination of Lowest Evaluated Tender

34.1 The Tender with the lowest evaluated price, from among those which are eligible, compliant and substantially responsive shall be the lowest evaluated Tender.

35. Post-qualification of Tenderer

35.1 After determining the lowest-evaluated tender, the Procuring Entity shall carry out the post-qualification of the Tenderer using only the requirements specified in the **Tender Data Sheet**.

35.2 Where the tender price of the lowest evaluate tenderer is considered to be abnormally low, the Procuring Entity shall perform price analysis as part of the post-qualification. The following process shall apply:

(a) The Procuring Entity may reject a tender if the Procuring Entity has determined that the price in combination with other constituent elements of the tender is abnormally low in relation to the subject matter of the procurement (scope of works or services) and raise concerns with the Procuring Entity as to the ability of the tenderer that presented that tender to perform the contract.

(b) Before rejecting an abnormally low tender the procuring entity shall: request the tenderer an explanation of the tender or of those parts which it considers contribute to the tender being abnormally low; take account of the evidence provided in response to a request in writing; and subsequently verify the tender or parts of the tender being abnormal

(c) The decision of the Procuring Entity to reject a tender and reasons for the decision shall be recorded in the procurement proceedings and promptly communicated to the tenderer concerned;

(d) The Accounting Officer (Procuring Entity) shall seek the approval of the Authority prior to rejecting a tender;

(e) Neither the Authority nor the Procuring Entity shall incur liability solely by rejecting abnormally tender; and

An abnormally low tender means, in the light of the Procuring Entity's estimate and of all the tenders submitted, the tender appears to be abnormally low by not providing a margin for normal levels of profit.

35.3 The Procuring Entity will determine to its satisfaction whether the Tenderer that is selected as having submitted the lowest evaluated responsive Tender is qualified to perform the contract satisfactorily, in accordance with the criteria listed in sub-Clause 13.3.

35.4 The determination will take into account the Tenderer's financial, technical, and production capabilities. It will be based upon an examination of the documentary evidence of the Tenderer's qualifications submitted by the Tenderer, pursuant to sub-Clause 13.3, as well as such other information as the Procuring Entity deems necessary and appropriate. Factors not included in these Tendering Documents shall not be used in the evaluation of the Tenderers' qualifications.

35.5 A Procuring Entity may seek independent references of a tenderer and the results of reference checks may be used in determining award of contract.

35.6 In case of a foreign company, a Procuring Entity shall seek independent reference of legal existence of a tenderer from

Tanzania diplomatic missions abroad or from any other reliable source.

35.7 An affirmative determination will be a prerequisite for award of the contract to the Tenderer. A negative determination will result in rejection of the Tenderer's Tender, in which event the Procuring Entity will proceed to the next lowest evaluated Tender to make a similar determination of that Tenderer's capabilities to perform satisfactorily.

F. Award of Contract

36. Criteria of Award

36.1 Subject to ITT Clause 35 and negotiations clause, the Procuring Entity will award the Contract to the Tenderer whose Tender has been determined to be substantially responsive to the Tendering Documents and who has offered the lowest Evaluated Tender Price, provided that such Tenderer has been determined to be:

a) eligible in accordance with the provisions of ITT Clause 3;
b) is determined to be qualified to perform the Contract satisfactorily; and
c) successful negotiations have been concluded, if any.

36.2 If, pursuant to sub-Clause 13.4, this Contract is being let on a slice and package" basis, the lowest evaluated Tender Price will be determined when evaluating this Contract in conjunction with other Contracts to be awarded concurrently, taking into account any discounts offered by the Tenderers for award of more than one Contract.

37. Negotiations

37.1 Negotiations may be undertaken with the lowest evaluated Tender relating to the following areas:

(a) a minor alteration to the technical details of the statement of requirements;

(b) reduction of quantities for budgetary reasons, where the reduction is in excess of any provided for in the solicitation documents;

(c) a minor amendment to the special conditions of Contract;

(d) finalizing payment arrangements;

(e) delivery arrangements;

(f) the methodology; or

(g) clarifying details that were not apparent or could not be finalized at the time of Tendering.

37.2 Where single source method was used or a competitive procurement method was used but only a single tender was received, negotiations may relate to other areas of the tender including the price tendered provided that the negotiation shall not increase price or affect the quality of the Goods.

37.3 Where negotiation fails to result into an agreement, the Procuring Entity may invite the next ranked Tenderer for negotiations.

Where negotiations are commenced with the next ranked Tenderer, the Procuring Entity shall not reopen earlier negotiations.

38. Procuring Entity's Right to Accept any Tender and to Reject any or All Tenders

38.1 Notwithstanding ITT Clause 37, the Procuring Entity reserves the right to accept or reject any Tender, and to annul the Tendering process and reject all Tenders at any time prior to contract award, without thereby incurring any liability to the affected Tenderer or Tenderers.

38.2 Notice of the rejection of all Tenders shall be given promptly to all Manufacturers that have submitted Tenders.

38.3 The Procuring Entity shall upon request communicate to any Tenderer the grounds for its rejection of its Tenders, but is not required to justify those grounds.

39. Procuring Entity's Right to Vary Quantities at the Time of Award

39.1 The Procuring Entity reserves the right at the time of contract award to increase or decrease the quantity of goods or related services originally specified in these Tendering documents (schedule of requirements) provided this does not exceed by the percentage indicated in the **Tender Data Sheet**, without any change in unit price or other terms and conditions of the Tender and Tendering Documents.

40. Notification of Award

40.1 Prior to awarding of the contract, the Procuring Entity shall issue a notice of intention to award the contract to all tenderers who participated in the tender in question giving them fourteen (14) days within which to submit complaints to the Procuring Entity thereof, if any.

40.2 Where no complaints have been lodged, the Tenderer whose Tender has been accepted will be notified of the award by the Procuring Entity prior to expiration of the Tender validity period in writing or electronic forms that provide record of the content of communication. The Letter of Acceptance will state the sum that the Procuring Entity will pay the successful tenderer in consideration for the execution of the scope of works as prescribed by the Contract (hereinafter and in the Contract called the "Contract Price).

40.3 The notification of award will constitute the formation of the Contract, subject to the Tenderer furnishing the Performance Security in accordance with ITT Clause 38.

40.4 Upon the successful Tenderer's furnishing of the performance security pursuant to ITT Clause 42, the Procuring Entity will promptly notify each unsuccessful Tenderer, the name of the successful Tenderer and the Contract amount and will discharge the Tender Security or Tender Securing Declaration of the Tenderers pursuant to sub-Clause 18.7

40.5 If, after notification of award, a tenderer wishes to ascertain the grounds on which it's Tender was not selected, it should address its request to the Procuring Entity. The Procuring Entity shall

promptly respond in writing or electronic forms that provide record of the content of communication to the unsuccessful Tenderer citing grounds for rejection of its Tender without disclosing information about other Tenderers.

41. Signing of Contract

41.1 Promptly after notification, Procuring Entity shall send the successful Tenderer the agreement and Special Conditions of Contract, incorporating all agreements between the parties obtained as a result of Contract negotiations.

41.2 Within twenty eight **(28)** days of receipt of the Contract Form, the successful Tenderer shall sign and date the contract and return it to the Procuring Entity.

42. Performance Security

42.1 Within twenty eight (28) days after receipt of the Letter of Acceptance, the successful Tenderer shall deliver to the Procuring Entity a Performance Security in the amount and in the form stipulated in the **Tender Data Sheet and the Special Conditions of Contract**, denominated in the type and proportions of currencies in the Letter of Acceptance and in accordance with the Conditions of Contract.

42.2 If the Performance Security is provided by the successful Tenderer, it shall be in any of the following forms:

(a) cash, certified cheque, cashier's or manager's cheque, or bank draft;
(b) irrevocable letter of credit issued by a reputable commercial bank or in the case of an irrevocable letter of credit issued by a foreign bank, the letter shall be confirmed or authenticated by a reputable local bank;
(c) bank guarantee confirmed by a reputable local bank or, in the case of a successful foreign tenderer, bonded by a foreign bank; or
(d) surety bond callable upon demand issued by any reputable surety or insurance company.

Any Performance Security submitted shall be enforceable in the United Republic of Tanzania.

42.3 Failure of the successful Tenderer to comply with the requirement of sub-Clause 42.1 shall constitute sufficient grounds for the annulment of the award and forfeiture of the Tender security, in which event the Procuring Entity may make the award to the next lowest evaluated Tenderer or call for new Tenders.

43. Advance Payment

43.1 The Procuring Entity will provide an Advance Payment on the Contract Price as stipulated in the General Conditions of Contract, subject to a maximum amount, as stated in the **Tender Data Sheet**.

43.2 The Advance Payment request shall be accompanied by an Advance Payment Security (Guarantee) in the form provided in Section IX. For the purpose of receiving the Advance Payment,

the Tenderer shall make and estimate of, and include in its tender, the expenses that will be incurred in order to commence Delivery of Goods. These expenses will relate to the purchase of equipment, machinery, materials, and on the engagement of labour during the first month beginning with the date of the Procuring Entity's "Notice to Commence" as specified in the Special Conditions of Contract.

44. Adjudicator

44.1 The Procuring Entity proposes the person named in the **Tender Data Sheet** to be appointed as Adjudicator under the Contract, at an hourly fee specified in the **Tender Data Sheet**, plus reimbursable expenses. If the Tenderer disagrees with this proposal, the Tenderer should so state in the Tender. If, in the Letter of Acceptance, the Procuring Entity has not agreed on the appointment of the Adjudicator, the Adjudicator shall be appointed by the Appointing Authority designated in the Special Conditions of Contract at the request of either party.

45. Fraudulent, Corrupt, Coercive, Collusive or Obstructive Practices

45.1 The Government requires that Procuring entities (including beneficiaries of Government funded projects and procurement) as well as Tenderers/Manufacturers/Contractors under Government financed contracts, observe the highest standard of ethics during the procurement and execution of such contracts. In pursuance of this policy, the Government.

a) defines, for the purpose of this provision, the terms set forth below as follows: -

i) "corrupt practice means the offering, giving receiving or soliciting of anything of value to influence the action of a public officer in the procurement process or contract execution;

ii) "coercive practice" means impairing or harming, or threatening to impair or harm directly or indirectly, any party or the property of the party for the purpose of influencing improperly the action or that party in connection with public procurement or in furtherance of corrupt practice or fraudulent practice;

iii) collusive practices" means impairing or harming, or threatening to impair or harm directly or indirectly, any part or the property of the Party for the purpose of influencing improperly the action or a part or in connection with public procurement or government contracting or in furtherance of a corrupt practice or a Fraudulent Practice;

iv) "fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Government or a public body and includes collusive practices among tenderers, prior to or after submission designed to establish tender prices at artificial non-competitive levels and to deprive the Government of

the benefits of free and open competition;

v) "obstructive practice" means acts intended to materially impede access to required information in exercising a duty under this Act.

b) Will reject a proposal for award if it determines that the Tenderer recommended for award has engaged in corrupt, fraudulent, coercive, collusive and obstructive practices in competing for the contract;

c) In pursuit of the policy defined in sub-Clause 45.1 the Government will cancel the portion of the funds allocated to a contract for goods, works, or services if it at any time determines that corrupt, fraudulent, coercive, collusive and obstructive practices were engaged in by representatives of the Procuring Entity or approving authority or of a beneficiary of the funds furring the procurement or the execution of that contract, without the Procuring Entity or approving authority having taken timely and appropriate action satisfactory to the Government of the united Republic of Tanzania to remedy the situation

d) Will declare a firm ineligible for a period of ten years, to be awarded a public-financed contract if it at any time it determines that the firm has engaged in corrupt or fraudulent practices in competing for, or in executing, a public – financed contract

45.2 The Government of the United Republic of Tanzania reserves the right, where a firm has been found by a foreign country, international organization or other foreign organization to have engaged in corrupt, coercive, collusive, fraudulent or obstructive practices, to declare that such a firm is ineligible, for a period of ten years to be awarded a public financed Contract in the region

45.3 Any communications between the Tenderer and the Procuring Entity related to matters of alleged corrupt, coercive, collusive, fraudulent or obstructive practices must be made in writing or in electronic forms that provide record of the content of communication.

G. Review of Procurement Decisions

46. Right to Review

46.1 A Tenderer who claims to have suffered or that may suffer any loss or injury as a result of breach of a duty imposed on a procuring entity by the Act or these Regulations may seek a review in accordance with Procurement Regulation 104.

47. Time Limit on Review

47.1 The Tenderer shall submit an application for review within twenty eight (28) working days of him becoming or should have become aware of the circumstances giving rise to the complaint or dispute.

48. Submission of Applications for Review

48.1 Any application for administrative review shall be submitted in writing or electronic forms that provide record of the content of communication to the Accounting Officer of a Procuring Entity and a copy shall be served to the Public Procurement Regulatory Authority (PPRA) at the address shown in the **Tender Data Sheet**.

48.2 The application for administrative review shall include:

a) details of the procurement requirements to which the complaint relates;

b) details of the provisions of the Act, Regulation or provision that has been breached or omitted;

c) an explanation of how the provisions of the Act, Regulation or provision has been breached or omitted, including the dates and name of the responsible public officer, where known;

d) documentary or other evidence supporting the complaint where available;

e) Remedies sought; and

f) any other information relevant to the complaint.

48.3 The head of a procuring entity shall not entertain a complaint or dispute or continue to do so after the procurement contract has entered into force.

49. Decision by the Head of Procuring Entity

49.1 The head of a Procuring Entity shall, within seven (7) working days after receipt of the complaint or dispute, deliver a written decision which shall indicate:

a) whether the application is upheld in whole, in part or rejected;

b) the reasons for the decision; and

c) any corrective measures to be taken;

49.2 Where the head of a Procuring Entity does not issue a decision within the time specified in sub-Clause 49.1, the Tenderer submitting the complaint or dispute or the Procuring Entity shall be entitled immediately thereafter to institute proceedings under sub-Clause 50.1 within seven (7) working days after such specified time and upon instituting such proceedings, the competence of the head of a Procuring Entity to entertain the complaint or dispute shall cease.

50. Review by the Public Procurement Appeals Authority

50.1 Complaints or disputes which-

a) are not settled within the specified period under Sub-Clause 49.1 [above];

b) are not amicably settled by the accounting officer;

c) arise after the procurement contract has entered into force, shall be referred to the Appeals Authority within seven (7) working days from the date when the tenderer received the decision of the accounting officer or;

d) in case no decision is issued after the expiry of the time stipulated under Sub-Clause 49.2 [above] or when the tender become aware or ought to have become aware of the circumstances giving rise to the complaint or dispute; arise out of provision of Section 62(6) of the Act.

50.2 PPAA may be contacted at the address shown in the Tender Data Sheet.

SECTION III: TENDER DATA SHEET

Tender Data Sheet

The following specific data shall complement, supplement, or amend the provisions in the Instructions to Tenderers (ITT). Whenever there is a conflict, the provisions in the Tender Data Sheet (TDS) shall prevail over those in the ITT.

TDS Clause	ITT Clause	Amendments of, and Supplement to, Clauses in the Instruction to Tenderers
		A. Introduction
1.	**ITT 1.1**	Name of Procuring Entity: **MEDICAL STORES DEPARTMENT** The subject of procurement is: **Supply of Pharmaceuticals and Medical supplies from Manufacturers to SADC Member states** (Angola, Botswana, Comoros, Democratic Republic of Congo (DRC), Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland, Tanzania, Zambia and Zimbabwe) **under Framework Agreement** Period for supply of goods: **Two Years** Commencement date for supply of Goods: 8 to 12 Weeks after LC opening. **This is an Open Framework Tender whereas the unit price and pack size shall appear in the resultant framework agreement(s). Note that the demand requirements established in this framework shall be lump sum requirements from Member states as determinant factor for pricing.** **Call off orders shall be raised and issued when need arises depending on the demand requirements established from SADC member states.**
2.	**1.2**	Completion date of this framework contract: **Two years from the date of contract signing**
3.	**2.1 & 2.2**	Financial year for the operations of the Procuring Entity: 2019/2020 and 2020/2021 Name of Project: **Supply of Pharmaceuticals and Medical supplies from Manufacturers to SADC Member states Under Framework Agreement** Name of financing institution: **Medical Stores Department.** Name and identification number of the Contract: **Tender No. IE-009/2018/2019/HQ/G/101 For The Supply of Pharmaceuticals and Medical supplies from Manufacturers to SADC Member states under Framework Agreement**
4.	**3.1**	Joint venture, consortium or association: N/A
5.	**4.1**	Ineligible country(s) is or are: **those as per current United Nations Embargo**

B. Tendering Documents

5.	**7.2**	**The number of copies to be completed and returned:** The number of copies to be returned: Two hard copies [2] One original and one copy, and one soft copy of the price schedule (**in excel format**) properly filled in the format provided. The completed soft copy should be submitted in a USB flash drive provided by the Manufacturers. The Manufacturers should also print the completed price schedule in Legal size (8.5" X 14") paper and submit with the bid package.
6.	**8.1**	The address for clarification of tendering documents is: **The secretary,** **Medical Stores Department Tender Board** **Medical Stores Department** **Off Nyerere Road, Keko Mwanga** **P.O.Box 9081,Dar es Salaam,Tanzania.** **Tel: (255-022) 2860890/7** **Fax: (255-022) 2865814/9** **E-mail: info@msd.go.tz** **website: www.msd.go.tz**
	8.2	Period to respond to clarifications is **3 working Days** Deadline for submission of clarifications is **14 working days before tender opening date.**

C. Preparation of Tenderers

7.	**ITT 10.1**	The language of all correspondence and documents related to the Tenderer is: **English** **Moreover, the key passages of all accompanying printed literature in any other language must be translated into English.** **Note: Other languages without translation in any documents will not accepted**
8.	**ITT 11.1(b) & 11.2(d)**	Form sample(s) to be submitted with the Tender are: **N/A**
9.	**ITT 11.1 (i)**	**Bidder must submit:** a) Anti-bribery policy/Code of conduct compliance program as per tender document provided in section X. b) Original power of Attorney certified by the lawyer and specific for this tender, authorizing the signatory of the tender to commit the bidder

		c) Copy of receipt for the tender fee issued by Medical Stores Department. d) Copy of Valid Manufacturing license e) Copies of registration certificates of registered products for human medicines for products tendered issued by the Member states National Drugs Regulatory Authority f) Litigation certificate/statement g) Proof of Indemnity insurance cover h) Certified Audited financial statements for the last three years 2015/16, 2016/2017, 2017/2018 i) Three (3) previous performed contracts and addresses of employers for verification
10.	**ITT 12.3 (c)**	**Other procurement specific documentation requirements are:** Certified Copy of registration certificate of product tendered from National Regulatory Authority (NRA) in the country of manufacture to supply the goods. Bids must contain copies of documentary evidence to prove that the Pharmaceuticals and Medical supplies tendered are manufactured according to GMP (Good manufacturing practice). Bidders shall be required to indicate batch size or lot size for each item quoted including the number of units /pack size per batch.
11.	**ITT 12.4(b)**	By the time of Contract signing, the successful Tenderer shall have complied with the following documentary requirements in order to register the Goods to be supplied under the Contract: **The tenderer must submit a letter from Member states' National Drugs Regulatory Authority confirming that the evaluation of the product has been completed and has been granted with registration/market authorization.** **Note**: Because of the potential for delay when various government agencies from the Member states must intervene in the registration process, Tenderers are alerted to inquire about registration requirements and procedures as early as possible from Member states.
12.	**ITT 12.4.1**	For the purpose of obtaining additional information about the requirements for registration, Tenderers may contact each respective Member states **National Regulatory Authority** where products are required to be registered.
13.	**ITT 13.3 (b)&(d)**	Qualification requirements for Tenderers are: - The qualification criteria required from Tenderers in ITT Clause 13.3(b) is modified as follows: The Bidder shall furnish copies of all certificates and documents issued by the proper National Regulatory Authorities (NRA), that the Manufacturer of the pharmaceuticals and Medical supplies proposed is authorized to manufacture and sell these products. Other requirements are: All tertiary, primary and secondary packaging shall have TZ-SADC printed

		as specified in Section VI. (Schedule of Requirements) **The following documents must be included with the Tenderer:** *Documentary evidence of the Tenderer's qualifications to perform the Contract if its Tenderer is accepted:* *i) that, in the case of a Tenderer offering to supply Goods under the Contract that the Tenderer manufactures or otherwise produces (using ingredients supplied by primary manufacturers) that the Tenderer:* *a) is incorporated in the country of manufacture of the Goods;* *b) has been licensed by the regulatory authority in the country of manufacture to supply the Goods;* *c) has manufactured and marketed the specific goods covered by this Tendering Document, for at least two (2) years, and for similar Goods for at least three (3) years;* *d) has received a satisfactory GMP inspection certificate in line with the WHO certification scheme on pharmaceuticals moving in International Commerce from the Regulatory Authority (RA) in the country of manufacture of the goods or has been certified by the competent authority of a member country of the Pharmaceuticals Inspection Convention (PIC), and has demonstrated compliance with the quality standards during the past two years prior to Tenderer submission;* *The Tenderer shall also submit the following additional information:* *(a) a statement of installed manufacturing capacity;* *(b) details of on-site quality control laboratory facilities and services and range of tests conducted;* *(c) list of major supply contracts conducted within the last three years;* *(d) Soft copy of the price schedule properly filled in the format provided;* *(e) All tertiary, primary and secondary packaging shall have TZ-SADC printed as specified in Section VI.*
14.	**ITT 15.6(a) (iii), (iv)**	The prices to be quoted shall be **DDP.** However, the tenderer must indicate **FOB, CFR** and **CIF** prices as specified in the price schedule.
15.	**ITT 15.7 (a) (i) & 15.6 (b)(i)**	Prices for goods offered from within and/or outside the SADC the region, shall be quoted as: **DDP.** However, the tenderer must indicate **FOB, CFR** and **CIF** prices as specified in the price schedule.

Note: The Port of Entry and their respective distances to the central medical stores of the SADC Member states are shown below;

1	Angola	Luanda (6 km from seaport and 4 km from the airport)
2	Botswana	Durban/Port Elizabeth/Capetown
3	Comoros	Moroni (estimated distance from sea port is 50 kms)
4	DRC	Dar es Salaam (estimated Distance from sea port to Central Medical Stores of DRC is 2000 km)
5	Eswatini	Durban (504 km from Durban to Central Medical Store matsapha; 64km from Sikhuphe airport to Central Medical Store)
6	Lesotho	Durban (632km from Durban seaport to Central Medical Store. Airport: 429 km from OR Tambo International airport. Johannesburg)
7	Madagascar	Toamasina (Estimated distance from seaport to Central Medical Stores is 230km)
8	Malawi	Dar es Salaam (Dar es Salaam-1700 km from CMST,Lilongwe and Beira-1000 km from Lilongwe. Airport-8km from CMST Head Office)
9	Mauritius	Port Louis (40 KMs from Harare Beira, 168 KMs from Harare Durban, 2659.3 from Harare Dar)
10	Mozambique	Beira/Nacala/Maputo (Beira Airport 15km, Beira seaport 7km; Nacala seaport 220km, Nampula airport 25km; Maputo seaport 25km, Maputo International Airport 20km)
11	Namibia	Walvis Bay (46.6 KMs from airport and 395.6 KMs from seaport)
12	Seychelles	Port Victoria (15 KMs from airport and 3 KMs from seaport/ Seychelles International airport, Victoria Port- Less than 10km

		from Central Medical Store) 13 South Africa Durban (estimated distance from seaport to Johannesburg is 567 km) 14 Tanzania Dar es Salaam (10 KMs from airport and 8 KMs from seaport 15 Zambia Dar es Salaam (estimated distance from seaport to Lusaka is 1950) 16 Zimbambwe Durban /Dar es Salaam/ Beira (577 KMs from airport and 395.6 KMs from seaport)
16.	**ITT 15.8**	The price shall be fixed for contract running period.
17.	**ITT 15.9**	Tenderers are being invited for: **One or more items. The Framework Agreements may be concluded with more than one tenderer for one item.**
18.	**ITT 16.1(a)**	a) For goods Manufactured and supplied from within SADC region the currency of the Tender shall be: **USD.** However, other currencies may be used in accordance with the agreed terms and conditions of the contract b) For goods Manufactured and supplied from outside the SADC region, currency of the Tenderer shall be express in **USD or EURO.** Other currencies may be used in accordance with the agreed terms and conditions of the contract.
19.	**ITT 16.2**	The rates of exchange to be used by the Tenderer shall be: N/A
20.	**ITT 17.1**	The Tender validity period shall be **120 days.**
21.	**ITT 18.1**	The amount of Tender security is: **N/A**
22.	**ITT 18.3(c)**	The tender Security shall be in the form of: **Tender Securing Declaration notarized by commission for oath.**
23.	**ITT 19.1**	Alternative Tenders to the requirements of the tendering documents **will not be permitted.**
24.	**ITT 20.1**	**Required number of copies of the Tenderer:** Two hard copies [2] One original and one copy, and one soft copy of the price schedule (**in excel format**) properly filled in the format provided. The completed soft copy should be submitted in a USB flash drive provided by the Manufacturers. Manufacturers should also print the completed price schedule in Legal size (8.5" X 14") paper and submit with the bid package.
25.	**ITT 20.2**	Written confirmation of authorization are: **Original Written power of Attorney certified and notarized by the lawyer and specific for this tender.**

D. Submission of Tenderers

26.	**ITT 21.2 (a)**	Tenders shall be submitted to:

		The secretary, **Medical Stores Department Tender Board,** **Medical Stores Department.** **Street address: Off Nyerere Road, Keko Mwanga, P.O. Box 9081** **Floor/Room No.: First Floor** **City/Town : Dar es Salaam, Tanzania**
27.	**ITT 21.2 (b)**	Project name: **Supply of Pharmaceuticals and Medical supplies from Manufacturers to SADC Member states under Framework Agreement** IFB title and number: **IE-009/2018/2019/HQ/G/101** Time and date for submission: **10:00HRS local time; Tuesday 21st May 2019**
28.	**ITT 22.1 & 22.3**	The deadline for Tender submission is**: Tuesday 21st May 2019**

E. Opening and Evaluation of Tenderers

29.	**ITT 25.1**	The Tender opening shall take place at: **Medical Stores Department.** **Street address: Off Nyerere Road, Keko Mwanga, P.O. Box 9081** **Floor/Room No.: First Floor** **City/Town: Dar es Salaam,** Country: **Tanzania** Day: **Tuesday** Date: **21st May 2019** Time: **10:00 hours Local time (East African time)**
30.	**ITT 31.2**	The currency that shall be used for Tender evaluation and comparison purposes to convert all Tender prices expressed in various currencies is: **Tanzanian Shillings.** The rates of exchange to be used by the Tenderer shall be those established by the **Bank of Tanzania exchange rates** prevailing on the day of Tender opening. *The date of exchange rate shall be* **Tuesday 21st May 2019**
31.	**ITT 32.4**	Criteria for Tender evaluation. Tenderers must submit the following documents (Major Criteria): a) Anti-bribery policy/Code of conduct compliance program as per tender document provided in section X. b) Original power of Attorney certified by the lawyer and specific for this tender c) Copy of receipt for the tender fee issued by Medical Stores Department. d) A duly completed and signed Form of Tender and Price Schedule e) Bid Securing Declaration in the format specified under Section IX. f) Copy of Valid Manufacturing license g) Copy of Valid Registration Certificate for each product from National Drugs Regulatory Authority Member states. h) Experiences of supplying health commodities for the past years

32.	**ITT 32.4 (c)**	Other specific criteria are (Minor Criteria): c) Copy of TIN, VAT and Tax Clearance d) Litigation certificate/statement e) Three (3) previous performed contracts and addresses of employers for verification
33.	**ITT 32.5**	The factors retained pursuant to ITT Sub – Clause 31.4 and the quantification methods are: N/A
34.	**ITT 32.5 (a)**	Inland transportation from EXW/port of entry/border point to *Central Medical Stores of each member states*, and insurance and incidentals: ***Applicable***
35.	**ITT 32.5(b) (i) (ii) & (iii)**	Delivery schedule: As per call off order
36	**ITT 32.5(c) (ii)**	Deviation in payment schedule: N/A
37.	**ITT 32.5 (d)**	Other specific additional criteria for evaluation: N/A
38.	**ITT 32.6**	In case of award to a single Tenderer of multiple lots, the methodology of evaluation to determine the lowest evaluated Lot combinations, including any discounts offered in the Form of Tender is: N/A
39.	**ITT 33.1**	A margin of domestic preference shall apply. If a margin of preference applies, the application methodology shall be: ***a maximum of 15% shall apply for manufacturers originating from Member states***

F. Post-qualification and Award of Contract

40.	**ITT 35.1**	Post-qualification shall be carried out using the following requirements: a) **Financial Capability** The Tenderer shall furnish documentary evidence that it meets the following financial requirement(s): b) Availability of financial resources: Provide evidence of availability of funds or credit facilities for the successful performance of the contract. • Litigation: Provide evidence that there are no claims, arbitrations, or other litigation pending or already resolved, with possible impact of more than 50% of total assets • That the amount of annul sales value should be at least five times the estimated contract value • Certified Audited financial statements for the last three years 2015/16, 2016/2017 and 2017/2018 c) **Experience and Technical Capacity** The Tenderer shall furnish documentary evidence to demonstrate that it meets the following experience requirement(s):

		d) **Experience requirement(s):** That Bidders must provide evidence of specific experience in manufacturing and supplying of pharmaceuticals drugs and Medical supplies of the same size and complexity as this one, within the three years through submitting copies of contracts awarded or listing clients dealt with (Name of client, type of work performed, year of completion and value of contract). e) **Supply Capacity requirement(s):** That has the technical capability to supply the drugs as specified in the schedule of supply. The Tenderers should have manufactured and marketed the specific goods subject of tendering for at least two years, and for similar goods for at least three years. That has the capability to supply the drugs of the size and in the quantity required. The Tenderers shall have to quote for the items and quantities listed in the schedule of requirement. Partial quantities will not be acceptable. That has the capability to complete the supply within the terms specified in the schedule of requirement: The Bidder shall have to abide to the delivery schedule as provided in section VI. Nonperforming Contracts: The Tenderer shall furnish documentary evidence to demonstrate that non-performance of a contract did not occur within the last five *[5]* years prior to the deadline for submission of Tenders.
41.	**ITT 42.1**	The Performance Security shall be: **10% of the call off value in the contract currency and shall be submitted within twenty eight (28) days after receipt and signing of the call off order. The performance security shall remain valid for 28 days after delivery of goods.**
42.	**ITT 43.1**	The Advance Payment shall be limited to: N/A
43.	**ITT 43.2**	Maximum amount of Advance payment shall be: N/A
44.	**ITT 44.1**	The Arbitrator proposed by the Procuring Entity is: Tanzania Institute of Arbitrators The hourly fee for this proposed Arbitrator shall be: As per prevailing fee in the Law The biographical data of the proposed Arbitrator is as follows: N/A

G. Review of Procurement Decisions

45.	**ITT 48.1**	The address to submit complaints: Chief Executive Officer, Public Procurement Regulatory Authority (PPRA) PSPF Dodoma Plaza, 9th floor, Jakaya Kikwete Road, P.O. Box 2865, DODOMA. Tel: +255 262963854, Fax: +255 262963855,

		email: ceo@ppra.go.tz Website: www.ppra.go.tz
46.	**ITT 50.2**	The address for Appeal to PPAA: The Secretary, Public Procurement Appeals Authority, Sukari House 1st Floor, P.O. Box 9310, DAR ES SALAAM. Tel: 2120451

Tender Data Sheet

PHARMACEUTICALS

(Additional Clauses)

C. Preparation of Tenders

TDS Clause	ITT Clause	Amendments of, and Supplement to, Clauses in the Instruction to Tenders
1	**ITT12.3 (c)**	[*Sample clauses]*

		The Goods offered should meet the specified pharmacopoeial standards as stated in the Technical Specification. If the Goods offered are not included in one of the specified pharmacopoeias (e.g., the case of a new drug), the Tenderer will provide testing protocols and alternative reference standards.
2	**ITT 13.1 (a) & (d)**	*Documentary evidence of the Tenderer's qualifications to perform the Contract if its Tender is accepted:* *(ii) (d) has a Good Distribution Practice (GDP) Certificate where appropriate.* The Tenderer will submit the following additional information: *(f) list of pharmaceuticals and Medical supplies being manufactured by the Tenderer with product registration / license number and date.* *(g) A certificate of Pharmaceutical and Medical Products as recommended by the WHO for each item offered.*

Tender Data Sheet

VACCINES

(Additional Clauses)

The following specific data for the Goods to be procured shall complement, supplement, or amend the provisions in the Instructions to Tenderers (ITT). Whenever there is a conflict, the provisions in the Tender Data Sheet (TDS) shall prevail over those in the ITT.

C. Preparation of Tenders

TDS Clause	ITT Clause	*Amendments of, and Supplement to, Clauses in the Instruction to Tenders*
1	**ITT 12.3 (c)**	*[Sample Clauses*] 1. The Goods to be supplied under the Contract must be licensed both in the country of manufacture and in the SADC Member states by the time of Contract signing by a recognized NCA. An NCA is an organization that performs all six critical functions for control of biological products as defined by the World Health Organization, namely: licensing based on published set of requirements; surveillance of vaccine field performance; system of lot release for vaccines; use of laboratory when need; regular inspections for good manufacturing practice and evaluation of clinical performance. The license from country of manufacture must state that the Tenderer is licensed to manufacture the Goods by the NCA in the manufacturing country. Documentary evidence in the form of a certified copy of the license and a copy of the vaccine license / registration that the offered vaccine has been licensed by the NCAs of the manufacturer's country shall accompany the Tender and a copy of the license issued by an NCA in the Member states must be submitted by Contract signing. If there is no NCA with specific biologics expertise in the SADC Member states, the Tenderer shall furnish evidence that the Goods meet the qualification criteria in the Technical Specifications. **2. Biological items will require submission of Bio-equivalence and or /Biosimilar studies between the innovators brand against the generic molecule** 3. If the Goods offered do not meet he specified pharmacopoeial standards as stated in the Technical Specification, the Tenderer will provide testing protocols and alternative reference standards.
2	**ITT 13.1 (a) & (d)**	Documentary evidence of the Tenderer's qualifications to perform the Contract if its Tender is accepted: (a) is certified by a competent authority in the country of manufacture according to resolution WHA 28 65 (2) of the World Health Organization's Certificate Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. The Tenderer will submit the following additional information: - (b) list of vaccines being manufactured by the Tenderer with product registration / license number and date.

SECTION IV: GENERAL CONDITIONS OF CONTRACT

Table of Clauses

General Conditions of Contract

1. Definitions

1.1 In this Contract, the following terms shall be interpreted as indicated:

(a) “Completion” means the fulfillment of the related services by the Manufacturers in accordance with the terms and conditions set forth in the contract.

(b) “Day" means calendar day.

(c) “Delivery” means the transfer of the goods from the Manufacturers equipment, machinery, and /or other materials which the Manufacturers is required to supply to the Procuring Entity under Contract.

(d) “Effective Date" means the date on which this Contract becomes effective pursuant to GCC Clause 6.2.

(e) “Eligible Country" means the countries and territories eligible for participation in procurements financed by the specified institution.

(f) “End User" means the organization(s) where the goods will be used, as **named in the SCC**.

(g) “Force Majeure” means an event or situation beyond the control of the Manufacturers and not involving the Manufacturer’s fault or negligence and not foreseeable, is unavoidable, and is not due to negligence or lack of care on the part of the Manufacturers.

(h) "GCC" means the General Conditions of Contract contained in this section.

(i) “SCC" means the Special Conditions of Contract.

(j) “Origin” means the place where the Goods were mined, grown, or produced or from which the Services are supplied. Goods are produced when, through manufacturing, processing, or substantial and major assembly of components, a commercially recognized new produce results that is substantially different in basic characteristics or in purpose or utility from its components.

(k) “Registration Certificate" means the certificate of registration or other documents in lieu thereof establishing that the Goods supplied under the Contract are registered for use in the SADC region in accordance with the Applicable Law.

(l) "The Contract" means the agreement entered into between the Procuring Entity and the Manufacturers, as recorded in the Contract Form signed by the parties,

including all attachments and appendices thereto and all documents incorporated by reference therein.

(m) "The Contract Price" means the price payable to the Manufacturers under the Contract for the full and proper performance of its contractual obligations.

(n) "The Goods" means all of the pharmaceuticals including nutritional supplement and oral and injectable forms of contraception, vaccines, and condoms that the Manufacturers is required to supply to the Procuring Entity under the Contract.

(o) "The Final Destination " where applicable, means the place or places **named in the SCC**.

(p) "The Procuring Entity" means the organization purchasing the Goods, as **named in the SCC**.

(q) "The Related Services" means those services ancillary to the supply of the Goods, such as transportation and insurance, and any other incidental services, such as installation, commissioning, provision of technical assistance, training, initial maintenance and other such obligations of the Manufacturers covered under the Contract.

(r) "The Services" means those services ancillary to the supply of the Goods, such as transportation and insurance, and any other incidental services, such as provision of technical assistance, training, and other such obligations of the Manufacturers covered under the Contract.

(s) "The Manufacturers" means the individual or firm supplying the Goods and Services under this Contract, as **named in the SCC**.

2.	**Application**	2.1	These General Conditions shall apply to the extent that they are not superseded by provisions of other parts of the Contract.
3.	**Governing Language**	3.1	The Contract shall be written in the language **specific, in the SCC.** Subject to GCC Clause 3.1, the version of the Contract written in the specified language shall govern its interpretation. All correspondence and other documents pertaining to the Contract that are exchanged by the parties shall be written in the same language.
4.	**Applicable Law**	4.1	The Contract shall be interpreted in accordance with the laws of the United Republic of Tanzania, unless otherwise **specified in the SCC.**
5.	**Country of Origin**	5.1	All Goods and Services supplied under the Contract shall have their origin in the countries and territories eligible under projects financed by the specified institution, as further **elaborated in the SCC**.

5.2 For purposes of this Clause, "origin" means the place where the Goods were mined, grown, or produced, or from which the Services are supplied. Goods are produced when, through manufacturing, processing, or substantial and major assembly of components, a commercially recognized new product results that is substantially different in basic characteristics or in purpose or utility from its components.

5.3 The origin of Goods and Services is distinct from the nationality of the Manufacturers.

6. Standards

6.1 The Goods supplied under this Contract shall conform to the standards mentioned in the Technical Specifications and, when no applicable standard is mentioned, to the authoritative standards appropriate to the Goods' country of origin. Such standards shall be the latest issued by the concerned institution.

7. Use of Contract Documents and Information; Inspection and Audit by the Government of the respective Member states

7.1 The Manufacturers shall not, without the Procuring Entity's prior written consent, disclose the Contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the Procuring Entity in connection therewith, to any person other than a person employed by the Manufacturers in the performance of the Contract. Disclosure to any such employed person shall be made in confidence and shall extend only so far as may be necessary for purposes of such performance.

7.2 The Manufacturers shall not, without the Procuring Entity's prior written consent, make use of any document or information enumerated in GCC sub-Clause 7.1 except for purposes of performing the Contract.

7.3 Any document, other than the Contract itself, enumerated in GCC sub-Clause 7.1 shall remain the property of the Procuring Entity and shall be returned (all copies) to the Procuring Entity on completion of the Manufacturer’s performance under the Contract if so required by the Procuring Entity.

7.4 The Manufacturers shall permit the Government of the United Republic of Tanzania to inspect the Manufacturer’s accounts and records relating to the performance of the Contract and to have them audited by auditors appointed by the Government, if so required by the Government.

8. Certification of Goods in Accordance with Laws

8.1 If required under the Applicable Law, Goods supplied under the Contract shall be registered for use in the SADC Member states as **specified in the SCC**. The Procuring Entity undertakes to cooperate with the Manufacturers to facilitate registration of the Goods for use in the Member states

8.2 Unless otherwise **specified in the SCC,** the Contract shall become effective on the date ('the Effective Date") that the Manufacturers receives written notification from the relevant authority in the SADC countries that the Goods have been registered for use in the

that respective country.

8.3 If thirty (30) days, or such longer period **specified in the SCC,** elapse from the date of Contract signing and the Contract has not become effective pursuant to Sub- Clause 8.2 above, then either party may, by not less than seven (7) days' written notice to the other party, declare this Contract null and void. In such event, the Manufacturer's performance security shall be promptly returned.

9. Patent Rights

9.1 The Manufacturers shall indemnify the Procuring Entity against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof in the SADC region.

10. Performance Security

10.1 Within thirty (30) days of receipt of the notification of Contract award, the successful Tenderer shall furnish to the Procuring Entity the performance security in the amount **specified in the SCC**.

10.2 The proceeds of the performance security shall be payable to the Procuring Entity as compensation for any loss resulting from the Manufacturer's failure to complete its obligations under the Contract.

10.3 The performance security shall be denominated in the currency of the Contract, or in a freely convertible currency acceptable to the Procuring Entity, and shall be in one of the following forms:

a) a bank guarantee or an irrevocable letter of credit issued by a reputable bank located in the SADC regionor abroad, acceptable to the Procuring Entity, in the format provided in the Tendering Documents or another format acceptable to the Procuring Entity; or

b) a cashier's or certified check.

10.4 The performance security will be discharged by the Procuring Entity and returned to the Manufacturers not later than thirty (30) days following the date of completion of the Manufacturer's performance obligations under the Contract, including any warranty obligations, unless **specified otherwise in the** SCC.

10.5 Where circumstances necessitate the amendment of the contract after signature, and such amendment is effected, the Procuring Entity shall require the Manufacturers to provide additional Performance Security to cover any cumulative increase of more than ten percent of the initial Contract Price.

11. Inspections and Tests

11.1 The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Contract specifications. The SCC and the Technical Specifications shall specify what inspections and tests the Procuring Entity requires and where they are to be conducted. The Procuring Entity shall notify the Manufacturers in writing or in electronic forms that provide record of the content of communication, in a timely manner, of the identity of any representatives retained for these

purposes.

(a) Said inspection and testing is for the Procuring Entity's account. In the event that inspection and testing is required prior to dispatch, the Goods shall not be shipped unless a satisfactory inspection and quality control report has been issued in respect of those Goods.

(b) The Manufacturers may have an independent quality test conducted on a batch ready for shipment. The cost of such tests will be borne by the Manufacturers.

(c) Upon receipt of the Goods at place of Final Destination, the Procuring Entity's representative shall inspect the Goods or part of the Goods to ensure at they conform to the condition of the Contract and advise the Procuring Entity that the Goods were received in apparent good order. The Procuring Entity will issue an Acceptance Certificate to the Manufacturers m respect of such Goods (or part of Goods). The Acceptance Certificate shall be issued within ten (10) days of receipt of the Goods or part of Goods at place of final destination.

11.2 Where the Manufacturers contests the validity of the rejection by the Procuring Entity or his representative, of any inspection as required by 9.1 above conducted before shipment or at ultimate destination, whether based on product or packing grounds, a sample drawn jointly by the Manufacturers and Procuring Entity or his or her representative and authenticated by both, will be forwarded for umpire analysis within four weeks of the time the Manufacturers contests to an independent agency mutually agreed by the Procuring Entity and Manufacturers. The umpire's finding, which will be promptly obtained, will be final and binding on both parties. The cost of umpire analysis will be borne by the losing party.

11.3 Nothing in GCC Clause 11 shall in any way release the Manufacturers from any warranty or other obligations under this Contract.

12. Packing

12.1 The Manufacturers shall provide such packing of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the Contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt, and precipitation during transit and open storage. Packing case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' final destination and the absence of heavy handling facilities at all points in transit.

12.2 The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the Contract, including additional requirements, if any, **specified in the SCC** or Technical Specifications, and in any subsequent instructions ordered by the Procuring Entity.

13. Delivery and Documents

13.1 Delivery of the Goods shall be made by the Manufacturers in accordance with the terms specified in the Schedule of Requirements. The details of shipping and/or other documents to be furnished by the Manufacturers are **specified in the SCC.**

13.2 For purposes of the Contract, "EXW," "FOB," 'FCA,' 'CIF," "CIP," and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of *Incoterms* published by the International Chamber of Commerce, Paris.

13.3 Documents to be submitted by the Manufacturers are **specified** in **the SCC.** *Incoterms* provides a set of international rules for the interpretation of the more commonly used trade terms.

14. Insurance

14.1 The Goods supplied under the Contract shall be fully insured in a freely convertible currency against loss or damage incidental to manufacture or acquisition, transportation, storage, and delivery in the manner **specified in the SCC**.

14.2 Where delivery of the Goods is required by the Procuring Entity on a CIF or CIP basis, the Manufacturers shall arrange and pay for cargo insurance, naming the Procuring Entity as beneficiary. Where delivery is on an FOB or FCA basis, insurance shall be the responsibility of the Procuring Entity.

15. Transportation

15.1 Where the Manufacturers is required under Contract to deliver the Goods FOB, transport of the Goods, up to and including the point of putting the Goods on board the vessel at the specified port of loading, shall be arranged and paid for by the Manufacturers, and the cost thereof shall be included in the Contract Price. Where the Manufacturers is required under the Contract to deliver the Goods FCA, transport of the Goods and delivery into the custody of the carrier at the place named by the Procuring Entity or other agreed point shall be arranged and paid for by the Manufacturers, and the cost thereof shall be included in the Contract Price.

15.2 Where the Manufacturers is required under Contract to deliver the Goods CIF or CIP, transport of the Goods to the port of destination or such other named place of destination in the SADC countries, as shall be specified in the Contract, shall be arranged and paid for by the Manufacturers, and the cost thereof shall be included in the Contract Price.

15.3 Where the Manufacturers is required under the Contact to transport the Goods to a specified place of destination within the SADC region, defined as the Site, transport to such place of destination in the SADC region, including insurance and storage, as shall be specified in the Contract, shall be arranged by the Manufacturers, and related costs shall be included in the Contract Price.

15.4 Where the Manufacturers is required under Contract to deliver the Goods CIF or CIP, no restriction shall be placed on the choice of carrier. Where the Manufacturers is required under Contract (a) to

deliver the Goods FOB or FCA, and (b) to arrange on behalf and at the expense of the Procuring Entity for international transportation on specified carriers or on national flag carriers of the SADC region, the Manufacturers may arrange for such transportation on alternative carriers if the specified or national flag carriers are not available to transport the Goods within the period(s) specified in the Contract.

16. Incidental Services

16.1 The Manufacturers shall provide such incidental services, if any, as are **specified in the SCC**.

16.2 Prices charged by the Manufacturers for incidental services, if not included in the Contract Price for the Goods, shall be agreed upon in advance by the parties and shall not exceed the prevailing rates charged to other parties by the Manufacturers for similar services.

17. Warranty

17.1 All goods must be of fresh manufacture and must bear the dates of manufacture and expiry.

The Manufacturers further warrants that all Goods supplied under the Contract will have remaining a minimum of five-sixths (5/6) of the specified shelf life upon delivery at port/airport of entry for goods with a shelf life of more than two years and three-fourths (3/4) for goods with a shelf life of two years or less, unless otherwise **specified in the SCC**; have "overages" within the ranges set forth in the Technical Specifications, where applicable; are not subject to recall by the applicable regulatory authority due to unacceptable 'quality or an adverse drug reaction; and in every other respect will fully comply in all respects with the Technical Specifications and with the conditions laid down in the Contract.

17.2 The Procuring Entity shall have the right to make claims under the above warranty for three months after the Goods have been delivered to the final destination indicated in the Contract. Upon receipt of a written notice from the Procuring Entity, the Manufacturers shall, with all reasonable speed, replace the defective Goods without cost to the Procuring Entity. The Manufacturers will be entitled to remove, at his own risk and cost, the defective Goods once the replacement Goods have been delivered.

17.3 In the event of a dispute by the Manufacturers, a counter- analysis will be carried out on the manufacturer's retained samples by an independent neutral laboratory agreed by both the Procuring Entity and the Manufacturers. If the counter-analysis confirms the defect, the cost of such analysis will be borne by the Manufacturers as well as the replacement and disposal of the defective goods. In the event of the independent analysis confirming the quality of the product, the Procuring Entity will meet all costs for such analysis.

17.4 If, after being notified that the defect has been confirmed pursuant to GCC sub-Clause 17.2 above, the Manufacturers fails to replace the defective Goods within the period specified in the SCC, the Procuring Entity may proceed to take such remedial action as may be necessary, including removal and disposal, at the Manufacturer’s

risk and expense and without prejudice to any other rights that the Procuring Entity may have against the Manufacturers under the Contract. The Procuring Entity will also be entitled to claim for storage in respect of the defective Goods for the period following notification and deduct the sum from payments due to the Manufacturers under this Contract.

17.5 *Recalls.* In the event any of the Goods are recalled, the Manufacturers shall notify the Procuring Entity within fourteen (14) days, providing full details of the reason for the recall and promptly replace, at its own cost, the items covered by the recall with Goods that fully meet the requirements of the Technical Specification and arrange for collection or destruction of any defective Goods. If the Manufacturers fails to fulfill its recall obligation promptly, the Procuring Entity will, at the Manufacturer's expense, carry out the recall.

18. Payment

18.1 The method and conditions of payment to be made to the Manufacturers under this Contract shall be **specified in the SCC**.

18.2 The Manufacturer's request(s) for payment shall be made to the Procuring Entity in writing or in electronic forms that provide record of the content of communication, accompanied by an invoice describing, as appropriate, the Goods delivered and Services performed, and by documents submitted pursuant to GCC Clause 13, and upon fulfillment of other obligations stipulated in the Contract.

18.3 Payments shall be made promptly by the Procuring Entity, but in no case later than sixty (60) days after submission of an invoice or claim by the Manufacturers.

18.4 The currency or currencies in which payment is made to the Manufacturers under this Contract shall be **specified in the SCC** subject to the following general principle: Payment will be made in the currency or currencies in which the payment has been requested in the Manufacturer's tender.

18.5 All payments shall be made in the currency or currencies specified in the SCC pursuant to GCC 18.4.

19. Prices

19.1 Prices charged by the Manufacturers for Goods delivered and Services performed under the Contract shall not vary from the prices quoted by the Manufacturers in its tender, with the exception of any price adjustments **authorized in the SCC** or in the Procuring Entity's request for tender validity extension, as the case may be.

20. Change Orders

20.1 The Procuring Entity may at any time, by a written order given to the Manufacturers pursuant to GCC Clause 21, make changes within the general scope of the Contract in any one or more of the following:

(a) specifications, where Goods to be furnished under the Contract are to be specifically manufactured for the

Procuring Entity;

(b) the method of shipment or packing;

(c) the place of delivery; and/or

(d) the Services to be provided by the Manufacturers.

20.2 If any such change causes an increase or decrease in the cost of, or the time required for, the Manufacturer's performance of any provisions under the Contract, an equitable adjustment shall be made in the Contract Price or delivery schedule, or both, and the Contract shall accordingly be amended. Any claims by the Manufacturers for adjustment under this clause must be asserted within thirty (30) days from the date of the Manufacturer's receipt of the Procuring Entity's change order.

21. Contract Amendments

21.1 Subject to GCC Clause 20, no variation in or modification of the terms of the Contract shall be made except by written amendment signed by the parties.

22. Assignment

22.1 The Manufacturers shall not assign, in whole or in part, its obligations to perform under this Contract, except with the Procuring Entity's prior written consent.

23. Delays in the Manufacturer's Performance

23.1 Delivery of the Goods and performance of Services shall be made by the Manufacturers in accordance with the time schedule prescribed by the Procuring Entity in the Schedule of Requirements.

23.2 If at any time during performance of the Contract, the Manufacturers or its subcontractor(s) should encounter conditions impeding timely delivery of the Goods and performance of Services, the Manufacturers shall promptly notify the Procuring Entity in writing or in electronic forms that provide record of the content of communication of the fact of the delay, its likely duration, and its cause(s). As soon as practicable after receipt of the Manufacturer's notice, the Procuring Entity shall evaluate the situation and may at its discretion extend the Manufacturer's time for performance, with or without liquidated damages, in which case the extension shall be ratified by the parties by amendment of Contract.

23.3 Except as provided under GCC Clause 26, a delay by the Manufacturers in the performance of its delivery obligations shall render the Manufacturers liable to the imposition of liquidated damages pursuant to GCC Clause 24, unless an extension of time is agreed upon pursuant to GCC Clause 23.2 without the application of liquidated damages.

24. Liquidated Damages

24.1 Subject to GCC Clause 24, if the Manufacturers fails to deliver any or all of the Goods or to perform the Services within the period(s) specified in the Contract, the Procuring Entity shall, without prejudice to its other remedies under the Contract, deduct from the Contract Price, as liquidated damages, a sum equivalent to the

percentage **specified in the SCC** of the delivered price of the delayed Goods or unperformed Services for each week or part thereof of delay until actual delivery or performance, up to a maximum deduction of the percentage **specified in the SCC.** Once the maximum is reached, the Procuring Entity may consider termination of the Contract pursuant to GCC Clause 25.

25. Termination for Default

25.1 The Procuring Entity, without prejudice to any other remedy for breach of Contract, by written notice of default sent to the Manufacturers, may terminate this Contract in whole or in part:

(a) if the Manufacturers fails to deliver any or all of the Goods within the period(s) specified in the Contract, or within any extension thereof granted by the Procuring Entity pursuant to GCC Clause 23; or

(b) if the Goods do not meet the Technical Specifications stated in the Contract; or

(c) if the Manufacturers fails to provide any registration or other certificates in respect of the Goods within the time specified in the Special Conditions; or

(d) if the Manufacturers, in the judgment of the Procuring Entity, has engaged in corrupt or fraudulent practices in competing for or in executing the Contract.

For the purpose of this clause:

"corrupt practice means the offering, giving receiving or soliciting of anything of value to influence the action of a public officer in the procurement process or contract execution;
"coercive practice" means impairing or harming, or threatening to impair or harm directly or indirectly, any party or the property of the party for the purpose of influencing improperly the action or that party in connection with public procurement or in furtherance of corrupt practice or fraudulent practice;

"collusive practices" means impairing or harming, or threatening to impair or harm directly or indirectly, any part or the property of the Party for the purpose of influencing improperly the action or a part or in connection with public procurement or government contracting or in furtherance of a corrupt practice or a Fraudulent Practice

"fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Government or a public body and includes collusive practices among tenderers, prior to or after submission designed to establish tender prices at artificial non-competitive levels and to deprive the Government of the benefits of free and open competition;

"obstructive practice" means acts intended to materially

impede access to required information in exercising a duty under this Act;

(e) if the Manufacturers fails to perform any other obligations) under the Contract.

25.2 In the event the Procuring Entity terminates the Contract in whole or in part, pursuant to GCC Clause 25.1, the Procuring Entity may procure, upon such terms and in such manner as it deems appropriate, Goods or Services similar to those undelivered, and the Manufacturers shall be liable to the Procuring Entity for any excess costs for such similar Goods or Services. However, the Manufacturers shall continue performance of the Contract to the extent not terminated.

26. Force Majeure

26.1 Notwithstanding the provisions of GCC Clauses 23, 24, and 25, the Manufacturers shall not be liable for forfeiture of its performance security, liquidated damages, or termination for default if and to the extent that it's delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure.

26.2 For purposes of this clause, "Force Majeure" means an event beyond the control of the Manufacturers and not involving the Manufacturer's fault or negligence and not foreseeable. Such events may include, but are not restricted to, acts of the Procuring Entity in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions, and freight embargoes.

26.3 If a Force Majeure situation arises, the Manufacturers shall promptly notify the Procuring Entity in writing or in electronic forms that provide record of the content of communication of such condition and the cause thereof. Unless otherwise directed by the Procuring Entity in writing, the Manufacturers shall continue to perform its obligations under the Contract as far as is reasonably practical and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event.

27. Termination for Insolvency

27.1 The Procuring Entity may at any time terminate the Contract by giving written notice to the Manufacturers if the Manufacturers becomes bankrupt or otherwise insolvent. In this event, termination will be without compensation to the Manufacturers, provided that such termination will not prejudice or affect any right of action or remedy that has accrued or will accrue thereafter to the Procuring Entity.

28. Termination for Convenience

28.1 The Procuring Entity, by written notice sent to the Manufacturers, may terminate the Contract, in whole or in part, at any time for its convenience. The notice of termination shall specify that termination is for the Procuring Entity's convenience, the extent to which performance of the Manufacturers under the Contract is terminated, and the date upon which such termination becomes effective.

28.2 The Goods that are complete and ready for shipment within thirty

(30) days after the Manufacturer's receipt of notice of termination shall be accepted by the Procuring Entity at the Contract terms and prices. For the remaining Goods, the Procuring Entity may elect:

(a) to have any portion completed and delivered at the Contract terms and prices; and/or

(b) to cancel the remainder and pay to the Manufacturers an agreed amount for partially completed Goods and Services and for materials and parts previously procured by the Manufacturers.

29. Settlement of Disputes

29.1 If any dispute or difference of any kind whatsoever shall arise between the Procuring Entity and the Manufacturers in connection with or arising out of the Contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.

29.2 If, after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the Procuring Entity or the Manufacturers may give notice to the other party of its intention to commence arbitration, as hereinafter provided, as to the matter in dispute, and no arbitration in respect of this matter may be commenced unless such notice is given.

29.2.1 Any dispute or difference in respect of which a notice of intention to commence arbitration has been given in accordance with this Clause shall be finally settled by arbitration. Arbitration may be commenced prior to or after delivery of the Goods under the Contract.

29.2.2 Arbitration proceedings shall be conducted in accordance with the rules of procedure **specified in the SCC**.

29.3 Notwithstanding any reference to arbitration herein,

(a) the parties shall continue to perform their respective obligations under the Contract unless they otherwise agree; and

(b) the Procuring Entity shall pay the Manufacturers any monies due the Manufacturers.

30. Limitation of Liability

30.1 Except in cases of criminal negligence or willful misconduct, and in the case of infringement pursuant to Clause 9,

(a) the Manufacturers shall not be liable to the Procuring Entity, whether in contract, tort, or otherwise, for any indirect or consequential loss or damage, loss of use, loss of production, or loss of profits or interest costs, provided that this exclusion shall not apply to any obligation of the Manufacturers to pay liquidated damages to the Procuring Entity and

(b) the aggregate liability of the Manufacturers to the

Procuring Entity, whether under the Contract, in tort or otherwise, shall not exceed the total Contract Price, provided that this limitation shall not apply to the cost of repairing or replacing defective equipment.

31. Notices

31.1 Any notice given by one party to the other pursuant to this Contract shall be sent to the other party in writing or in electronic forms that provide record of the content of communication and confirmed in writing or in electronic forms that provide record of the content of communication to the other party's address **specified in the SCC.**

31.2 A notice shall be effective when delivered or on notice's effective date, whichever is later.

32. Taxes and Duties

32.1 A Manufacturers supplying Goods from abroad shall entirely responsible for all taxes, stamp, duties, license fees, and other such levies imposed outside the Unit Republic of Tanzania.

32.2 A Manufacturers supplying Goods offered locally shall entirely responsible for all taxes, duties, license fees, etc., incurred until delivery of the contracted Goods the Procuring Entity.

33 Suspension of Financing

33.1 In the event that the source of financing is suspended to the Employer, from which part of the payments to the Contractor are being made:

(a) The Employer is obligated to notify the Contractor of such suspension within 7 days of having received the financing agency's suspension notice.

(b) If the Contractor has not received sums due it within the 28 days for payment provided for in Sub-Clause 45.1, the Contractor may immediately issue a 14-day termination notice.

SECTION V: SPECIAL CONDITIONS OF CONTRACT

Special Conditions of Contract

The following Special Conditions of Contract shall supplement the General editions of Contract. Whenever there is a conflict, the provisions herein shall prevail over those in the General Conditions of Contract. The corresponding clause number of the GCC is indicated in parentheses.

SCC Clause Number	GCC Clause Number	Amendments of, and Supplements to, Clauses in the General Conditions of Contract
	Definitions (GCC Clause 1)	
1.	GCC 1.1 (p)	The Procuring Entity is: **Medical Stores Department** **Off Nyerere Road, Keko Mwanga** **P.O. Box 9081** **Dar Es Salaam, Tanzania** **TEL: 255 22 2860890/7** **FAX: 255 22 2865814/9**
2.	GCC 1.1 (s)	The Manufacturer is: To be determined after award
3.	GCC 1.1 (o)	The Final Destination is/are: **DDP (as per specified port of entry for distances from the port to the Central Medical Stores of the Member states)**
4.	GCC 1.1 (f)	The end user is: **SADC *Member states***
	Governing Language (GCC Clause 3)	
5.	GCC 3.1	Governing language shall be: ***English***
	Applicable Law (GCC Clause 4)	
6.	GCC 4.1	The Contract shall be interpreted in accordance with the ***Laws of Tanzania***
7.	GCC 5.1	Country of Origin is: **Any eligible country**
8.	GCC 8.1	**All products tendered must meet the requirements of manufacturing legislation and regulation of pharmaceutical and Medical products in the country of origin and copies of registration must be submitted with tender document.**
9.	*GCC 8.2*	***NOT USED.***
10.	GCC 8.3	The time period shall be: ***Two years***
11.	GCC 10.1	Performance security shall be: ***ten (10) percent of the call off price in the contract currency.***
12.	GCC 10.4	Discharge of the Performance Security shall take place in accordance with GCC Sub-Clause 10.4.
13.	GCC 12.2	The following SCC shall supplement GCC Clause 11.2: The Goods shall be packed properly in accordance with standard export packing specified by the Procuring Entity in the Technical Specification. The Goods shall be packed properly in accordance with standard required to facilitate easy storage and prevent them from damage or deterioration during transit to Member states. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperature, sunlight, humidity, salt and precipitation during

		transit and storage. **In addition:** **a. All products must have the dates of manufacture and expiry where applicable and they must reach at Member states with a remaining shelf life of not less than 85%. Label for products should include** **- Content per pack, Special storage requirements, batch number, date of manufacture and date of expiry where applicable** **b. Print/Emboss TZ-SADC logo on primary and/or secondary packages as specified in the schedule of requirements** **The outer carton should also display the above information.**
	Delivery and Documents	
14.	GCC 13.1 & 13.3	***For Goods supplied from abroad:*** Upon shipment, the Manufacturers shall notify the Procuring Entity, recipients (Member states) and the insurance company in writing the full details of the shipment including Contract number, description of the Goods, quantity, date and place of shipment, mode of transportation, and estimated date of arrival at place of destination. In the event of Goods sent by airfreight, the Manufacturers shall notify the Procuring Entity and the recipient a minimum of forty-eight (48) hours ahead of dispatch, the name of the carrier, the flight number, the expected time of arrival, and the waybill number. The Manufacturers shall fax and then send by courier the following documents to the recipient, with a copy to the procurement entity and insurance company: **i)** two copies of the Manufacturer's invoice, showing Procuring Entity as **Director General Medical Stores Department, Off Nyerere road, Keko Mwanga, P.O. Box 9081 Dar es Salaam, Tanzania**; the Contract number, loan number, Goods description, quantity, unit price, and total amount. Invoices must be signed in original, stamped, or sealed with the company stamp/seal. **ii)** two copies of the negotiable, clean, on-board through bill of lading marked "freight prepaid" and showing Procuring Entity as **Director General Medical Stores Department, Off Nyerere road, Keko Mwanga, P.O.Box 9081 Dar es Salaam, Tanzania** and Notify Party as stated in the Contract, with delivery through to final destination as per the Schedule of Requirements and two copies of non-negotiable bill of lading, or three copies of railway consignment note, road consignment note, truck or air waybill, or multimodal transport document, marked "freight prepaid" and showing delivery through to final destination as per the Schedule of Requirements; (ii) four copies of the packing list identifying contents of each package; (iii) one copy of the Manufacturer's Warranty Certificate covering all items supplied; (iv) one copy of the Manufacturer's Certificate of Origin

		covering all items supplied; (v) one copy of the Certificate of Inspection furnished to Manufacturers by the nominated inspection agency and six copies (where inspection is required); (vi) any other procurement-specific documents required for delivery / payment purposes. **Address for the recipient** i. Upon shipment, the manufacturers must send one original and two copies of the Manufacturer's invoice to the address of the recipient which will be given to the manufacturer during issuing of call offs. The details must comprises of the Contract number, loan number, Goods description, quantity, unit price, and total amount. Invoices must be signed in original, stamped, or sealed with the company stamp/seal. ii. One original copy of the negotiable, clean, on-board through bill of lading marked "freight prepaid" and showing recipient as its address would be specified during call offs and Notify Party as stated in the Contract, with delivery through to final destination as per the Schedule of Requirements and two copies of non-negotiable bill of lading, or three copies of railway consignment note, road consignment note, truck or air waybill, or multimodal transport document, marked "freight prepaid" and showing delivery through to final destination as per the Schedule of Requirements; (vii) one original copy of the packing list identifying contents of each package; (viii) one original copy of the Warranty Certificate covering all items supplied; (ix) one original copy of the Manufacturer's Certificate of origin covering all items supplied; (x) one original copy of the Certificate of Inspection furnished to Manufacturers by the nominated inspection agency and six copies (where inspection is required); (xi) any other procurement-specific documents required for delivery / payment purposes. ***For Goods from within the SADC region.*** Upon shipment of the Goods, the Manufacturers shall notify the recipient, Procuring Entity and insurance company in writing and deliver the documents in a manner as provided as if the goods supplied from abroad **Note:** In the event that the documents presented by the Manufacturers are not in accordance with the Contract, then payment will be made against issue of the Acceptance Certificate, to be issued in accordance with SCC 9 (GCC 9) above.
15.	GCC 14.1	The insurance shall be in an amount equal to 110 percent of the CIF or CIP value of the Goods from "warehouse" to "warehouse" on "All Risks" basis, including war risks and strikes.
16.	GCC 16.1	Incidental services to be provided are:

		There are no special conditions of contract applicable to GCC 16.1
	Warranty (GCC Clause 17)	
17.	GCC 17.1	*There are no special conditions of contract applicable to GCC 17.1*
18.	GCC 17.4	The period for the replacement of defective goods is: **90 days**
	Payment (GCC Clause 18)	
19.	GCC 18.1 & 18.4	The method and conditions of payment to be made to the Manufacturers under this Contract shall be as follows: **Payment for Goods supplied from abroad:** Payment of foreign currency portion shall be made in *currency of the Contract Price* in the following manner: i) **On Shipment:** Eighty (80) percent of the shipped goods price shall be paid through irrevocable letter of credit opened in favor of the Manufacturers in a bank in its country, upon submission of documents specified in GCC Clause 13 or, alternatively, at the Manufacturer's option, within thirty (30) days of submission of documents specified in GCC Clause 13 above by direct bank transfer to the Manufacturer's nominated bank account. Opening charges and charges for amendment of the letter of credit at the request of or due to a fault or default of the Procuring Entity are for the account of the Procuring Entity. Confirmation charges and charges for amendment to letters of credit at the request of or due to a fault, or default on behalf of the Manufacturers, are for the account of the Manufacturers Remaining twenty (20) percent of the shipped goods price shall be paid within thirty (30) days after receipt of the Goods upon submission of an invoice (showing Procuring Entity's name; the Contract number, loan number; description of payment and total amount, signed in original, stamped or sealed with the company stamp/seal) supported by the Acceptance Certificate issued by the Procuring Entity. **or** ii) **On delivery and acceptance** hundred (100) percent of the shipped goods price shall be paid through telegraphic transfer.
	Prices (GCC Clause 19)	
20.	GCC 19.1	There are no special conditions of contract applicable to GCC 19.1
	Manufacturer's Performance (GCC Clause 23)	
21	GCC 23.1	These performance criteria identified shall be used in monitoring and evaluating manufacturer's performance based on cost efficiency, timely delivery, lead time, quality and payment process as the detailed definition measurements will be stated in the contract.
	Liquidated Damages (GCC Clause 24)	

21.	GCC 24.1	Applicable rate: **0.5 percent per week** of undelivered goods value. Maximum deduction is equal to the performance security **10% of the call off price.**
	Settlement of Disputes (GCC Clause 29)	
22.	GCC 29.2.2	The dispute resolution mechanism to be applied pursuant to GCC sub-Clause 29.2.2 shall be as follows: All disputes arising in connection of this contract shall be settled through arbitration in accordance with the laws of Tanzania.
	Notices (GCC Clause 31)	
23.	GCC 31.1	The Procuring Entity's address for notice purposes: **Director General** **Medical Stores Department** **Off Nyerere road, Keko Mwanga** **P.O.Box 9081** **Dar es Salaam, Tanzania** **Tel: 255 22 2860890/7** **Fax: 255 22 2865814/9** The Manufacturer's address for notice purposes*:* To be determined after award

Special Conditions of Contract

PHARMACEUTICALS

(Additional Clauses)

	The below data should be included in the Special Conditions of Contract used in Tendering Documents for the procurement of pharmaceuticals.	
13. Delivery and Documents (GCC Clause 13)		
14.	GCC 13.1 & 13.3	***For Goods supplied from abroad:*** (ii) One original of the Certificate of Pharmaceutical Product as recommended by the WHO for each of the items supplied. (iii) Certificate of quality control test results in conformity with the World Health Organization "Certification Scheme on the Quality of Pharmaceutical Products Moving in International Trade" stating quantitative assays, chemical analysis, sterility, pyrogen content, uniformity, microbial limit, and other tests as appropriate to the Goods. (iv) Original copy of the certificate of weight issued by the port authority / licensed authority and six copies.

Special Conditions of Contract

VACCINES

(Additional Clauses)

	The below data should be included in the Special Conditions of Contract used in Tendering Documents for the procurement of vaccines	
13. Delivery and Documents (GCC Clause 13)		
14.	GCC 13.1 & 13.3	***For Goods supplied from abroad**:* (xii) One copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped. (xiii) Certificate of quality control test results in conformity with the World Health Organization "Certification Scheme on the Quality of Pharmaceutical Products Moving in International Trade" stating quantitative assays, chemical analysis, sterility, pyrogen content, uniformity, microbial limit, and other tests as appropriate to the Goods. (xiv) Original copy of the certificate of weight issued by the port authority / licensed authority and six copies. ***For Goods from within the SADC region:*** (x) One copy of the Lot Release Certificate issued by the NCA of the country of manufacture for each lot shipped.

17. Warranty (GCC Clause 17)		
17.	GCC 17.1	The Procuring Entity reserves the right to request evidence of bio-availability and/ or bio-equivalence data and / or evidence of the basis for expiration dating and other stability data concerning the goods to verify shelf life claimed for the Goods. If an adverse event following immunization (AEFI) occurs in the SADC region and the cause of such event cannot be immediately established, the Procuring Entity will, with all urgency and in accordance with the procedures laid down by the NRA of the Member states, take steps to advise the Manufacturers in order that an investigation may be launched immediately. If the vaccine has been supplied through an agency of the United Nations, the most current procedures laid down by the WHO for such situations will be used.

SECTION VI: SCHEDULE OF REQUIREMENTS

1. List of Supplies

Procurement Reference Number: IE-009/2018/2019/HQ/G/101

Manufacturers are expected to honor the price submitted throughout the duration of the contract. Supplies will be purchased through Call-Off orders in accordance with the actual demand from SADC member states and the Manufacturers are obligated to quote prices for both FOB, CFR, CIF and DDP.

DELIVERY OF GOODS COMMENCES 8-12 WEEKS AFTER CALL OFF ORDER SIGNING. FOR EMERGENCY CALL OFF DELIVERY SHALL BE MADE WITHIN 8 WEEKS.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
1	1001SMT	ACICLOVIR 200MG TABLET	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
2	1002SMT	AMODIAQUINE 150-200MG TABLET	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states country where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
3	1003SMT	AMOXYCILLIN 125MG/5ML SUSPENSION	24BT	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states country where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack -Name, strength and pharmaceutical form,	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary To be shipped by Sea/road		
4	1004SMT	AMOXYCILLIN 500MG TABLET/CAPSULE	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC membere states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
5	1005SMT	ARTEMETHER + LUMEFANTRINE 20+120MG 12 TABLETS*	12TB	BP/USP Compendium or any other recognized compendium. Blister of 12 Tablets package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Membered states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
6	1006SMT	BLEOMYCIN 15IU INJ	1VL	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		
7	1007SMT	CHLORAMPHENICOL 250MG CAPSULE	100CP	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
8	1008SMT	CHLOROQUINE 150MG TABLET	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
9	1009SMT	DPT VACCINE INJECTION	1VL	"BP/USP Compendium or any other recognized compendium, should comply with general specifications described under vaccine, and should have Vaccine Vial Monitor (VVM) with published vaccine stability data. Evidence of registration/import approval of the medicinal product	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Air		
10	1010SMT	MEASLES VACCINE	1VL	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		size and units per carton.
11	1011SMT	MEDROXY PROGESTERON ACETATE 150MG/ML INJECTION	100VL	1. The product containing 150mg of Medroxyprogesterone acetate in vials of 1ml for depot intramuscular injection 2. Packed in aseptically closed glass containers (vial) with rubber stopper	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				protected with Aluminum foil containing 1ml sterile suspension of 150mg of medroxyprogesterone acetate in sterile water for injection for IM use 3. Sterile, complies with endotoxin test, PH and osmotic pressure 4. GMP compliant, Certificates of registration in country of origin must be attached. 5. Compliant to Pharmacopeia standards like USP, Ph Eur/EP, BP or other recognized standards. Certificates of Pharmaceutical product as per WHO guidelines should be submitted. 6. Shelf life of the product should be at least 60 months (5 years), and should have at least 85% of the shelf life remaining at delivery time. 7. The product should be supplied with sterile Auto disable syringes, 2mL; sterilized by ethylene oxide (EO), 3parts luer lock, with detachable or fixed needle. The barrel should have coloured graduation lines in units of 0.1mL non prefilled transparent and bubble exclusion mechanism. The needle should be 21GX1.5 (0.8mmX40mm). The shelf life for syringes should be at least 60 months (5 years) and should be at least 85% remaining at time of delivery. Syringes should be GMP/GCP/CE compliant		measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				(certificates should be attached), registered in country of origin (registration Certificates should be attached). Should be compliant to the current ISO requirements: ISO 7886, 7864, 13485. 8. Packaging requirements: 100 vials in units of 10's in sealed polystyrene boxes each box containing 10 vials should have one set of information leaflet. 400 vials and 400 syringes should be packed in one carton. However syringes should be packed individually in sterile peel back blister packs or strip pack. 9. Labelling should include name of the manufacturer, lot number, manufacturing and expiry dates. Cartons should be strong enough (5 ply) to withstand handling and transportation and must be food grade. 10. The product must have demonstrated evidence that; are stable on storage up to 30°C throughout the product lifecycle. " -to be shipped by Sea/Road		
12	1012SMT	NYSTATIN 100,00 IU PESSARY	15PES	Product specifications BP/USP Compendium or any other recognized compendium. Pack of 15 pessaries. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
13	1013SMT	SIMVASTATIN 20MG TABLET	30TB	BP/USP Compendium or any other recognized compendium. Blister of 30 Tablets package. Evidence of registration/import	TZ-SADC print on the primary pack secondary	Carton should be five ply. The carton must be well labeled with Product name, strength,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road	pack and tertiary pack.	Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
14	1014SMT	SODIUM VALPROATE 200MG/5ML SYRUP	1BT	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary To be shipped by Sea/road	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
15	1015SMT	TAMOXIFEN 20MG TABLET	30TB	BP/USP Compendium or any other recognized compendium. Blister of 30 Tablets package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include:	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
16	1016SMT	AMLODIPINE TABLETS 5MG	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		carton.
17	1017SMT	AMOXICILLIN 250MG CAPSULES	100CP	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
18	1018SMT	AMOXICILLIN DISPERSIBLE TABLETS 250MG	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal	TZ-SADC print on the primary pack secondary pack and	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road	tertiary pack.	dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
19	1019SMT	ARTESUNATE INJ, 60MG	EACH	Product specifications BP/USP Compendium or any other recognized compendium. 60mg powder in a vial, packed with 10mls water for injection for reconstitution. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		
20	1020SMT	ATENOLOL 50MG TABLET	28TB	BP/USP Compendium or any other recognized compendium. Blister of 28 Tablets package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
21	1021SMT	ATORVASTATIN 20MG TABLETS	10TB	BP/USP Compendium or any other recognized compendium. Blister of 10 Tablets package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered,, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include:	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
22	1022SMT	AZITHROMYCIN DEHYDRATE 250MG CAPSULES	6CP	BP/USP Compendium or any other recognized compendium. Blister of 6 capsules package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
23	1023SMT	CATGUT CHROMIC 2, 75CM, 1/2 CIRCLE, ROUND BODY,45MM	12PC	Should be sterile and should comply with BP and/ or USP specifications. Primary and secondary packages should be labelled with product name, name of manufacturer and country of origin, lot number, manufacturing and expiry dates. Should be ISO/CE certified. Sample should be submitted.	TZ-SADC both on primary,secondary and tertisry packages. Sample should be submitted. (Minimum of 2 (two) dozens)	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
24	1024SMT	CEFTRIAXONE PDR F INJ 1G	1AMP	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered,	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
25	1025SMT	CHLOROPROMAZINE 100MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal	TZ-SADC print on the primary pack secondary pack and	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road	tertiary pack.	dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
26	1026SMT	COATED POLYGLYCOLIC ACID 1, 75CM, 1/2 CIRCLE, ROUND BODIED,TAPER POINT, 30MM	12PC	Should be sterile and should comply with BP and/ or USP specifications. Primary and secondary packages should be labelled with product name, name of manufacturer and country of origin, lot number, manufacturing and expiry dates. Should be ISO/CE certified. Sample should be submitted.	TZ-SADC both on primary,secondary and tertisry packages. Sample should be submitted. (Minimum of 2 (two) dozens)	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
27	1027SMT	CO-PACK FOR DIARRHOEA TREATMENT KIT (ORS+ZINC 20MG)	1KT	Product specifications BP/USP compendium; the kit should comply with UNICEF approved pack contents. Either Co-pack 10.2g/0.5l ORS flavoured 4 sachets with 10mg Zinc Sulphate (10 Tablets) or 20.5g/1l ORS flavoured 4 sachets with 10mg Zinc Sulphate (10 Tablets). 1. Zinc Suphate Tablet. Blister of 10 tablets of Dispersible 10mg Zinc Suphate tablet, BP/USP Compendium or any other recognized compendium. 2. Oral Rehydration Salt (ORS). 1 Pack of ORS containing Sodium Chloride, Potassium Chloride, Anhydrous Glucose, Trisodium citrate dehydrate. Certificate of analysis for each component of the kit to be submitted. All products should have remaining shelf	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				life of 85% during delivery. Primary Pack labels for each component should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary. Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
28	1028SMT	COTTON WOOL ABSORBENT 500 G	500g	BP quality non-sterilized, Not pre-cut, should have high absorbency, carefully purified, bleached and carded. Weight 500g. Primary packaging should be labelled with name of manufacturer, lot number, manufacturing and expiry dates. Should be ISO/CE certified. Should meet current standard KS	TZ-SADC both on primary and secondary packages. Sample should be submitted. Minimum 5 pcs and a Secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				508:2009 or Tanzania Bureau of Standards (TBS) specifications (TZS 320.1987). Secondary package should be Five ply carton labelled with Product name, Quantity, UOM, Manufacturer name, Exp.andMfg.dates, Batch No. Weight, size and units per carton. Sample should be submitted.		Batch No. Weight, size and units per carton.
29	1029SMT	DICLOFENAC SODIUM 25MG/ML, 3ML AMP	10AMP	Product specifications BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85%. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
30	1030SMT	DOXYCYCLINE 100MG CAPSULES	100CP	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC membere country where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
31	1031SMT	FLUCONAZOLE 150MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
32	1032SMT	FLUPHENAZINE DECANOATE 25 MG/ML INJECTION	10VL	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		
33	1033SMT	FOLIC ACID 10MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
34	1034SMT	FRUSEMIDE 2ML INJ 10MG/ML	10AMP	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		size and units per carton.
35	1035SMT	FRUSEMIDE 40MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
36	1036SMT	GAUZE ABSORBENT BPC 90 CM X 100 M	1RL	BP quality non-sterilized, with Good Absorbency, width & Length 90cm x 100M - 4 ply. Mesh size 40s x 40s, 19 x 15. Should be	TZ-SADC both on primary and secondary packages.	Carton should be five ply. The carton must be well labeled with Product name, strength,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				CE/ISO certified. Primary packaging should be labelled with product name, name of manufacturer, lot number, manufacturing and expiry dates. Each roll wrapped with paper and covered with plastic material. Sample should be submitted.	Sample should be submitted. Minimum 2 Roll	Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
37	1037SMT	GLOVES EXAMINATION LATEX NON-STERILE DISPOSABLE LARGE	50PR	Pre-powdered, latex rubber and with clear indication of size on box. Tested according to ASTM D3578 or similar test with AQL of not more than 1.5, and level of latex protein not exceeding 200mg/g. Primary packaging should be labeled with name of manufacturer, country of origin, lot number, manufacturing and expiry dates. ISO/CE certified.	TZ-SADC both on primary and secondary packages. Sample should be submitted. (Minimum of two P/50)	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
38	1038SMT	GLOVES EXAMINATION LATEX NON-STERILE DISPOSABLE MEDIUM	50PR	Pre-powdered, latex rubber and with clear indication of size on box. Tested according to ASTM D3578 and the current ISO 11193-1 as well as other similar test with AQL of not more than 1.5, and level of latex protein not exceeding 200mg/g. primary packaging should be labeled name of manufacturer country of origin, lot number, manufacturing and expiry dates. ISO/CE certified.	TZ-SADC both on primary and secondary packages. Sample should be submitted. (Minimum of two box)	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
39	1039SMT	GLOVES SURGICAL LATEX RUBBER STERILE SIZE 7.5	50PR	Sterile with clear indication of manufacturer, manufacturing/ sterilization date and expiry date. Tested according to ASTM D3577 and the current ISO 10282 as well as other similar with an AQL of not more than 1.5; and the level of latex protein not exceeding 200mg/g., not less than 300mm total length unstretched. Packed in sterile peel-back/blister or Ribbon packs. Both Primary and secondary packaging should be labelled with TZ-SADC logo, size of the glove, name of primary manufacturer, lot number, manufacturing and expiry dates. ISO/CE mark and certified.	TZ-SADC both on primary and secondary packages. Sample should be submitted. (Minimum of two box)	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
40	1040SMT	HALOPERIDOL 1.5MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
41	1041SMT	HEPATITIS B VACCINES INJ. SINGLE DOSE	1AMP	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Air.		
42	1042SMT	HYDRALAZINE 25MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered Certificate of analysis of the product to be submitted. The product	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		carton.
43	1043SMT	I.V. CANULA 18 G	50PC	Cannulas with injection port and fixation wings. Ultra-sharp siliconized cannula, luer fitting, sterile disposable, in peel-back/blister packs meeting the requirements of the current ISO 10555 and should be CE certified. Packed in 50 units. Blister	TZ-SADC both on primary and secondary packages. Sample should be submitted. Secondary pack with	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				packing, Primary packaging should be labelled with name of manufacturer, lot number, manufacturing and expiry dates. 18G needle. Secondary package: consists of 50 units labelled with Product name, Quantity, Unit of measure , Manufacturer name, Mfg and Exp .dates, Batch No. Tertiary package should be Five ply carton that must be well labelled with Product name, Quantity, Unit of measure , Manufacturer name, Mfg and Exp .dates, Batch No. Weight, size and units per carton. Sample should be submitted.	10 Cannulas	Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
44	1044SMT	I.V. CANULA 20 G	50PC	Cannulas with injection port and fixation wings. Ultra-sharp siliconized cannula, luer fitting, sterile disposable, in peel-back/blister packs meeting the requirements of the current ISO 10555 and should be CE certified.. Packed in 50 units. Blister packing, Primary packaging should be labelled with name of manufacturer, lot number, manufacturing and expiry dates. 20G needle. Secondary package: consists of 50 units labelled with Product name, Quantity, Unit of measure , Manufacturer name, Mfg and Exp .dates, Batch No.	TZ-SADC both on primary and secondary packages. Sample should be submitted. Secondary pack with 10 Cannulas	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
45	1045SMT	I.V. GIVING SET	25PC	Sterile, pyrogen free 15-20 drops/ml , Vented IV infusion set with – roller clamp for flow adjustment, latex rubber connector to facilitate medication, siliconized needle size 20G x 1''(yellow) or 21G x1.5'' (green), drip chamber with fluid filter (15 micron) and sharp airway plastic needle. ISO/CE certified. Packed individually in sterile peel-back/blister or Ribbon packs. Primary packaging should be labelled with name of manufacturer, lot number, manufacturing and expiry dates. Secondary package consists of 25 pieces labeled with product name, quantity, batch, Mfg and expiry date, batch no. Evidence of sterilization must be submitted during delivery along with certificate of analysis/conformity.	TZ-SADC both on primary and secondary packages. Sample should be submitted. Twenty Five pieces (25) in its Secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
46	1046SMT	LOSARTAN 50MG + HYDROCHLORTHIAZIDE 12.5MG	30TB	BP/USP Compendium or any other recognized compendium. Blister of 30 Tablets package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
47	1047SMT	METHYLDOPA 250MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		size and units per carton.
48	1048SMT	NIFEDIPINE RETARD 20 MG TABLET	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
49	1049SMT	PHENOBARBITAL 30MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import	TZ-SADC print on the primary pack secondary	Carton should be five ply. The carton must be well labeled with Product name, strength,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road	pack and tertiary pack.	Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
50	1050SMT	PHENOBARBITAL SODIUM 100MG/ML INJECTION 2ML	10VL	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				may be necessary -Required storage condition. -to be shipped by Sea/Road		
51	1051SMT	POVIDONE IODINE LIQUID 10%	250ml	BP/USP Compendium or any other recognized compendium, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition.	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
52	1052SMT	PREGNANCY TEST STRIPS	KT25	Principle of action: One-step rapid qualitative test for detecting the HCG pregnancy hormone (human chorionic Gonadotrophin) in urine. Test by using urine sample without addition of any other reagent Shelflife: Not less than 24Months Minimum Sensitivity-25mIU/ml Storage: Room temperature (Below 30) Pack size: Individually pouched strip packed (25 Strips/Pack) Labelling: All primary, secondary and tertiary Packaging should be well printed with the product description, Manufacturer Name and Country of Origin, Lot/Batch Number, Manufacturer Name, Manufacturing and Expiry Date with recommended storage condition	TZ-SADC print on the primary pack, secondary pack and tertiary package.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
53	1053SMT	RABIES VACCINE USP(POTENCY OF RABIES ANTIGEN < 2.5 IU/DOSE)	1AMP	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Air		Mfg and Exp. dates, Batch No. Weight, size and units per carton.
54	1054SMT	SILK BRAIDED 0, 75CM, 3/8 CIRCLE, REVERSE - CUTTING 45MM	12PC	Should be sterile and should comply with BP and/ or USP specifications. Primary and secondary packages should be labelled with product name, name of manufacturer and country of	TZ-SADC both on primary and secondary packages. Sample should be	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				origin, lot number, manufacturing and expiry dates. Should be CE certified.	submitted. (Minimum of 2 (two) dozens)	Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
55	1055SMT	SODIUM CHLORIDE + DEXTROSE INJECTION ISOTONIC,500MLS	24BT	Product specifications:Clear colourless sterile solution packed in 500mls plastic collapsible bottle. BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Product must be sterile Primary Pack- should be a plastic collapsible bottle Label should be easily legible, clearly comprehensible and indelible and must include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary -Should indicate sterile product. Secondary	TZ-SADC print on the primary pack and secondary pack	Carton should be 5 ply labeled with: -Product name (Generic and brand names), strength and pharmaceutical form, -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Package. -Directions for use, and any warning or precautions that may be necessary -Required storage condition. - Weight, size and units per carton -Should indicate sterile product. To be shipped by Sea/road		
56	1056SMT	SODIUM CHLORIDE INJECTION 0.9% FOR IV,500ML	24BT	Product specifications:Clear colourless sterile solution packed in 500mls plastic collapsible bottle. BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Product must be sterile Primary Pack- should be a plastic collapsible bottle Label should be easily legible, clearly comprehensible and indelible and must include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that	TZ-SADC print on the primary pack and secondary pack	Carton should be 5 ply labeled with: -Product name (Generic and brand names), strength and pharmaceutical form, -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				may be necessary -Should indicate sterile product. Secondary Package. -Directions for use, and any warning or precautions that may be necessary -Required storage condition. - Weight, size and units per carton -Should indicate sterile product. To be shipped by Sea/road		
57	1057SMT	SODIUM DICHLOROISOCYANURATE	100TB	Product specifications BP/USP Compendium or any other recognized compendium. Pack of 100 Tablets. The product should have remaining shelf life of 85% o during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
58	1058SMT	SODIUM LACTATE COMPOUND (HARTMANN'S),500MLS	24BT	Product specifications BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary To be shipped by Sea/road	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
59	1059SMT	SYRINGE AUTO DISABLE 10CC WITH NEEDLE	100PC	Disposable, sterile, non toxic, non pyrogenic reuse prevention syringe. Type 1B with polypropylene (PP) plunger and barrel and thermoplastic elastomer stopper. Needles should be of stainless steel, must be sharp and should not bend on injecting. Needle size: 21Gx1 ½ "(0.80mm x40mm)". Needle with protective cap and should be sterile. All syringe components should meet ISO 10993 current requirements for biocompatibility. Barrel should be sufficiently transparent to allow easy measurement of the volume contained in the syringe and detection of air bubble. Graduation should be numbered in indelible ink resistant to 70% isopropyl alcohol (IPA) Graduated scale on the barrel should be easy to read, with scale interval of 0.2 ml and 1 ml increment between graduation lines. Luer slip nozzle. Position of the Luer nozzle should be concentric and should meet EN 20594-1/ISO 594 current Standard. Syringes should not leak. Plunger should be well fitting inside the barrel to allow for free and smooth movement. Syringe automatically disabled upon usage and the plunger breaks when pulled. Sterilization by Ethylene Oxide and	TZ-SADC both on primary, secondary and tertiary packages. Sample should be submitted. Secondary pack with 50 syringes	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				should meet current ISO-10993-7: Biological Evaluation of Medical Devices –Part 7. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered. Should conform to the current ISO 7886-1 and ISO 7886-4 Type 1B Standards. Should be CE marked. Each unit of syringe and needle should be blister parked in an individual sterilized easy peel-pack made of medical paper and /or thermoformed polymer film (Ribbon pack) and packed in a box of 100pcs.Both Primary and secondary packaging should be labelled with name of manufacturer and country of origin, lot number, manufacturing and expiry dates, required storage condition Evidence of sterilization and certificate of conformity must be submitted during delivery, manufacturing and expiry date.		
60	1060SMT	SYRINGE AUTO DISABLE 2ML	100PC	Disposable Auto disable syringe, sterile 3 parts, (Type 1A) plunger, barrel, and elastomeric piston rubber seal (gasket). CE/ISO certified. Conforms to the current ISO 7886-4 Single use polypropylene material, prevented from re-use by	TZ-SADC both on primary, secondary and tertiary packages. Sample should be submitted.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				locked/broken plunger, Colored graduation lines on barrel in units 0.1ml, with needle 23G x 1″ (0.6mm x 25mm), with very sharp tip, conical fitting stainless steel material (Should conform to ISO7864). Each syringe mounted or un mounted with needle should be packed individually in sterile peel-off blister pack or ribbon pouch made of paper and plastic. Sterilized by; e.g. Ethylene Oxide (EO). Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Primary packaging should be labelled with name of manufacturer, brand name, lot number, manufacturing and expiry date, quality standard code e.g. ISO, CE etc. Evidence of sterilization and certificate of conformity must be submitted during delivery. Secondary package should be labeled with packaging should be labeled with name of manufacturer and country of origin, brand name, lot number, required storage condition, manufacturing and expiry date.	Secondary pack with 50 syringes	measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
61	1061SMT	SYRINGE AUTO DISABLE 5CC WITH NEEDLE	100PC	Disposable Auto disposable syringe, sterile 3 parts, (Type 1A) pl-nger, barrel, and elastometric piston rubber seal (gasket). CE/ISO certified. Conforms to the current ISO 7886 -4 Single use polypropylene material, prevented from re-use by locked/broken plunger Colored graduation lines on barrel in units 0.2ml, with needle 21G x 1.5 (0.8mm x 40mm), with very sharp tip, conical fitting stainless steel material (Should conform to the current ISO 7864). Each syringe mounted or un mounted with needle should be packed individually in sterile peel-off blister pack or ribbon pouch made of paper and plastic. Sterilized by; e.g. Ethylene Oxide (EO). Evidence of registration/import approval of the product issued by the competent regulatory authority in the respective SADC membered country where the products are intended to be delivered. Primary packaging should be labeled with name of manufacturer and country of origin, brand name, lot number, manufacturing and expiry date, quality standard code e.g. ISO, CE etc.	TZ-SADC both on primary, secondary and tertiary packages. Sample should be submitted. Secondary pack with 50 syringes	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
62	1062SMT	YELLOW FEVER VACCINE INJ 10 DOSES	1AMP	BP/USP Compendium or any other recognized compendium, should comply with general specifications described under vaccine, and should	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				have Vaccine Vial Monitor (VVM) with published vaccine stability data. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Air		dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
63	1063SMT	ALBENDAZOLE TABS 200MG	2TB	BP/USP Compendium or any other recognized compendium. Blister of 2 tablets package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
64	1064SMT	AMITRIPTYLINE 25MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
65	1065SMT	CAPTOPRIL 25 MG TABLETS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
66	1066SMT	CEPHALEXIN 250MG	100CP	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
67	1067SMT	CIPROFLOXACIN TABLETS 500MG	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
68	1068SMT	CO-TRIMOXAZOLE 480MG TABLET	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, -Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
69	1069SMT	DIAZEPAM 5MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
70	1070SMT	DICLOFENAC 50 MG TABLETS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form,	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
71	1071SMT	ERYTHROMYCIN 250MG TABLETS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery.	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
72	1072SMT	FERROUS SULPHATE 200MG +FOLIC ACID 0.25MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC membered country where the products are intended to be delivered,	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates,

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, -Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		Batch No. Weight, size and units per carton.
73	1073SMT	GLIBENCLAMIDE 5MG TABLETS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the	TZ-SADC print on the primary pack secondary pack and tertiary	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road	pack.	Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
74	1074SMT	INSULIN HUMAN ZINC SUSPENSION INJECTION 100IU (LENTE)	10VL	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				may be necessary -Required storage condition. -to be shipped by Air		
75	1075SMT	MAGNESIUM SULPHATE 500MG/ML (50%)	25AMP	Product specifications BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road		
76	1076SMT	METFORMIN 500MG TABLETS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names)	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
77	1077SMT	METRONIDAZOLE 200MG TABS	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, -Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
78	1078SMT	OMEPRAZOLE 20MG CAPSULE.	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		
79	1079SMT	ORAL REHYDRATION SALTS (ORS) FOR 1 LITRE POWDER	100SC	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC membered Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary. -to be shipped by Sea/Road		
80	1080SMT	OXYTOCIN 1ML INJ 5IU/ML	10AMP	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include: -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. -to be shipped by Sea/Road if stored at room tempersture or Air lifted if irt requires cold chain storage.		
81	1081SMT	PARACETAMOL SYRUP 120MG/5MLS,100MLS	24BT	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary To be shipped by Sea/road	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
82	1082SMT	SALBUTAMOL AEOROSOL INHALATION 0.1 MG/DOSE, 200DOSES	1BT	BP/USP Compendium or any other recognized compendium. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack -Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary To be shipped by Sea/road	TZ-SADC print on the primary pack and secondary pack	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.
83	1083SMT	SULPHADOXINE+PYRIMETHAMINE 500MG/25MG TABLET.	100TB	BP/USP Compendium or any other recognized compendium. Blister (10*10) package. Evidence of registration/import approval of the medicinal product issued by the competent regulatory authority in the respective SADC Member states where the products are intended to be delivered, Certificate of analysis of the product to be submitted. The product should have remaining shelf life of 85% during delivery. Primary Pack label should include:	TZ-SADC print on the primary pack secondary pack and tertiary pack.	Carton should be five ply. The carton must be well labeled with Product name, strength, Pharmaceutical dosage form, Required Storage condition, Quantity, Unit of measure, Manufacturer name, Mfg and Exp. dates, Batch No. Weight, size and units per carton.

SN	ITEM #	ITEMS DESCRIPTION	UOM	SPECIFICATION	IDENTIFICATION MARK ON THE PRODUCT	SHIPPING CARTON SPECIFICATIONS
				-Name, strength and pharmaceutical form, -Name and physical address of the manufacturing site -Batch number -Mfg and Exp. Dates -Directions for use and any warning or precautions that may be necessary Secondary Package Label should be easily legible, clearly comprehensible and indelible and must include: -Product name (Generic and brand names) -Amount of each active pharmaceutical ingredient present in a dosage unit -List of excipients -Pharmaceutical dosage form and unit of measure -Manufacturer name, - Mfg and Exp. dates, - Batch Number -Directions for use, and any warning or precautions that may be necessary -Required storage condition. To be shipped by Sea/road		

NOTE:

PRODUCTS MUST BE REGISTERED IN THE SADC MEMBER STATES EXCEPT IN THOSE COUNTRIES WHERE PRODUCT REGISTRATION IS NOT REQUIRED. REGISTRATION NUMBERS SHOULD ALSO APPEAR IN THE LABELS OF PRODUCTS SUPPLIED

ADDITIONAL INFORMATON

1. For costing purposes, the estimated quantities for two years from ten (10) countries have been attached in the bidding documents as a guidance (see attachment below). The quantities are subjected to increase once all the 16 SADC countries will submit their requirements.

2. Call off orders shall be raised and issued when need arises depending on the prevailing average consumption figures which will be established from Member states.
3. Submission of representative sample(s) for primary package of each unit pack size per item is mandatory.
4. For secondary package, the box cut portion indicating the ply and strength from the food grade sample must be submitted.
5. Logo and labelling is mandatory where applicable as indicated in the table above. This will entail engraving and/or embossing both primary and secondary packaging with TZ-SADC.
6. For small volume injections and vials proper labelling which is not easily erased, removed or replaced preferably labelled will be required.
7. For items with blister package, very well labeling including TZ-SADC is one of the criteria for responsiveness. The batch /Lot Number, Manufacturing, expiry dates and TZ-SADC will be engraved/typed on the blister. (Stamping on the blister will not be allowed)

8. All items should be palletized by Batch during Shipment. The standard pallet size is 120X80X20 Centimeters (Euro standard pallet size).

9. The lowest bidder will be subjected to the one with the lowest prices in comparison to international references to be selected by the procuring entity and local prevailing prices in the SADC region. However, quality will be prioritized and should not be compromised;

10. All tenderers must be flexible to adjust accordingly in case of any circumstances that might create any changes during implementation of this framework contract. The procuring entity shall communicate any issues pertaining to the contract to all parties within two (2) months well in advance for appropriate actions;

11. All tenderers who shall win the tender, in the course of transacting with the procuring entity which is MSD, the respective manufacturer will not be allowed to enter into another contract of the same nature with any SADC member states; where the procuring entity is the sole supplier;

12. All tenderers should ensure that drug product information (labels and packing sets) are in the following languages; English, French and Portuguese; data sheet.

13. All tenderers shall be required to quote prices of all SADC Member states price schedule that includes FOB, CFR, CIF and DDP incoterms. A tenderer who will submit price schedules of less than sixteen (16) SADC Member states will not be considered for evaluation unless stated otherwise.

Logo Specification

Clearly visible logo should be printed or embossed on packaging and product as specified in the table above.

The artwork for the logo should be submitted with the bid and approved before being used in mass production.

TZ-SADC

- Logo printed on primary and secondary packaging as specified
- The font type is: Arial
- Navy Blue color should be used unless packaging is dark, in which case light color such as white maybe used

And last

The attached commodity specific conditions will form an integral part of any resulting contract

`

SECTION VII: TECHNICAL SPECIFICATIONS

`

Technical Specifications

PHARMACEUTICALS

1. Product Quality and Package Specifications

1.1 The goods to be purchased under this bid for SADC Pooled Procurement Services are not obligated to be included in the Procuring Entity's current national essential drugs list (Standard Treatment Guidelines and National Essential Medicines List). The required packaging standards and label should meet the current requirements of the World Health Organization (WHO) Good Manufacturing Practices (cGMP) standards in all aspects. "Good Practices in the Manufacture and Quality Control of Drugs.")

1.2 Product specification should indicate dosage form (e.g., tablet, liquid, injection, emulsion, suspension, etc.) and the drug content (exact number of mg or % v/v per doses with acceptable range). The product should conform to standards specified in the latest edition of one of the following compendia: the British Pharmacopoeia (BP), the United State Pharmacopoeia (USP), European Pharmacopoeia (EP) or the International Pharmacopoeia (IP). In case the pharmaceutical is not included in the specified compendium, the Manufacturers must provide the reference standards and testing protocols to allow for quality control testing.

1.3 The packaging components (e.g., bottles and closures) should meet specifications suitable for the purpose and have no detrimental effects on the pharmaceutical product. Primary packing materials must give adequate protection against external influence and potential contamination. All light sensitive pharmaceuticals should be packed in amber or opaque containers to give maximum protection from light.
Tablets and capsules should be packed in blister pack, sealed, waterproof containers with replaceable lids that protect the contents against light and humidity. No drugs will be supplied in tins.

1.4 Secondary packaging material should be strong enough to resist breakages during transportation and normal handling.
As specified in the schedule of requirements and specific for products, carton quantities given under that section must be followed: Instruction leaflets should be inserted. Each unit should have package insert/instruction leaflets. All packing must be properly sealed and tamper-proof.

1.5 Palletisation and cartonization**.** All products quoted must be supplied in cartons and pallets specifically in units specified here and under the section VII 'schedule of requirements'. Cartons should bear the label the information on the dimensions (size and volume) and weight.

`

Cartons should be strong enough to withstand handling. The cartons should be made of corrugated boxes in 5-Ply and should be food grade. The box cut portion indicating the ply and strength from the food grade sample must be submitted

All cartons should be palletized. Pallets must be shrinking strapped and should contain only one batch. The pallets should have information clearly indicated in the parking list. Information on the packing list should show the number of shippers/cartons, their identities in relation to the total number of cartons in each batch, quantity in each carton, shipper dimension, and number of pallets, pallet wise boxes and actual height.

The pallets must meet the criteria stipulated by International Plant Protection Convention (abbreviated IPPC), and evidence that they are incapable of being a carrier of invasive species of insects and plant diseases. The standards for these pallets are specified in ISPM 15. The pallets must have logo (stamped on two opposite sides) by the competent authority and certificate to show that they have been treated to comply with this requirement must accompany the consignment.

1.6 Pharmaceuticals requiring refrigeration or freezing for stability should specifically indicate storage requirements on labels and containers and should be shipped in special container to ensure stability in transit from point of shipment to SADC Member states. These goods must have retrievable temperature monitoring devices throughout the transportation chain up to time they are handed to Member states.

1.7 Shelf life at time of delivery. All products must indicate the dates of manufacture and expiry in a clear language and NOT codes. In addition, all products must arrive at SADC Member states, central medical stores with a remaining shelf life of at least 85% of the total stipulated shelf life at the time of manufacture.

1.8 Sample requirement. Non-returnable representative unit pack sample with all the labelling and logo specifications listed in this tender document should be submitted with the bid. The sample should be offered with Certificate of Analysis relevant to the sample. Label artwork/copy of actual label should be submitted. The sample should have package insert in three languages; English, Portuguese and French.

2. Labelling Instructions

2.1 The label of the primary container for each pharmaceutical and vaccine products shall meet the cGMP standard and include:

(a) All labelling made on all the packages used (including batch numbers and expiry dates) shall be made of waterproof ink in a clearly legible manner. Stamping shall not be accepted.

(b) The international nonproprietary name (INN) or generic

`

name prominently displayed and above the brand name, where a brand name has been given. Brand names should **not** be bolder or larger than the generic name;

(c) Dosage form, e.g., tablet, injectable, syrup, etc;

(d) the active ingredient "per unit, dose, tablet or capsule, etc.";

(e) the applicable pharmacopoeia standard;

(f) content per pack;

(g) instructions for use;

(h) special storage requirements;

(i) TZ-SADC logo in the format and description herein described, and based on only approved artwork that should be submitted with the bid (see under unique identifiers below)

(j) batch number;

(k) date of manufacture and date of expiry (in clear language, not code);

(l) Full name and address of manufacturer;

(m) Registration number of the product issued by the medicine control authority of each country

(n) any additional cautionary statement.

2.2 The outer case or carton should also display the above information in three languages; English, French and Portuguese.

3. Case/Carton Identification

3.1 All cases should prominently indicate the following:

(a) Procuring Entity's line and code numbers;

(b) the generic name of the product;

(c) the dosage form (tablet, ampoule, syrup);

(d) date of manufacture and expiry (in clear language not code);

(e) batch number;

(f) quantity per case/carton;

(g) special instructions for storage;

(h) Full name and address of manufacturer;

`

(i) TZ-SADC logo in the format and description herein described, and based on only approved artwork that should be submitted with the bid (see under unique identifiers below)

(j) Registration number of the product issued by the medicine control authority of each Member states

(k) any additional cautionary statements

3.2 No case should contain pharmaceutical products from more than one batch.

4. Unique Identifiers

4.1 TZ-SADC logo in the format and description described in this subsection must be submitted with the bid for evaluation. Both soft and hard copy of the artwork must be submitted. The confirmation of approval of the artwork of such logo shall be provided to the Manufacturers at the time of contract award. Take note also on the individual product requirements explained on the schedule of requirement.

Logo Specifications

Clearly visible logo should be printed or embossed on packaging and product as specified in the table above

TZ-SADC

- Logo printed on primary and secondary packaging as specified
- The font type is: Arial
- Navy Blue color should be used unless packaging is dark, in which case light color such as white maybe used
- Logo engraved all stainless steel items
- For printed logo manufacturer may use his own choice of color to ensure visibility

5. Standards of Quality Control for Supply

5.1 The successful Manufacturers will be required to furnish to the Procuring Entity:

(a) With each consignment, and for each item a WHO certificate of quality control test results concerning quantitative assay, chemical analysis, sterility, pyrogen content uniformity, microbial limit, and other tests, as applicable to the Goods being supplied and

(b) The manufacturer's certificate of analysis.

(c) Assay methodology of any or all tests when requested.

(d) Evidence of bio-availability and/or bio- equivalence for all narrow therapeutic index items. These include Psychotropic substances, opioid analgesics, Digoxin formulations, aminophylline formulations, warfarin formulations etc. This information would be supplied on a strictly confidential basis only.

(e) Evidence of basis for expiration dating and other stability data concerning the commercial final package, approved by Medicine Control Authority of each Member states to show that the product is stable in the region. The information on the storage requirements should be well indicated in both the primary and secondary packages. Exact limits of temperature, relative humidity and light for which the evidence is attached should be well indicated on the label. (Words like room temperature won't be accepted)

5.2 The Manufacturers shall provide the Procuring Entity with access to its manufacturing facilities to aspect the compliance with the GMP requirements and quality control mechanisms. Evidence to compliance with cGMP must be submitted. **Copies of GMP certificates issued by each Member State Medicine Control Authority must be submitted with the bid for each product tendered**. The other certificates and that must be submitted include the following:

(a) Certified copies of registration certificate in the country of Origin issued by National Regulatory Authority

(b) Copies of registration certificate in Member states issued by National Regulatory Authority of each Member states

(c) Original Manufacturer's Authorization for all bidders who are not primary manufacturers of all products tendered

(d) Good Distribution Practices (GDP) Certificate for all distributors (WHO type)

(e) Certificates of Pharmaceutical Products (CPP)

(f) Summary of product specifications for Finished Pharmaceutical Product (FPP) including labelling information, container and closure types and systems, packaging sizes, volume of containers and unit count/fill size.

(g) ISO and other relevant Quality Management Systems

`

certificates.

5.3 The Procuring Entity shall carry post qualification of all successful bidders and shall require extra information on the previous performance of the contracts of the similar nature and batch sizes of all items to be supplied. In addition, criteria for post qualification will include contract performance on delivery schedules, quality of products, and levels of supply as compared to call off orders and communications efficiency.

`

Technical Specification

VACCINES

1. Product Qualification Requirements

1.1 The goods to be purchased under this Invitation of bid must be produced under the control of a recognized, well-functioning National Control Authority (NCA) for biologicals which performs all six critical functions as defined by the World Health Organization (WHO).

(a) Licensing based on published set of requirements
(b) Surveillance of vaccine field performance
(c) System of lot release for vaccines
(d) Use of laboratory when needed
(e) Regular inspections for good manufacturing practices (GMP)
(f) Evaluation of the clinical performance

2. Product Specifications

The following information should be clearly indicated

2.1 Dosage form (e.g. oral or injectable, liquid or freeze dried with sterile diluents packed separately, etc)

2.2 Type (e.g. live attenuated, manufactured from purified inactivated, obtained from human plasma or manufactured using recombinant DNA technology etc

2.3 Administration (e.g. intended for intramuscular injection, etc,)

2.4 Description of intended use (e.g. immunization of newborn infants, etc)

2.5 Dosage size (if not restrictive) or expected immunogenic reaction (e.g. each dose shall contain that amount of HbsAg protein with micrograms/ml specified by the manufacturer for newborn dosage that when given as of part of a primary immunization series (3 doses) is capable of producing specific humoral antibody (anti HBs) at a level of at least 10 milli international units in >90 percent of recipients, etc)

2.6 Dose package (e.g. 5 infant dose stérile glass Vial, etc.)

2.7 Filling volume (e.g. final product should contain 15% overfill etc.)

`

2.8 Closures (e.g. vaccine vials shall be fitted with closures that conform to ISO standard 8362-2)

2.9 Storage temperature (e.g.2-8 degrees Celsius, don't freeze, or as appropriate, etc)

2.10 The product should remain stable up to the indicated test expiry date if kept according to the required storage temperature

2.11 Standards (e.g. The vaccine should conform to the standards established by each SADC country or where no standard has been given, meet the current requirements published by the WHO Expert committee on Biologicals Standardization or the requirements of an established body of equivalent stature such as US Pharmacopoeia, the British Pharmacopoeia, the French Pharmacopoeia, or the International Pharmacopoeia etc.).

3. Labelling Requirements

3.1 Each vial or ampoule shall carry the manufacturers standard label in three languages; English, French and Portuguese at no extra charge.

3.2 Each vial or ampoule label shall state the following:

(a) name of the vaccine;
(b) name of the manufacturer;
(c) place of manufacture;
(d) lot number;
(e) composition;
(f) concentration;
(g) dose mode for administration;
(h) expiration date;
(i) storage temperature; and
(j) TZ-SADC and/or any special marking on the vial/ampoule as specified in the schedule of requirements; and
(k) any other information that is appropriate.

3.3 All labelling shall withstand immersion in water and remain intact.

4. Packing Requirements

4.1 Inner boxes shall be made sturdy white cardboard outfitted with individual segments for protecting and separating each vial/ampoule

4.2 Each inner box shall contain Manufacture standard package inserts in the English, French and Portuguese languages at no extra charge.

4.3 Over packing: the inner boxes must be over packed so that the vaccines remain refrigerated. The over packing must be suitable for extort handling and be in accordance with WHO Expanded Program on Immunization (EPI) guidelines on

`

International Packaging and Shipping of vaccines including all measures needed to maintain required temperature for seventy-two (72) hours. It must have adequate insulation and sufficient refrigerant to ensure that the warmest storage temperature of the vaccines does not rise above the designated when exposed to continuous outside temperature of +43 degrees Celsius not fall below that specified of -20 degrees Celsius during transit and for a period of 24 hours after arrival at airport destination. Additional cushioning shall be provided sufficient to protect the vials/ampoules from breakage during transit.

4.4 Exterior shipping cartons: Product and printed materials packaged as described above shall be packed in the weather resistant, triple wall corrugated fibreboard cartons with bursting strength of not less than 1,900 kPa. The overall dimension of the exterior shipping cartons should be such that the product does not become damaged during transportation and storage. No shipping carton should contain the vaccines from more than one lot.

4.5 Cold Chain monitor cards: Each insulated shipping container must include appropriate temperature monitoring devices in such a way that at least two suitable cold chain monitor cards shall be packed in each transportation case of vaccine. In addition, freeze watch indicators shall be included in each transport case.

5. Marking Requirements

5.1 All containers and invoices must bear the following information:

(a) the name of the vaccine;
(b) manufacture and expiration date
(c) appropriate storage temperature.

5.2 Inner boxes containing the vaccine vials or ampoules shall be marked with the following information in clearly legible manner:

(a) Generic name and trade name of the vaccine;
(b) Manufacturer's name and trade registered address;
(c) Manufacturer's national registration number;
(d) Lot or batch number;

(e) Composition and concentration;
(f) Number of vials/Ampoules contained in box;
(g) Expiration date (month and year in clear language, not code);
(h) Instructions for storage and handling; and
(i) Place of manufacture (Made in ____).

5.3 Exterior shipping cartons: The following information shall be labelled on the exterior cartons on two opposing sides in bold

`

letter in waterproof ink in a clearly legible manner:

(a) Generic name and trade name of the vaccine
(b) Manufacturer's name and trade registered address
(c) Manufacturer's national registration number
(d) Lot or batch number
(e) Destination airport and routing
(f) Consignee name and address
(g) Consignee contact name and telephone number
(h) Number of vials / ampoules contained in a box
(i) Expiration date (in clear language not code)
(j) Instruction for storage and handling
(k) Gross weight of each carton (in Kg)
(l) Carton number ____ of _____
(m) Contract number
(n) Place of Manufacture (made in___)

6. Quality Control for Supply

6.1 All goods must:

(a) meet the requirements of manufacturing legislation and regulation of vaccines in the country of origin;

(b) meet internationally recognized standards for safety, efficacy, and quality;

(c) conform to all the specifications and related documents contain herein;

(d) be fit for the purposes expressly made known to the Manufacturers by the Procuring Entity;

(e) be free from defects in workmanship and materials; and

(f) be certified by a competent authority in the manufacturer's country according to resolution WHA 28-65(2), of the WHO release certificate.

6.2 The Manufacturers will be required to furnish to the Procuring Entity with each consignment:

(a) A certificate of quality control and test results in conformity with the WHO release certificate;

(b) Assay methodology of any or all tests if required; and

(c) Evidence of basis for expiration dating and other stability data concerning the commercial final package upon request.

6.3 Pre-shipment inspection and testing: The Manufacturers will be required to provide the Procuring Entity or his

representative with access to product as packaged for shipment at the seller's factory and/or warehouse mutually agreeable time prior to shipment of the product:

(a) The Procuring Entity may inspect and sample or cause to be sampled such product

(b) The Procuring Entity may cause independent laboratory testing to be performed as deemed necessary to ensure that the Goods comply to prescribed requirements. The testing laboratory shall be the Procuring Entity's choice and suitably equipped and qualified to conduct quality control tests on biological products.

`

Technical Specifications

MEDICAL SUPPLIES

1. Product and Package Specifications

1.1 The Goods to be purchased by the Purchaser under this Invitation for Bids should be manufactured and packed in compliance to the following standards: GMP, SADC Member states National Regulatory Authorities and other Internationally recognized standards and as indicated in the schedule of requirements per each product.

1.2 Manufacturer, upon award of the Contract, must provide the reference, standards and testing protocols to allow for quality control testing.

1.3 Packaging and labelling components should also meet specifications suitable for distribution, storage, and use in a climate similar to that prevailing in the region. All packaging must be properly sealed and tamper-proof.

1.4 All labelling and packaging inserts shall be in English, Portuguese and French

1.5 Upon award, the successful Manufacturer shall, on demand, provide a translated version in the language of the bid of the prescriber's information for any specific goods the Purchaser may request.

2. Labelling Instructions

2.1 The label of the primary container for each Medical supplies and equipment shall be made of waterproof ink in a clearly legible manner. Stamping shall not be allowed. The detaIls shall include:

(a) The Purchaser's logo (see under TZ-SADC) and their specific requirements): TZ-SADC logo in the format and description herein described, and based on only approved artwork.

TZ-SADC

`

- Logo printed on primary and secondary packaging as specified
- The font type is: Arial
- Navy Blue color should be used unless packaging is dark, in which case light color such as white maybe used

TZ-SADC

- Logo engraved all stainless steel items
- For printed logo manufacturer may use his own choice of color to ensure visibility

(b) Item code numbers
(c) content per pack;

(d) instructions for use;

(e) special storage requirements;

(f) batch number;

(g) date of manufacture and date of expiry (in clear language, not code);

(h) Registration number of the product issued by the Member states' National Regulatory Authority For Class B,C And D Medical Supplies And Equipment

(i) Full name and address of the manufacturer; and

(j) Any additional cautionary statement.

2.2 The **outer case or carton** should also display the above information.

3. Case Identification

3.1 All cases/cartons should prominently indicate the following information:

(l) Purchaser's line and Item code numbers;
(m) The Purchaser's logo (see under TZ-SADC logo,

`

and their specific requirements): TZ-SADC logo in the format and description herein described, and based only on approved artwork.

(n) Registration number of the product issued by the Member states' National Regulatory Authority for class B,C and D Medical Supplies and Equipment

(o) date of manufacture and expiry (in clear language not code) when applicable

(p) batch number;

(q) quantity per case;

(r) special instructions for storage;

(s) name and address of manufacturer; and

(t) Any additional cautionary statements.

3.2 No case should contain products from more than one batch.

4. Unique Identifiers

4.1 TZ-SADC logo in the format and description described under 'logo specification' must be submitted with the bid for evaluation. Both soft and hard copy of the artwork must be submitted. The confirmation of approval of the artwork of such logo shall be provided to the Manufacturer at the time of contract award. Take note also on the individual product requirements explained on the schedule of requirements

5. Standards of Quality Control for Supply

5.1 The successful Manufacturer will be required to furnish to the Purchaser:

(a) With each consignment, and for each item a WHO certificate of quality control test results or other tests, as **applicable to the Goods** being supplied and the manufacturer's certificate of analysis/conformance;

(b) Assay methodology of any or all tests when requested. **The samples will be tested against the standards and requirements issued during registration by Member states' National Regulatory Authority.**

(c) Evidence of basis for expiration dating and other stability data concerning the commercial final package, approved by Member states' National Regulatory Authority to show that the product is stable in the SADC region. The information on the storage requirements should be well indicated

in both the primary and secondary packages. Exact limits of temperature, relative humidity and light for which the evidence is attached should be well indicated on the label. (Words like room temperature won't be accepted)

(d) The Manufacturer shall provide the Purchaser with access to its manufacturing facilities to inspect the compliance with the GMP requirements and quality control mechanisms. Evidence to compliance with GMP must be submitted. **Copies of GMP certificates issued by Member states' Medicines Control Authority must be submitted with the bid for each product tendered**. The other certificates and that must be submitted include:

1) Certified copies of registration certificate in the country of Origin issued by National Regulatory Authority or other competent authority
2) Copies of registration certificate in SADC Member states issued by Member states' National Regulatory Authority for Class B, C and D. Medical Supplies and Equipment
3) Good Distribution Practices (GDP) Certificate for all distributors (WHO type)
4) Summary of finished product specifications including labelling information, container and closure types and systems, packaging sizes, volume of containers and unit count/fill size and performance features and standards.
5) **ISO, CE** mark and other relevant Quality Management Systems certificates and market authorizations.
6) Manufacturer's Warranty certificates as explained in schedule of requirements

(e) Shelf life at time of delivery

All products must indicate on the labels, the dates of manufacture and expiry in a clear language and NOT codes. In addition all products must arrive at Medical Stores Department, Dar es Salaam with a remaining **shelf life of at least 85%** of the total stipulated shelf life at the time of manufacture.

(f) Sample requirement

Non-returnable representative unit pack sample with all the

`

labelling and logo specifications listed in this tender document should be submitted with the bid. The sample should be offered with Certificate of Analysis/conformance relevant to the sample. Label artwork/copy of actual label should be submitted.
The sample should have package insert/usage instructions/catalogue in English.
In addition to the product, **the box cut portion indicating the ply and strength of the packaging material should be submitted.**

5.2 **Palletization and cartonization**

All products quoted must be supplied in cartons and pallets specifically in units specified here and under the section VII 'schedule of requirements'. Cartons should bear the label the information on the dimensions (size and volume) and weight.
Cartons should be strong enough to withstand handling. **The cartons should be made of corrugated boxes in 5-Ply and the box cut portion indicating the ply and strength of the packaging material should be submitted as sample.**
All cartons should be palletized on non-returnable Euro Size pallets according to ISO 445/EN 13698-1 with dimensions of 800 X 1200 X 144MM (WXLXH). The goods should be packed securely and pallets must be shrinking-wrapped or strapped and should contain only one batch. The pallets should have information clearly indicated in the parking list. Information on the packing list should show the number of shippers/cartons, their identities in relation to the total number of cartons in each batch, quantity in each carton, shipper dimension, and number of pallets, pallet wise boxes and actual height.
The pallets must meet the criteria stipulated by International Plant Protection Convention (abbreviated IPPC), and evidence that they are incapable of being a carrier of invasive species of insects and plant diseases. The standards for these pallets are specified in ISPM 15. The pallets must have logo (stamped on two opposite sides) by the competent authority and certificate to show that they have been treated to comply with this requirement must accompany the consignment.

`

SECTION VIII: FORMS OF TENDER

`

Table of Forms of Tender

`

1. Form of Tender

Date: [*insert date of Tender*]

[*Procuring Entity specify: "IFT No.: [specify number]*"]

[*Insert: name of Contract*]

To: [***Procuring Entity**: insert Name and address of Procuring Entity]*

Dear Sir or Madam:

Having examined the Tendering Documents including Addenda Nos: *[insert numbers],* the receipt of which is hereby duly acknowledged, we, the undersigned, offer to supply and deliver *[description of goods and services]* in conformity with the said Tendering Documents for the sum of *[total Tender Amount in words and figures]* or such other sums as may be ascertained in accordance with the Schedule of Prices attached herewith and made part of this Tender.

We undertake, if our Tender is accepted, to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements.

If our Tender is accepted, we undertake to provide a Performance Security in the form, in the amounts, and within the times specified in the Tendering Documents.

We agree to abide by this Tender for the Tender Validity Period specified in Clause 17.1 of the Tender Data Sheet, and it shall remain binding upon us and may be accepted at any time before the expiration of that period.

We are not participating, as Tenderers, in more than one Tender in this tendering process, other than alternative offers in accordance with the Tendering Documents.

Our firm, its affiliates or subsidiaries – including any subcontractors or Manufacturerss for any part of the contract – has not been declared ineligible by the Government of the United Republic of Tanzania under Tanzania's laws or official regulations or by an act of compliance with a decision of the United Nations Security Council.

The following commissions or gratuities have been paid or are to be paid by us to agents relating to this Tender, and to contract execution if we are awarded the contract:-

Name and address of agent Or recipient	**Amount and currency**	**Purpose of Commission or gratuities**
…….. (*if none state "none*")	…….	……

Until a formal Contract is prepared and executed, this Tender, together with your written acceptance thereof and your notification of award, shall constitute a binding Contract between us.

We understand that you are not bound to accept the lowest or any tender you may receive.

`

We certify/confirm that we comply with the eligibility requirements as per ITT Clause 3 of the Tendering Documents

Dated this [*insert number*] day of [*insert month*], [*insert year*]

Signed: _____

Date: _____

In the capacity of *[insert: **title or position**]*

Duly authorized to sign this Tender for and on behalf of *[insert: **name of Tenderer**]*

`

2. **STANDARD POWER OF ATTORNEY**

TO ALL IT MAY CONCERN

THAT BY THIS POWER OF ATTORNEY given on the *[insert date, month and year*],
WE the undersigned [*insert name of the company/donor*] of *[insert address of the company/donor*], by virtue of authority conferred to us by the Board Resolution No.....of .....day of ....[*insert year*], do hereby ordain nominate and appoint [*insert name of donee*] of [*insert address of the donee*] to be our true lawful Attorney and Agent, with full power and authority, for us and in our names, and for our accounts and benefits, to do any, or all of the following acts, in the execution of tender No. *[insert tender number*] that is to say;

> To act for the company and do any other thing or things incidental for [*insert tender Number*] of *[insert description of procurement]* for the [*insert name of the procuring entity*];

AND provided always that this Power of Attorney shall not revoke or in any manner affect any future power of attorney given to any other person or persons for such other power or powers shall remain and be of the same force and affect as if this deed has not been executed.

AND we hereby undertake to ratify everything, which our Attorney or any substitute or substitutes or agent or agents appointed by him under this power on his behalf herein before contained shall do or purport to do in virtue of this Power of Attorney.

SEALED with the common seal of the said *[[insert name of the company**]*** and delivered in the presence of us this *[insert date]* day of *[insert month] [insert year]*.

IN WITNESS whereof we have signed this deed on this *[insert date]* day of *[insert month] [insert year]* at *[insert region]* for and on behalf of *[insert name of the company]* ……

SEALED and **DELIVERED** by the
Common Seal of [*insert name of the donor/coy]*
This *[insert date, month and year*]

.....
DONOR

BEFORE ME:

.....
COMMISSIONER FOR OATHS

`

ACKNOWLEDGEMENT

I [*insert name of donee*] doth hereby acknowledge and accept to be Attorney of the said [*insert name of the company/donor*] under the terms and conditions contained in this POWER OF ATTORNEY and I promise to perform and discharge my duties as the lawfully appointed Attorney faithfully and honestly.

SIGNED AND DELIVERED by the said
[*insert name of donee*] Identified to me
by ***[insert name]***
The latter known to me personally
This *[insert date, month and year*],

.....
DONEE

BEFORE ME

.....
COMMISSIONER FOR OATHS

Price Schedule for Goods Manufactured outside and within the region

(Group C Tenders)

Name of Tenderer:_____. IFB Number __. Page _ of ____.

1	2	3	4	5	6				7	7(a)	8	8(a)	9	9(a)	10	11	12	13	14	15
SN	Item code	Name	Unit pack Size	Currency	Unit prices				Total Unit price (**CFR**) **[a+b]**		Total Unit price (**CIF**) **[a+b+c]**		Total Unit price (**DDP**) **(a+b+c+d**)		Name of Manufacturer	Country of origin	Pharmacopoeia standard	**Member states Medicine Control Authority Registration No.**	**Lead time (weeks)**	**Batch Capacity/ Lot capacity**
					[a] Unit price **FOB** Port of Loading	[b] Freight	[c] Insurance	[d] Clearing, port charges & Inland transport costs	Country	Price	Country	Price	Country	Price						
									Angola Botswana Comoros DRC Lesotho Madagascar Malawi Mauritius Mozambique Namibia Seychelles South Africa Eswatini Tanzania Zambia Zimbabwe		Angola Botswana Comoros DRC Lesotho Madagascar Malawi Mauritius Mozambique Namibia Seychelles South Africa Eswatini Tanzania Zambia Zimbabwe		Angola Botswana Comoros DRC Lesotho Madagascar Malawi Mauritius Mozambique Namibia Seychelles South Africa Eswatini Tanzania Zambia Zimbabwe						

Signed: ……..

Dated: ……..

In the capacity of: *[insert: title or other appropriate designati*

6. Letter of Acceptance

[*Letterhead paper of the Procuring Entity*]

[*date*]

To: *[name and address of the Manufacturers]*

This is to notify you that your Tender dated *[date]* for execution of the *[name of the Contract and identification number, as given in the Special Conditions of Contract]* for the Contract Price of the equivalent of *[amount in numbers and words] [name of currency]*, as corrected and modified in accordance with the Instructions to Tenderers is hereby accepted by us.

We confirm that *[insert name proposed by Procuring Entity in the Tender Data Sheet]*,

Or

We accept that *[name proposed by Tenderer]* be appointed as the Adjudicator

Or

We do not accept that *[name proposed by Tenderer]* be appointed as adjudicator, and by sending a copy of this letter of acceptance to *[insert the name of the Appointing Authority]*, we are hereby requesting *[name]*, the Appointing Authority, to appoint the Adjudicator in accordance with Clause 44.1 of the Instructions to Tenderers

You are hereby instructed to proceed with the execution of the said Contract for the provision of Services in accordance with the Contract documents.

Please return the attached Contract dully signed

Authorized Signature:

Name and Title of Signatory:

Name of Agency:

Attachment: Contract

7. Form of Contract Agreement

THIS AGREEMENT made the _____ day of _____ 20_____ between *[name and address of Procuring Entity]* of Tanzania (hereinafter called "the Procuring Entity") of the one part and *[name of Manufacturers]* of *[city and country of Manufacturers]* (hereinafter called "the Manufacturers") of the other part:

WHEREAS the Procuring Entity invited Tenders for certain goods and ancillary services, *viz.,* [*insert brief description of goods and services*] and has accepted a Tender by the Manufacturers for the supply of those goods and services in the sum of [*insert contract price in words and figures*] (hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.

2. The following documents shall constitute the Contract between the Procuring Entity and the Manufacturers, and each shall be read and construed As an integral part of the Contract:

(a) This Contract Agreement;

(b) Special Conditions of Contract;

(c) General Conditions of Contract;

(d) Technical Requirements (including Technical Specifications);

(e) The Manufacturers's Tender and original Price Schedules;

(f) The Procuring Entity's Notification of Award; and

(g) [*Add here: **any** other documents*]

3. In consideration of the payments to be made by the Procuring Entity to the Manufacturers as hereinafter mentioned, the Manufacturers hereby covenants with the Procuring Entity to provide the Goods and Services and to remedy defects therein in conformity in all respects with the provisions of the Contract.

4. The Procuring Entity hereby covenants to pay the Manufacturers in consideration of the provision of the Goods and Services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

IN WITNESS whereof the parties hereto have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

For and on behalf of the Procuring Entity

Signed: _____

in the capacity of [*insert: title or other appropriate designation*]

In the presence of_____

For and on behalf of the Manufacturers

Signed: _____
in the capacity of [*insert:* ***title or other appropriate designation***]

in the presence of _____

SECTION IX: FORMS OF SECURITIES

1. Tender Security Form

Date: [*insert date*]

IFT: [*insert name and number of IFT*]
Contract: [*insert name and number of Contract*]

To: [*insert name and address of Procuring Entity*]

WHEREAS [*insert name of Tenderer* (hereinafter called "the Tenderer") has submitted its Tender dated [*insert date of Tender*] for the supply of *[name and/or description of the goods]* (hereinafter called "the Tender").

KNOW ALL PERSONS by these present that WE [*insert name of Financial Institution*] of *[name of country]*, having our registered office at *[address of Financial Institution]* (hereinafter called "the Bank"), are bound unto [*insert name of Procuring Entity*] (hereinafter called 'the Procuring Entity") in the sum of [*insert amount**]*, for which payment well and truly to be made to the said Procuring Entity, the Bank binds itself, its successors and assigns by these presents.

Sealed with the Common Seal of the said Bank this [*insert number*] day of [*insert month*], [*insert year***].**

THE CONDITIONS of this obligation are the following:

1. If, after the Tender submission deadline, the Tenderer

   (b) have withdrawn or modified our Tender during the period of tender validity specified in the Form of Tender;

   (c) disagreement to arithmetical correction made to the tender price; or

   (d) having been notified of the acceptance of our Tender by the Procuring Entity during the period of tender validity, (i) failure to sign the contract if required by Procuring Entity to do so or (ii) fail or refuse to furnish the Performance Security or to comply with any other condition precedent to signing the contract specified in the tendering documents; or

2. We undertake to pay to the Procuring Entity up to the above amount upon receipt of its first written demand, without the Procuring Entity having to substantiate its demand, provided that in its demand the Procuring Entity will note that the amount claimed by it is due it, owing to the occurrence of any one of the two above-named CONDITIONS, and specifying the occurred condition or conditions.

This guarantee will remain in full force up to and including twenty eight (28) *after the period of Tender Validity*, and any demand in respect thereof must reach the Bank not later than the above date.

For and on behalf of the Bank

Signed: _____

Date: _____

In the capacity of: _____
[*insert title or other appropriate designation*]

Common Seal of the Bank

[*Note: In case of a Joint Venture, the Tender Securing Declaration must be in the name of all partners to the Joint Venture that submits the tender.]*

2. Tender-Securing Declaration

[The Tenderer shall fill in this Form in accordance with the instructions indicated.]

Date: *[insert date (as day, month and year)]*
Tender No.: *[insert number of Tendering process]*
Alternative No.: *[insert identification No if this is a Tender for an alternative]*

To: *[insert complete name of Procuring Entity]*

We, the undersigned, declare that:

We understand that, according to your conditions, Tenders must be supported by a Tender-Securing Declaration.

We accept that we will automatically be suspended from being eligible for tendering in any contract with the Procuring Entity for the period of time determined by the Authority, if we are in breach of our obligation(s) under the Tender conditions, because we:

(a) have withdrawn or modified our Tender during the period of tender validity specified in the Form of Tender;

(b) Disagreement to arithmetical correction made to the tender price; or

(c) having been notified of the acceptance of our Tender by the Procuring Entity during the period of tender validity, (i) failure to sign the contract if required by Procuring Entity to do so or (ii) fail or refuse to furnish the Performance Security or to comply with any other condition precedent to signing the contract specified in the tendering documents.

We understand this Tender Securing Declaration shall expire if we are not the successful Tenderer, upon the earlier of (i) our receipt of your notification to us of the name of the successful Tenderer; or (ii) twenty-eight (28) days after the expiration of our Tender.

Signed: *[insert signature of person whose name and capacity are shown]* in the capacity of *[insert legal capacity of person signing the Tender Securing Declaration]*

Name: *[insert **complete name of person signing the Tender Securing Declaration**]*

Duly authorized to sign the Tender for and on behalf of: *[insert **complete name of Tenderer**]*

Dated on _____ day of _____, _____ *[insert **date of signing**]*
Corporate Seal (where appropriate)

[Note: In case of a Joint Venture, the Tender Securing Declaration must be in the name of all partners to the Joint Venture that submits the Tender.]

3. Performance Security Bank Guarantee

(Unconditional)

Date: [insert*: date*]

IFT; [*insert: name or number of IFT]*

Contract: [*insert: name or number of Contract*]

To: [*insert name and address of Procuring Entity]*

Dear Sir or Madam:

WHEREAS *[name of Manufacturers]* (hereinafter called "the Manufacturers") has undertaken, in pursuance of Contract No. *[reference number of the contract]* dated *[insert date]* to supply *[description of goods and services] (*hereinafter called "the Contract").

AND WHEREAS it has been stipulated by you in the said Contract that the Manufacturers shall furnish you with a Bank Guarantee by a reputable bank for the sum specified therein as security for compliance with the Manufacturers's performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the Manufacturers a guarantee:

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Manufacturers, up to a total of *[amount of the guarantee in words and figures]*, and we undertake to pay you, upon your first written demand declaring the Manufacturers to be in default under the Contract and without cavil or argument, any sum or sums within the limits of *[amount of guarantee]* as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until the *:[insert date]*

Signature and seal of the Guarantors

_____

[name of bank or financial institution]

_____

[address]

_____

[date]

4. Bank Guarantee Form for Advance Payment

Date: [*insert date*]

IFT: [*insert name and number of IFT*]

Contract*:* [*insert name and number of Contract]*

*To: [**insert name and address of Procuring Entity**]*

Dear Sir or Madam

In accordance with the payment provision included in the Special Conditions of Contract, which amends Clause 18 of the General Conditions of Contract to provide for advance payment, *[name and address of Manufacturers]* (hereinafter called "the Manufacturers") shall deposit with the Procuring Entity a Bank Guarantee to guarantee its proper and faithful performance under the said Clause of the Contract in an amount of *[amount of guarantee in figures and words]*.

We, the *[bank or financial institution]*, as instructed by the Manufacturers, agree unconditionally and irrevocably to guarantee as primary obligator and not as surety merely, the payment to the Procuring Entity on its first demand without whatsoever right of objection on our part and without its first claim to the Manufacturers, in the amount not exceeding *[amount of guarantee in figures and words]*.

We further agree that no change or addition to or other modification of the terms of the Contract to be performed there under or of any of the Contract documents which may be made between the Procuring Entity and the Manufacturers, shall in any way release us from any liability under this guarantee, and we hereby waive notice of any such change, addition, or modification.

This guarantee shall remain valid and in full effect from the date of the advance payment received by the Manufacturers under the Contract until *[date]*.

Yours truly,

Signature and seal of the Guarantors

_____

[name of bank or financial institution]

_____

[address]

_____

[date]

5. Manufacturer's Authorization Form

(Manufacturer's or Producer's letterhead)

To: [*insert name of the Procuring Entity*]

WHEREAS *[name of the Manufacturer]* who are established and reputable manufacturers of *[name and/or description of the goods]* having factories at *[address of factory]*

do hereby authorize *[name and address of Agent]* to submit a Tender, and subsequently negotiate and sign the Contract with you against IFT No. *[reference of the Invitation to Tender]* for the above goods manufactured by us.

We hereby extend our full guarantee and warranty as per Clause 17 of the General Conditions of Contract for the goods offered for supply by the above firm against this Invitation for Tenders.

_____

[signature for and on behalf of Manufacturer]

Note: *This letter of authority should be on the letterhead of the Manufacturer and should be signed by a person competent and having the power of attorney to bind the Manufacturer. It should be included by the Tenderer in its Tender.*

6. Specimen Certificate of a Pharmaceutical Product

Certificate of a Pharmaceutical Product[1]

This certificate conforms to the format recommended by the World Health Organization *(general instructions and explanatory notes attached).*

No. of certificates:_____

Exporting (certifying) country: _____

Importing (requesting) country: _____

1. Name and dosage form of product:
_____

1.1 Active ingredients[2] and amount(s) per unit dose[3].
_____

_____
For complete qualitative composition including excipients, see attached[4].

1.2 Is this product licensed to be placed on the market for use in the exporting country?[5] Yes / no (*key in as appropriate*)

1.3 Is product actually on the market in the exporting country? yes/no/unknown *(key in as appropriate)*

If the answer to 1.2 is yes, continue with section 2A and omit section 2B.

If the answer to 1.2 is no, omit section 2A and continue with section 2B.[6]

2A. 1 Number of product license[7] and date of issue:
_____

2A.2 Product-license holder (name and address):
_____
_____
_____

[1] This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.

[2] Use, whenever possible, international non-proprietary names (INNs) or national non-proprietary names.

[3] The formula (complete composition) of the dosage form should be given on the certificate or be appended

[4] details of quantitative composition are preferred, but their provision is subject to the agreement of the product-license holder.

[5] When applicable, append details of any restriction applied to the sale, distribution, or administration of the product that is specified in the product license.

[6] Sections 2A and 2B are mutually exclusive

[7] Indicate, when applicable, if the license is provisional or if the product has not yet been approved.

2A.3 Status of product-license holder:[8] a/b/c *(key in appropriate category as defined in note 8)*

2A.3.1 For categories b and c the name and address of the manufacturer producing the dosage form are: [9]

_____
_____
_____

2A.4 Is Summary Basis of Approval appended?[10] yes/no *(key in as appropriate)*
2A.5 Is the attached, officially approved product information complete and consonant with the license?[11] Yes/no/not provided *(key in as appropriate)*
2A.6 Applicant for certificate, if different from license holder (name and address):[12]
2B. I Applicant for certificate (name and address):
2B.2 Status of applicant: a/b/c *(key in appropriate category as defined in note 8)*
2B.2.1 For categories b and c the name and address of the manufacturer producing the dosage form are:[13]

_____
_____
_____

2B.3 Why is marketing authorization lacking?
not required/not requested/under consideration/refused (*key in as appropriate)*

2B.4 Remarks:[14]

i. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced?

yes/no/not applicable[15] *(key in as appropriate)*

---

[8] Specify whether the person responsible for placing the product on the market:
(a) manufactures the dosage form;
(b) packages and / or labels a dosage form manufactured by an independent company; or
(c) is involved in none of the above

[9] This information can be provided only with the consent of the product – license holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information. It should be noted that information concerning the site of production is part of the product license. If the production site is changed, the license must be updated or it will cease to be valid.

[10] This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.

[11] This refers to product information approved by the competent national regulatory authority, such as a Summary of Product Characteristics (SPC).

[12] In this circumstance, permission for issuing the certificate is required from the product-license holder. This permission must be provided to the authority by the applicant.

[13]

[14] Please indicate the reason that the applicant has provided for not requesting registration:
(a) The product has been developed exclusively for the treatment of conditions – particularly tropical diseases – not endemic in the country of export.
(b) The product has been reformulated with a view to improving its stability under tropical conditions.
(c) The product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import
(d) The product has been reformulated to meet a different maximum dosage limit for an active ingredient
(e) Any other reason, please specify.

If no or not applicable proceed to question 4.

3.1 Periodicity of routine inspections (years): _____

3.2 Has the manufacture of this type of dosage form been inspected? yes/no (*key in as appropriate*)

3.3 Do the facilities and operations conform to GMP as recommended by the World Health Organization?[16]

yes/no/not applicable[17] *(key in as appropriate)*

ii. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product? [24]

yes/no (key *in as appropriate)*

If no, explain: _____

Address of certifying authority: _____

Telephone number: _____ Fax number: _____

Name of authorized person:
_____

Signature:
_____

Stamp and date:
_____

General instructions

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

---

[15] Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.

[16] The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 823, 1992, annex 1). Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).

[17] This section is to be completed when the product – license holder or applicant conforms to status (b) or (c) as described in note 7 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

The layout for this Model Certificate is available on diskette in Word Perfect from the Division of Drug Management and Policies, World Health Organization, 1211 Geneva 27, Switzerland.

The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

SECTION X: FORMS OF INTEGRITY

UNDERTAKING BY TENDERER ON ANTI – BRIBERY POLICY/ CODE OF CONDUCT AND COMPLIANCE PROGRAMME

(Made under Regulation 78 (2) of GN 446 of 2013

Each tenderer must Submit a statement, as part of the tender documents, in either of the formats in this section.

MEMORANDUM (Format 1)

(Regulation 78(2) of the Public Procurement Regulations, 2013 - Government Notice No. 446 of 2013.)

This company _____*(name of company)* places importance on competitive Tendering taking place on a basis that is free, fair, competitive and not open to abuse. It is pleased to confirm that it will not offer or facilitate, directly or indirectly, any improper inducement or reward to any public officer their relations or business associates, in connection with its Tender, or in the subsequent performance of the contract if it is successful.

This company has an Anti-Bribery Policy/Code of Conduct and a Compliance Program which includes all reasonable steps necessary to assure that the No-bribery commitment given in this statement will be complied with by its managers and employees, as well as by all third parties working with this company on the public sector projects, or contract including agents, consultants, consortium partners, sub- contractors and Manufacturers. Copies of our Anti-Bribery Policy/Code of Conduct and Compliance Program are attached

Authorized Signature:_____

Name and Title of Signatory: _____

Name of Tenderer: _____

Address: _____

MEMORANDUM (Format 2)

(*Regulation 78(2) of the Public Procurement Regulations, 2013 - Government Notice No.446 of 2013.)*

This company _____*(name of company)* has issued, for the purposes of this Tender, a Compliance Program copy attached -which includes all reasonable steps necessary to assure that the No-bribery commitment given in this statement will be complied with by its managers and employees, as well as by all third parties working with this company on the public sector projects or contract including agents, consultants, consortium partners, subcontractors and Manufacturers')"

Authorized Signature:_____

Name and Title of Signatory: _____

Name of Tenderer: _____

Address: _____

ESTIMATED DEMAND REQUIREMENTS OF TWO YEARS FOR TEN (10) SADC COUNTRIES . QUANTITIES ARE SUJCETED TO INCREASE UPON SUBMISSION OF DEMAND REQUIREMENTS OF THE OTHER SIX (6) SADC COUNTRIES.

SN	ITEM #	ITEMS DESCRIPTION	UOM	ESTIMATED QUNTITIES FOR TWO YEARS
1	1001SMT	ACICLOVIR 200MG TABLET	100TB	204,612
2	1002SMT	AMODIAQUINE 150-200MG TABLET	100TB	-
3	1003SMT	AMOXYCILLIN 125MG/5ML SUSPENSION	24BT	159,680
4	1004SMT	AMOXYCILLIN 500MG TABLET/CAPSULE	100TB	679,240
5	1005SMT	ARTEMETHER + LUMEFANTRINE 20+120MG 12 TABLETS*	12TB	588,306
6	1006SMT	BLEOMYCIN 15IU INJ	1VL	20,244
7	1007SMT	CHLORAMPHENICOL 250MG CAPSULE	100CP	252,112
8	1008SMT	CHLOROQUINE 150MG TABLET	100TB	15,400
9	1009SMT	DPT VACCINE INJECTION	1VL	2,533,598
10	1010SMT	MEASLES VACCINE	1VL	4,703,862
11	1011SMT	MEDROXYPROGESTERON ACETATE 150MG/ML INJECTION	100VL	513,524
12	1012SMT	NYSTATIN 100,00 IU PESSARY	15PES	337,356

SN	ITEM #	ITEMS DESCRIPTION	UOM	ESTIMATED QUNTITIES FOR TWO YEARS
13	1013SMT	SIMVASTATIN 20MG TABLET	30TB	31,289
14	1014SMT	SODIUM VALPROATE 200MG/5ML SYRUP	1BT	86,280
15	1015SMT	TAMOXIFEN 20MG TABLET	30TB	99,137
16	1016SMT	AMLODIPINE TABLETS 5MG	100TB	783,801
17	1017SMT	AMOXICILLIN 250MG CAPSULES	100CP	11,604,227
18	1018SMT	AMOXICILLIN DISPERSIBLE TABLETS 250MG	100TB	12,067,546
19	1019SMT	ARTESUNATE INJ, 60MG	EACH	736,663
20	1020SMT	ATENOLOL 50MG TABLET	28TB	2,106,685
21	1021SMT	ATORVASTATIN 20MG TABLETS	10TB	2,327,248
22	1022SMT	AZITHROMYCIN DEHYDRATE 250MG CAPSULES	6CP	630,122
23	1023SMT	CATGUT CHROMIC 2, 75CM, 1/2 CIRCLE, ROUND BODY,45MM	12PC	76,898
24	1024SMT	CEFTRIAXONE PDR F INJ 1G	1AMP	6,639,465
25	1025SMT	CHLOROPROMAZINE 100MG TABS	100TB	341,536

SN	ITEM #	ITEMS DESCRIPTION	UOM	ESTIMATED QUNTITIES FOR TWO YEARS
26	1026SMT	COATED POLYGLYCOLIC ACID 1, 75CM, 1/2 CIRCLE, ROUND BODIED,TAPER POINT, 30MM	12PC	38,494
27	1027SMT	CO-PACK FOR DIARRHOEA TREATMENT KIT (ORS+ZINC 20MG)	1KT	11,054,650
28	1028SMT	COTTON WOOL ABSORBENT 500 G	500g	1,126,150
29	1029SMT	DICLOFENAC SODIUM 25MG/ML, 3ML AMP	10AMP	695,931
30	1030SMT	DOXYCYCLINE 100MG CAPSULES	100CP	1,175,190
31	1031SMT	FLUCONAZOLE 150MG TABS	100TB	230,328
32	1032SMT	FLUPHENAZINE DECANOATE 25 MG/ML INJECTION	10VL	199,385
33	1033SMT	FOLIC ACID 10MG TABS	100TB	123,600
34	1034SMT	FRUSEMIDE 2ML INJ 10MG/ML	10AMP	734,362
35	1035SMT	FRUSEMIDE 40MG TABS	100TB	842,200
36	1036SMT	GAUZE ABSORBENT BPC 90 CM X 100 M	1RL	478,383
37	1037SMT	GLOVES EXAMINATION LATEX NON-STERILE DISPOSABLE LARGE	50PR	2,616,987
38	1038SMT	GLOVES EXAMINATION LATEX NON-STERILE DISPOSABLE MEDIUM	50PR	4,867,553

SN	ITEM #	ITEMS DESCRIPTION	UOM	ESTIMATED QUNTITIES FOR TWO YEARS
39	1039SMT	GLOVES SURGICAL LATEX RUBBER STERILE SIZE 7.5	50PR	1,404,695
40	1040SMT	HALOPERIDOL 1.5MG TABS	100TB	171,701
41	1041SMT	HEPATITIS B VACCINES INJ. SINGLE DOSE	1AMP	237,782
42	1042SMT	HYDRALAZINE 25MG TABS	100TB	50,316
43	1043SMT	I.V. CANULA 18 G	50PC	166,382
44	1044SMT	I.V. CANULA 20 G	50PC	175,922
45	1045SMT	I.V. GIVING SET	25PC	327,949
46	1046SMT	LOSARTAN 50MG + HYDROCHLORTHIAZIDE 12.5MG	30TB	266,788
47	1047SMT	METHYLDOPA 250MG TABS	100TB	568,350
48	1048SMT	NIFEDIPINE RETARD 20 MG TABLET	100TB	1,981,457
49	1049SMT	PHENOBARBITAL 30MG TABS	100TB	1,123,699
50	1050SMT	PHENOBARBITAL SODIUM 100MG/ML INJECTION 2ML	10VL	58,971
51	1051SMT	POVIDONE IODINE LIQUID 10%	250ml	1,430,308

SN	ITEM #	ITEMS DESCRIPTION	UOM	ESTIMATED QUNTITIES FOR TWO YEARS
52	1052SMT	PREGNANCY TEST STRIPS	KT25	188,356
53	1053SMT	RABIES VACCINE USP(POTENCY OF RABIES ANTIGEN < 2.5 IU/DOSE)	1AMP	697,466
54	1054SMT	SILK BRAIDED 0, 75CM, 3/8 CIRCLE, REVERSE - CUTTING 45MM	12PC	37,164
55	1055SMT	SODIUM CHLORIDE + DEXTROSE INJECTION ISOTONIC,500MLS	24BT	141,696
56	1056SMT	SODIUM CHLORIDE INJECTION 0.9% FOR IV,500ML	24BT	412,556
57	1057SMT	SODIUM DICHLOROISOCYANURATE	100TB	132,304
58	1058SMT	SODIUM LACTATE COMPOUND (HARTMANN'S),500MLS	24BT	345,832
59	1059SMT	SYRINGE AUTO DISABLE 10CC WITH NEEDLE	100PC	428,068
60	1060SMT	SYRINGE AUTO DISABLE 2ML	100PC	703,710
61	1061SMT	SYRINGE AUTO DISABLE 5CC WITH NEEDLE	100PC	899,057
62	1062SMT	YELLOW FEVER VACCINE INJ 10 DOSES	1AMP	40,055
63	1063SMT	ALBENDAZOLE TABS 200MG	2TB	3,672,129
64	1064SMT	AMITRIPTYLINE 25MG TABS	100TB	475,641

SN	ITEM #	ITEMS DESCRIPTION	UOM	ESTIMATED QUNTITIES FOR TWO YEARS
65	1065SMT	CAPTOPRIL 25 MG TABLETS	100TB	1,155,849
66	1066SMT	CEPHALEXIN 250MG	100CP	161,768
67	1067SMT	CIPROFLOXACIN TABLETS 500MG	100TB	658,943
68	1068SMT	CO-TRIMOXAZOLE 480MG TABLET	100TB	4,032,210
69	1069SMT	DIAZEPAM 5MG TABS	100TB	262,347
70	1070SMT	DICLOFENAC 50 MG TABLETS	100TB	2,259,262
71	1071SMT	ERYTHROMYCIN 250MG TABLETS	100TB	1,565,426
72	1072SMT	FERROUS SULPHATE 200MG +FOLIC ACID 0.25MG TABS	100TB	4,200,530
73	1073SMT	GLIBENCLAMIDE 5MG TABLETS	100TB	969,339
74	1074SMT	INSULIN HUMAN ZINC SUSPENSION INJECTION 100IU (LENTE)	10VL	96,122
75	1075SMT	MAGNESIUM SULPHATE 500MG/ML (50%)	25AMP	87,449
76	1076SMT	METFORMIN 500MG TABLETS	100TB	3,727,447
77	1077SMT	METRONIDAZOLE 200MG TABS	100TB	2,431,094

SN	ITEM #	ITEMS DESCRIPTION	UOM	ESTIMATED QUNTITIES FOR TWO YEARS
78	1078SMT	OMEPRAZOLE 20MG CAPSULE.	100TB	817,689
79	1079SMT	ORAL REHYDRATION SALTS (ORS) FOR 1 LITRE POWDER	100SC	488,725
80	1080SMT	OXYTOCIN 1ML INJ 5IU/ML	10AMP	750,446
81	1081SMT	PARACETAMOL SYRUP 120MG/5MLS,100MLS	24BT	495,758
82	1082SMT	SALBUTAMOL AEOROSOL INHALATION 0.1 MG/DOSE, 200DOSES	1BT	2,258,569
83	1083SMT	SULPHADOXINE+PYRIMETHAMINE 500MG/25MG TABLET.	100TB	305,501